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Summary 
In this thesis, a novel procedure for linear amplification of messenger RNA 
(mRNA) molecules and labeling with fluorescently modified nucleotides was 
developed, that can be used to perform genome-wide expression analysis from 
minute tissue samples using microarrays of long gene-specific oligonucleotide 
DNA probes. The procedure was then applied to analyze core needle biopsies 
taken at time of diagnosis from tumors of female primary breast carcinoma 
patients. Upon receiving chemotherapy consisting of gemcitabine, epirubicin 
and docetaxel, the patients were classified according to their response to the 
chemotherapy into responders, defined as patients with a pathological 
complete remission of the tumor, and non-responders, defined as patients with 
no change or pathological partial remission. 
The gene expression profiles of the tumors from these patients were then 
bioinformatically processed and analyzed to identify a gene expression 
signature, which could be used to predict the response of the patients. 
Additionally, this gene signature was inspected for the significantly enriched 
pathways and biological processes, and a subset of genes was analyzed in the 
patient's biopsies with respect to RNA expression as validated by real-time 
quantitative polymerase chain reaction and protein expression as measured by 
immuno-histochemistry. 
The gene expression signature contained 512 genes, which allow a prediction of 
the patient response with an overall accuracy of 88%, a sensitivity of 78% and 
a specificity of 90%. Signaling pathways and biological processes identified 
with significant enrichment in the gene set were the Ras pathway, TGF β 
signaling, DNA damage response and apoptosis. From these pathways, the 
genes DAPK2, BAMBI, LMO4 and SMAD3 could be validated by RQ-PCR, but 
not SRC. In protein analysis by IHC, BAMBI was strongly associated with the 
patient's outcome, while BMP4, LMO4, SMAD3 and SRC were not directly 
associated. Additionally, BAMBI protein expression showed strong relationship 
with BRCA1 expression in the primary female breast carcinoma. 
Taken together, these results show the applicability of the novel developed 
procedure for amplification and labeling of mRNA for genome-wide gene 
expression analysis with the long oligonucleotide microarray technique and the 
successful use in biological and clinical investigations. The analysis of gene 
expression profiles of the primary breast tumors revealed an association of the 
Ras pathway, TGF β signaling, DNA damage response and apoptosis with the 
outcome of the patients after chemotherapy, as well as associations of several 
genes within these pathways and biological processes. 
 x 
Zusammenfassung 
In der vorliegenden Dissertation wurde eine neue Methode zur Amplifikation 
von Boten-RNS und der Markierung mit fluoreszierenden Nukleotiden 
entwickelt, die sich zur Erstellung von Genexpressions-Profilen aus sehr 
kleinen Gewebeproben mit Hilfe genspezifischer Proben aus langen DNS-
Oligonukleotiden auf Microarrays eignet. Nachfolgend wurde diese Methode 
angewendet, um Feinnadel-Biopsien aus Mamma-Karzinomen zu untersuchen, 
die den Patientinnen bei Diagnose entnommen worden waren. Nachdem die 
Patientinnen eine Kombinations-Chemotherapie aus Gemcitabin, Epirubicin 
und Docetaxel erhalten hatten, wurden sie je nach Ansprechen in "Responder", 
definiert als Patientinnen mit pathologisch gesicherter kompletter Remission, 
oder "Non-Responder", definiert als Patientinnen ohne Veränderung oder mit 
partialem Rückgang des Tumors, klassifiziert. 
Die Genexpressions-Profile dieser Tumoren wurden mit Hilfe bioinformatischer 
Methoden verarbeitet und analysiert, um eine Gensignatur zu identifzieren, die 
eine Vorhersage des Therapieansprechens erlaubt. Zusätzlich wurde diese 
Gensignatur auf signifikant überrepräsentierte Signalwege und biologische 
Prozesse hin untersucht. Ein Teil der Signaturgene wurde in den Biopsien der 
Patientinnen bezüglich der RNS- und Protein-Expression mit Hilfe von 
quantitativer Echtzeit-PCR bzw. immunhistochemischer Färbungen analysiert. 
Die ermittelte Genexpressions-Signatur enthält 512 Gene, und ermöglicht die 
Vorhersage des Therapieansprechens mit einer Gesamtgenauigkeit von 88%, 
einer Sensitivität von 78% und einer Spezifität von 90%. Als für das 
Ansprechen relevante Signalwege und biologische Prozesse wurden der Ras-
Signalweg, die TGF-β-Kaskade, Antwortprozesse bei DNS-Schädigungen sowie 
der Apoptosemechanismus identifiziert. Aus diesen Signalwegen konnten die 
Gene DAPK2, BAMBI, LMO4 und SMAD3 durch qEZ-PCR validiert werden, 
nicht jedoch die Expression von SRC. Die Proteinanalyse zeigte eine starke 
Assoziation von BAMBI mit dem Therapieansprechen, während BMP4, LMO4, 
SMAD3 sowie SRC nicht direkt assoziiert waren. Zudem wurde ein starker 
Zusammenhang zwischen der Proteinexpression von BAMBI und BRCA1 in den 
primären Brusttumoren festgestellt. 
Zusammengefaßt zeigen die Ergebnisse die Einsetzbarkeit der neu ent-
wickelten Methode zur Amplifikation und Markierung von Boten-RNS für die 
genomweite Expressionanalyse mit der verwendeten Microarray-Technik, sowie 
die erfolgreiche Anwendung der Methode zur Untersuchung biologischer und 
klinischer Fragestellungen. Die Analyse der Genexpressions-Profile der Primär-
tumoren von Brustkrebspatientinnen zeigte Assoziationen des Ras-Signalwegs, 
der TGF-β-Kaskade, der Antwortprozesse bei DNS-Schädigungen sowie des 
Apoptosemechanismus mit dem Ansprechen der Patientinnen auf die 
Chemotherapie. Zudem wurden Abhängigkeiten zwischen diesen Signalwegen 
und biologischen Prozessen anhand verschiedener Gene nachgewiesen. 
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1. Introduction 
 
1.1. Cancer 
Cancer is a very heterogeneous disease, comprising more than 100 different 
types of malignant tumors. Concurrently, it is the second leading cause of 
death, with a rate of 22.7% of all deaths worldwide in 2003.1 Only the 
cardiovascular diseases, with a share of 28%, have a larger percentage. 
 
1.1.1. Development of Cancer 
The formation of a tumor depends on the transformation of at least one cell 
within the organism. The transformation can be fostered by cancerous agents, 
which due to their DNA mutating effect are also called mutagens. Such 
substances or media include different toxins, like those contained in tobacco 
smoke, free radicals like reactive oxygen or nitric oxide species, but they also 
include physically damaging sources like UV light or ionizing irradiation. Other 
sources of degeneration on the level of DNA include different viruses, like 
hepatitis B or C viruses (HBV, HCV) or human papilloma viruses (HPV). DNA 
damage can also occur on during chromosome segregation, leading to 
aneuploidy or translocations of chromosome parts. 
Many of these events happen often during the life time of a cell. Even in an 
environment that is free of mutagens, mutations will occur spontaneously at 
an estimated rate of about 10-6 mutations per gene per cell division. Compared 
to the total number of cell divisions, estimated as 1016 in the course of a 
lifetime, this equates to approximately 1010 mutation events per gene in the 
whole human body.2 
Nonetheless, most of these events do not lead to a cancerous cell. First of all, 
cells possess DNA repair mechanisms that check and repair single nucleotide 
mutations, e.g. during replication. Secondly, not all mutations actually lead to 
an amino-acid change in the protein, or the change translates but does not 
lead to a functional change. Thirdly, if the function of the protein or even the 
cell is severely restricted, it usually leads to a cell death program called 
apoptosis. And lastly, few cells actually live for the entire time span of the 
organism, as most somatic cells have a turnover rate and also stem cells are 
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limited in the number of cell divisions they are allowed to make by restriction 
mechanisms, e.g. through the length of their telomeres. 
Only if the deteriorations are severe, like chromosomal translocations, genetic 
mutations that lead to a defect in the above-mentioned safeguard mechanisms 
themselves or several mutations that happen in a short interval, will they likely 
cause transformation and subsequently can lead to tumor formation. 
In the year 1971, Alfred G. Knudsen proposed his model based on statistical 
analysis of retinoblastoma, which is today called the "two-hit" model.3,4 In 
short, his hypothesis implies that dominantly inherited predisposition to 
cancer entails a germline mutation, while tumorigenesis requires a somatic 
mutation of the second copy of the respective gene. Only by the manifestation 
of both mutations, the early and frequent development retinoblastoma could be 
explained. This very specific finding is still seen as a basic but key concept in 
tumor genetics, even if certain modifications are necessary. As explained 
before, a single somatic mutation mostly does not lead to cancer. Conversely, if 
for example the DNA repair mechanisms are disabled by mutations in the 
respective repair genes, other mutations can easily manifest and lead to a 
degeneration of the cell, e.g. resulting in its micro-environmental survival 
advantage. Another example is a mutation leading to the activation of the 
hTERT gene, which encodes the human telomerase protein. The telomerase is 
capable of lengthening the telomeres, the ends of chromosomes, which 
normally are gradually lost by cell division and finally initiate the death of the 
cells after their complete breakdown. An activation of the telomerase protein in 
somatic cells leads to their immortalization, allowing other mutations in the 
affected cells to accumulate over time. These mutations then have a much 
higher probability to manifest and in effect cause such cells to transform. 
 
1.1.2. Cancer Progression Models 
Following the transformation of a cell to gain tumorigenic potential, for example 
by two or more mutation events, a clonal outgrowth may occur, if the cell has a 
survival advantage over those in its neighboring tissue environment. 
In 1993, Bert Vogelstein and Kenneth Kinzler proposed a model that also 
explained the occurrence of sporadic tumors, in which they argued that for a 
cell or small group of cells to become a tumor, many subsequent steps are 
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necessary.5 This multistep process involves several pathways and interactions, 
both within the tumor and its surrounding stroma, including inflammation, 
invasion, metastasis and vascularization. Vogelstein and Kinzler worked on 
colon carcinoma, which develop in well-defined morphological stages, a fact 
that could not be explained with the models existing at the time. They 
demonstrated that certain subsequent mutations, which happen rather in 
preferential than in a fixed order, could be associated with the disruption or 
over-activation of certain pathways and consequently lead from benign to pre-
cancerous lesions, then to malignant carcinoma and finally to invasive 
carcinoma. 
In recent research, another aspect of tumorigenesis has come into focus, 
namely the emergence of cancer stem cells.6-9 There are two major questions in 
this respect to be answered: (i) Do tumors (and metastases) develop from a 
single or few progenitor cell(s), analogous to tissues deriving from one or few 
stem cells? (ii) Do tumors develop from mutations that had already occured in 
natural stem or progenitor cells? Of course, many more questions are 
connected to this concept, e.g. whether there is an asymmetric division of the 
tumor stem cell and a progression of its progenitor cells. However, the 
existence of cancer stem cells or tumor initiating cells, as they are sometimes 
more carefully referred to, seems to provide a valuable idea for understanding 
the progressive behavior of tumors. Nonetheless, some refinements to the very 
simple idea have to be taken into consideration as well, like the influence of 
tumor-stroma interaction, cross-talking processes involved in tumor invasion 
and vascularisazion, and the existence of so-called "dormant" cells. The latter 
appear for example in the bone marrow of breast cancer patients, but clearly 
show properties they inherited from the primary breast tumor.10-13 The cancer 
stem cell idea seems also very valuable in the explanation of tumor relapse and 
the formation of distant metastases. 
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1.2. Breast Cancer 
Breast cancer is the most common malignant tumor in women, both world-
wide and in the high-income countries, as defined by the World Bank. It leads 
to more than 500,000 deaths per year in the world, and belongs to the top ten 
mortal diseases in the high-income countries, with a mortality rate of 1.9% for 
2002.14 In order to put these absolute numbers into a more substantial 
measure, the lifetime risk of a woman living in the USA to develop cancer is 
estimated to be between 33% and 43%, while her lifetime risk to develop breast 
cancer dropped from one in eight to one in 13 individuals in the last five 
years.1,15  
 
According to the American Society of Cancer, in the USA there were an 
estimated 270,000 new cases of breast cancer in the year 2005, and 40,410 
deaths caused by the disease in the same time period.15 Even though breast 
cancers display a relatively high survival rate compared to cancers of e.g. lung, 
stomach or colorectum, the vast numbers of cases and high incidence rates of 
approximately 128 invasive breast cancers per 100,000 US women plus 
approximately 30 non-invasive cases per 100,000 for the years 2000-2004, 
make breast cancer a clinically very important and highly investigated disease. 
 
Besides the large number of cases, breast carcinoma is also among the most 
heterogeneous types of cancer: firstly, in terms of the clinical course and 
classification; secondly, in terms of the cellular and genetic background of the 
actual tumor mass. A successful treatment of patients with primary breast 
carcinoma is therefore highly dependent on an in-depth characterization of 
each individual case. This comprises not only acquiring standard clinical data 
like age, menopausal status or histopathological staging of the cancer. A more 
profound examination, e.g. concerning the local spread, the tissue origin 
(ductal, lobular, and others), the estrogen and progesterone hormone receptor 
status, as well as a detailed histochemical characterization of expressed 
proteins like HER2/NEU, P53, BCL-2 or the proliferation marker KI67, is 
today's clinical standard.16 
 5
Figure 1 
 
US Incidence rates of Primary Breast Cancer. Depicted are females of all ethnities, separated for age and 
malignancy. From the National Cancer Institute (NIH), 2007.15 
 
1.2.1. Breast Cancer Types 
As the incidence rates demonstrate, the large majority of breast cancer cases 
are comprised of malignant or invasive forms of breast cancer. However, while 
the incidence rate of these has not changed significantly over the past three 
decades, the incidence rate of the non-invasive in situ lesions has increased 
considerably from the early 1980s (up to five per 100,000) to the late 1990s 
(more than 11 per 100,000; Fig. 1). This is due to the fact that the introduction 
of mammography screening, at least in high-income countries like the USA 
represented here, has lead to a great improvement of the early diagnosis. 
Almost all invasive breast tumors are adenocarcinoma (96.9%), with the only 
other histology worth mentioning being the sarcoma (0.3%), the rest are of 
mixed histologies (2.7%). Among the adenocarcinoma, the largest subgroup is 
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comprised of the invasive or infiltrating ductal carcinoma with 67.3% of all 
breast carcinoma, followed by the infiltrating ductal and lobular carcinoma 
(12.7%) and the infiltrating lobular carcinoma (8.0%). Other adenocarcinoma 
subtypes, like mucinous, tubular, papillary, medullary or those not otherwise 
specified (NOS) arise only to very low percentages (2.6%, 1.6%, 0.4%, 0.7%, 
and 1.1%, respectively).15 
Following the consistent screening for breast cancer since the 1980s, the 
percentage of non-invasive lesions has increased from 3% to currently 
20 - 35%.17,18 The largest proportion of non-invasive breast cancer cases in 
high income countries is comprised of the ductal carcinoma in situ (DCIS) with 
approximately 85%, followed by the lobular carcinoma in situ (LCIS) with 12% 
(numbers for USA, averaged for 1998-2002). 
 
1.2.2. Hereditary Mammary Carcinoma 
Albeit the immense number of cases, only a small proportion of patients 
presenting with mammary carcinoma could be associated with an inherited 
susceptibility to develop breast cancer. The hereditary breast tumors differ 
from the sporadic cases mostly by their incidence at an earlier age (mostly 
premenopausal), higher prevalence of bilateral manifestations and, of course, 
the significant number of associated tumors within families.19 Genetic factors 
that have been directly associated with breast cancer comprise for 
approximately 5% of all patients, and the risk to develop breast cancer is 
significantly larger in families with a mammary carcinoma history.20 On the 
other hand, in hereditary breast carcinoma carriers, general risk factors like 
late pregnancy, the number of pregnancies or the menopausal state do not 
alter the risk of developing the tumor significantly.21 
In the middle of the 1990s two major susceptibility genes, BRCA1 
(Chromosome 17q21) and BRCA2 (13q12), were discovered to be directly 
associated with the development of the disease.22 These harbor autosomal 
dominant mutations, and have therefore found their way into clinical patient 
management in cases with a family history.23 
However, since there are familial patterns that cannot be associated with 
BRCA1/2 genes, the importance of other genetic factors in this context has 
been under constant investigation. Yet, whether these contribute only to small 
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subgroups of patients each, or if many genes have to be considered to form a 
polygenic model, is still not known.24-26 Proposed genes to contribute to the 
predisposition to develop breast cancer are TP53, PTEN, LKB1, ATM, PALB2 and 
CHEK2, but less than 1% of cases have been reported with a positive 
association.27,28 
 
More than 60% of breast cancer patients with a BRCA1/2 mutation develop the 
tumor before 50 years of age. These patients have a very high incidence of a 
tubular carcinoma, but their histopathology does not differ significantly from 
those of sporadic cases. The 5-year survival rate is also similar to that of 
sporadic cases, so currently, the therapeutic options remain the same as well. 
The poly(ADP-ribosyl)-transferases (PARP) 1 and 2, which are thought to be 
potential modulators of DNA-repair-mediated resistance to cytotoxic therapy, 
are targeted by novel PARP inhibitors, which are now investigated in clinical 
trials as therapeutic option for BRCA-positive cases of cancers.29,30 
 
1.2.3. Clinical Treatment of Breast Cancer 
Following the diagnosis of an invasive mammary carcinoma, the standard 
therapeutic approach is surgical removal of the tumor, either through local 
excision (breast-conserving) or by removal of the entire breast (mastectomy).  
Of course, breast conserving strategies are favored; however, there are cases for 
which the mastectomy indisputably is the only option, namely those of an 
inflammatory carcinoma, multicentric carcinoma or an intraductal carcinoma 
in situ with a particular classification (Van Nuys score 7-9).31 
 
Systemic therapies, consisting of either chemotherapy, endocrine (hormonal) 
treatment, or a combination of both, have been developed and new protocols 
are constantly under investigation in clinical studies.32 In the adjuvant setting, 
the systemic treatment is given after surgery, to prevent relapse of the breast 
tumor. In the primary systemic (neo-adjuvant) setting, the treatment precedes 
surgical removal of the tumor, with the additional advantage of performing a 
systemic treatment and monitoring of the therapeutic effect on the tumor. 
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In order to investigate the long-term effect of adjuvant chemotherapy, a meta-
analysis of several studies was conducted.33,34 In summary, 33% of the 
patients investigated showed a relapse and 36% of the patients deceased (of 
which 5% not due to the treatment). In respect to no chemotherapy, the 
relative risk of death decreased by 14.9% with poly-chemotherapy, while the 
occurrence of relapse was reduced by 23.7% relatively. The number of deaths 
not directly associated with the breast cancer was not significantly different in 
the poly-chemotherapy treated patients. 
The analysis also revealed that therapy protocols containing anthracyclines 
(e.g. doxorubicine, epirubicine) have a significant survival advantage for the 
patients in comparison with protocols of the CMF combination scheme 
(cyclophosphamide, methotrexate, and 5-fluorouracil), but the long-term 
toxicity has not been investigated well enough for a final conclusion. 
 
Endocrine therapies are relevant for patients with a hormone receptor status of 
at least 10% of tumor cells being positive for the estrogen or progesterone 
receptors (ER, PR).35,36 These patients are treated effectively with tamoxifen 
doses starting at 20 mg/day, and it could be shown that a 5-year treatment 
has a significant advantage for the patients versus no, only one or two years of 
treatment. 
ER-positive patients treated with tamoxifen for 5 years showed a proportional 
recurrence reduction after 10 years of follow-up of 47%, and the relative risk of 
death was reduced by 26%. The proportional mortality reductions were similar 
for women with node-positive and node-negative breast cancer, but the 
absolute mortality reductions were greater in node-positive women: In the trials 
of about 5 years of adjuvant tamoxifen, the absolute improvements in 10-year 
survival were 10.9% for node-positive and 5.6% for node-negative patients. 
 
The primary systemic (neo-adjuvant) treatment has become the standard 
therapy for inoperable or inflammatory mammary carcinoma.37 Other than 
that, patients who are candidates for mastectomy but wish to have a breast-
conserving therapy and patients participating in clinical studies are treated 
currently with primary systemic therapy protocols.38 A major advantage of this 
method, is the possibility to monitor the effect of treatment on the tumor and 
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thus the sensitivity of the tumor to the applied drugs before its surgical 
removal.39 It was also shown that for the use in primary systemic therapy, the 
third generation aromatase inhibitors, e.g. letrozole and anastrozole or 
exemestane show an improvement compared to tamoxifen40-42, whereas the 
results for raloxifen are not conclusive.43,44 
The NSABP-B-27 study shows an improvement of the response rate by 
sequentially adding 4 x Doc (docetaxel) to the standard neoadjuvant therapy of 
4 x AC (doxorubicine, cyclophosphamide).45,46 
The effectiveness in terms of disease-free and overall survival of the 
neoadjuvant therapies was shown to be the same as in the adjuvant setting, 
but there is an improvement in the number of breast conserving tumor 
surgeries.39,47 
 
New developments in systemic therapy of breast cancer include mostly the use 
of trastuzumab (Herceptin) in addition to or as substitution of chemotherapy, 
since it has been approved both in combination to chemotherapy or as a mono-
therapy.48 The mode of action of this monoclonal antibody against the HER2 
protein is not only given by blocking of the HER2 signaling pathway, but also 
through activation of cytotoxic lymphocytes and the inhibition of 
angiogenesis.49 However, side effects to the cardiac system have been reported; 
therefore, the therapy is restricted to clinical studies and not in use as a 
primary therapy option.50,51 The prerequisite is a standardized characterization 
of HER2 overexpression in the patients (HERCEP test). Besides, trastuzumab is 
becoming increasingly used in palliative therapy. 
To overcome the problem of resistance and improve the tolerance to the 
trastuzumab treatment, current research in the field includes different kinds of 
combinations with other antibodies (e.g. against EGFR and VEGF proteins), as 
well as the development and testing of pertuzumab, an improved anti-HER2 
antibody directed against the dimerization domain of the protein, that could be 
used in addition in case of resistance or as successor of the trastuzumab anti-
HER2 antibody.52-55 
 
Another emerging therapy is the adjuvant use of bisphosphonates. It has been 
shown that these decrease the risk of bone marrow metastasis.56-59 However, 
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their therapeutic use is controversial, since they have also been reported to 
increase the rate of visceral metastases.60 Long-term studies are currently 
ongoing to prove their therapeutic applicability.  
 
The therapy of non-invasive mammary carcinoma has gained importance by 
the increasing early detection of non-invasive lesions.61 However, the two major 
histologies, DCIS and LCIS, show little similarities, especially in respect to their 
tumorigenic potential. This results in two separate strategies for the therapy of 
these patients. 
 
The ductal carcinoma in situ develops from cells within the ductal system, 
which show at this stage no infiltration of surrounding stroma tissue. The 
histopathology of DCIS is very heterogeneous, as well as the clinical course of 
the patients and their prognosis. Without any therapy, approximately 30% of 
patients develop an invasive breast carcinoma within 3 - 10 years. Patients 
undergoing a mastectomy have a 98% probability to be completely cured, while 
breast conserving surgery and excision of the lesion lead to a relapse rate of 
50%.62 The risk of relapse can be reduced by approximately 10% as a result of 
the application of radiotherapy after excision. 
A breakthrough in reducing the rate of mastectomies in the therapy of DCIS 
was the development of the Van Nuys Prognostic Index by Silverstein et al. in 
1996.63,64 Depending on their risk group, patients can be cured by a more 
extensive excision of the lesion alone, additional radio therapy (NSABP-B-17 
study) and additional tamoxifen treatment (NSABP-B-24), allowing to limit the 
need to perform a mastectomy to the cases with indisputably no other 
option.65,66 
 
The lobular carcinoma in situ differs in its biology from the DCIS, as the lesion 
is formed by proliferation of relatively uniform cells in the lobuli and often in 
the terminal ducts. The LCIS is very difficult to detect early and often an 
incidental diagnostic finding, since there is no perceptibility of small tumors by 
palpation or mammography screening due to the lack of micro-calcifications. 
The LCIS is relatively uncommon, its incidence amounts to 1 - 2% of all breast 
tumors. It leads to a mammary carcinoma in about 35% of the cases identified 
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even with a follow-up of 35 years.67 Therefore, the current clinical management 
of patients with an LCIS is a regular examination of the lesion's spread by 
mammary sonography. 
 
1.2.4. Diagnosis and Treatment Options 
The attempt to achieve an individualized approach to cope with the 
heterogeneity of the clinical course and biology of breast cancer cases requires 
an exact and differentiated diagnosis of each patient, including e.g. the local 
spread of the lesion or carcinoma and the estimation of lymphatic 
metastases.68 
Imaging techniques to facilitate diagnostics not only include mammography 
and sonography, but also newer and more detailed methods. Examples for 
these are Magnetic Resonance (MR) mammography and Sentinel Lymph Node 
Biopsy (SLNB). 
MR mammography is used as an additional method for refinement or validation 
of conventional mammography and sonography findings. Indications for its use 
are in-breast relapse in previously surgically treated cases, axillary lymph 
nodes containing metastases, evaluation of response to primary systemic 
chemotherapy, screening of high risk populations (hereditary risk patients, 
BRCA1/2) or patients with silicone implants. A great advantage of the MR 
mammography is its high sensitivity, and the resolution of blood vessels; its 
disadvantage, however, is the high number of false positive findings in cases of  
DCIS.69 
Sentinel Lymph Node Biopsy is used selectively as a minimally invasive staging 
of the nodal status. Its advantage is the additional opportunity to check the 
lymph nodes by immuno-histochemical examination. A large disadvantage of 
its use is the overestimation of very small tumor lesions or cell populations, 
such as micro-metastases, in respect to the therapeutic course of action for 
these patients. Therefore, the currently favored proceeding in such cases is to 
dissect the axillary lymph nodes.70 
 
Beyond determination of the actual state of the carcinoma or lesion, the 
individual therapeutic plan of action is highly dependent on the estimation of 
the progression of the disease and the clinical course of the patient. Therefore, 
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the goal is to make a profound prognosis for each patient and give a prediction 
of each therapeutic action to be implemented.71 
Generally, patients can be classified as those with a very good prognosis, 
showing little risk of a relapse; these can be treated locally, and do not need 
any chemotherapy. On the other end of the spectrum are patients with a poor 
prognosis, who definitely need a systemic treatment, including chemotherapy 
or more aggressive therapy. To assess each patients options and the optimal 
course of action, it is therefore most important to predict the therapy response 
versus resistance or relapse. 
 
In order to estimate the prognostic value of certain parameters, Hayes et al. 
published in 1996 a list of criteria to be fulfilled.72 It consists of (i) the 
understanding of the biological model, (ii) the quick and reliable estimation, 
including quality assurance, of the test, (iii) a prospective planning of the 
statistical analysis, e.g. the establishment of threshold values, (iv) the 
independent validation of the test and finally, (v) the clinical relevance for the 
decision of the therapy choice. Meeting all these criteria, there are currently the 
following clinically relevant prognostic factors for breast cancer.73,74 
(a) Lymph node status, especially in axillary lymph nodes, displays the highest 
prognostic value: patients with a negative lymph node status can be cured 
by local treatment with a success rate of 70%. 
(b) Tumor size: patients with tumors smaller than 1 cm have a very good 
prognosis.75-77 
(c) Histological type of cancer: tubular, mucinous and medullary carcinoma 
show very good prognosis.78  
(d) Grading: very well differentiated (WHO grade: G1) tumors have a 
significantly better prognosis than undifferentiated tumors (G3);79 however, 
70 - 80% of carcinoma are intermediately differentiated (G2). 
(e) Hormone receptor status: 75% of patients are ER and/or PR positive and 
have a significantly better prognosis.76,77 However, the hormone receptor 
status is more important as a predicitve factor for hormone treatment. 
(f) Age: very young patients (<35 years) show a very bad prognosis, and have 
extremely aggressive tumors.80 In contrast, menopause is more of a 
predictive factor for hormone treatment than a prognostic factor. 
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Newly developed prognostic factors, which are currently under validation, are 
the urokinase type plasminogen activator (uPA) and its inhibitor PAI-1.81 They 
have been reported to play a key role in invasion and metastasis; however, 
classification is difficult because these factors show a heterogeneous 
expression in both tumor and stroma cells. Patients expressing low levels of 
both uPA and PAI-1 have a good prognosis, and patients who additionally have 
a negative nodal status do not need chemotherapy.82 uPA and PAI-1 could 
therefore prove to be important prognostic factors for patients with 
intermediate grading (G2). 
Another factor of high prognostic value is the growth factor receptor HER2.76,77 
However, the classification is still not uniform enough to make a reliable 
prognosis due to a lack of standardization. ERBB2/HER2/NEU gene 
amplification has shown to be of higher prognostic value than immuno-
histochemical detection of HER2 protein.83-85 Patients with a high expression or 
gene amplification have a bad prognosis. 
Proliferation markers, like the mitotic index and the expression of marker 
proteins (KI67, MIB1, PCNA) as measured by IHC, have currently no prognostic 
value useful for the clinical routine. Nevertheless, they are continuously 
measured for later analyses. Other prognostic characteristics currently under 
investigation are invasion (e.g. laminin receptors), angiogenesis (VEGF), 
oncogenes (TP53 or NM23), and apoptotic markers (BCL-2). 
 
Predictive factors relevant for the clinical use are currently not sufficiently 
available for chemotherapeutic protocols. The steroid hormone receptors can 
predict the response to anti-hormonal therapy like tamoxifen: ER negativity is 
significantly correlated with no response.34 HER2 gene amplification or 
overexpression has been shown to predict the response to trastuzumab 
(Herceptin), either as systemic therapy or in palliative use during 
chemotherapy.48 Again, FISH and RQ-PCR data correlate better than protein 
overexpression measured by IHC;86,87 and additionally, it was shown that the 
serum level could also be correlated with response.88 HER2 positive patients 
have also been reported to respond poorly to CMF chemotherapy 
(cyclophosphamide, methotrexate, and 5-fluorouracil), but well to 
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chemotherapies containing anthracyclines (doxorubicine, epirubicine, and 
others) and taxanes (docetaxel, paclitaxel).89-91 An overview of predictive factors 
currently in clinical use is given in Table 1. 
 
 
The promising results achieved by prognostic and predictive factors currently 
used for some therapies in the clinic show the importance of developing more 
and improving the existing ones. This is especially important in the case of 
chemotherapeutic treatment, both in the adjuvant and the primary systemic 
setting. From the presently available factors, a benefit could be achieved by 
combining some of these into multifactorial models, but this approach requires 
advanced mathematic models, which have to be developed and validated. To 
integrate many factors and limit the laboratory effort at the same time, there is 
a strong need to miniaturize and to integrate multiple measurements into a 
smaller number of experiments. Efforts in this direction have been and still are 
currently undertaken in many laboratories and clinical institutions, both in the 
proteome analysis92 as well as in great numbers on the level of DNA and RNA 
analysis, e.g. by molecular profiling.93 
 
1.2.5. Molecular Profiling in Prognosis and Therapy Response Prediction 
The characterization of tumor patients as currently feasible in the clinical 
routine has not led to a reliable means of classification into tumor subtypes 
according to the patients prognosis after chemotherapy and does not allow 
predicting their response to chemotherapeutic treatment.16,94,95 This is 
especially unfortunate, since in breast cancer the chemotherapy has a 
Table 1 Predictive Factors for Mammary Carcinoma with Clinical Relevance 68 
   
  Factor Class Predictive for response to   
   
  steroid hormone receptors positive endocrine therapy   
  menopausal status premenopausal ovary ablation   
  positive Herceptin, palliative use   
  positive chemotherapy (Anthracyclines/Taxanes)§   
  negative chemotherapy (CMF)
§   
  
HER2 status 
negative endocrine therapy§   
§ Currently not recommended for selection of therapy, only retrospective data available 
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substantial therapeutic impact on the clinical outcome of the patients. To 
successfully cure the patients with this method, there are many different 
therapeutic agents, combinations of these and protocols including delivery 
schedules, that are currently under investigation.96,97 None of these has a 
proven general applicability to treat patients with a substantially better 
response compared to other protocols, yet their success may differ largely when 
applied to individual patients. 
The measure taken into consideration for the success of any individual 
chemotherapy protocol is the rate of pathological complete remission (pCR), 
defined as the disappearance of all viable tumor cells in the tissue. Since the 
pCR rate is highly correlated with the disease-free and overall survival rates of 
treated patients, it can be used as an early and direct surrogate marker for 
treatment success.98-101 
 
Current chemotherapy treatment protocols, as for example the neoadjuvant 
therapy administered in the study investigated in this dissertation, yield pCR 
rates of approximately 25 - 30%.45,47,102-104 These rates could be substantially 
improved, if there was a more reliable way to predict the success of the 
treatment for each individual patient before application. Considering the 
multitude of treatment options just in the case of chemotherapy alone, this 
would hopefully result in an improvement of the overall treatment success. 
The only way to substantially improve the pCR rates in the currently known 
chemotherapies seems to be an extensive and detailed multifactorial 
assessment of each patient's genetic or biochemical record, or likewise of the 
tumor to be treated, as a prerequisite to a tailored application of optimal 
therapy options.  
To perform this multifactorial assessment, a number of methods are 
applicable. On the molecular biology level, array-based comparative genome 
hybridization (aCGH), expression profiling by means of microarrays and real-
time quantitative polymerase chain reaction (RQ-PCR) provide suitable 
information. On the protein level, currently only advanced classical methods 
like two-dimensional electrophoresis followed by transfer to Western blots and 
immuno-histochemical staining, or IHC staining of tissue sections or tissue 
microarrays have the necessary precision and laboratory applicability. More 
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recent methods, like antibody or protein microarrays as well as small volume 
applications have not yet a proven reliability and lack necessary 
standardization. 
All these procedures, however, are currently not feasible to be performed for 
each single patient on a daily clinical routine basis. Therefore, the genes or 
proteins used for determination of prognosis and prediction need to be 
identified first, and then narrowed down to a suitable number, in order to be 
effective both in regards to time and costs. 
  
Recent developments to achieve prognosis of disease-free and overall survival 
after breast cancer have come from studies using cDNA microarrays, 
oligonucleotide microarrays or RQ-PCR (Table 2).95,105 In order to find good 
prognostic markers, an unsupervised clustering of gene expression 
measurements in tumor samples from patients with breast cancer revealed 
different tumor subtypes than the clinically established ones. These groups 
show distinct gene expression patterns and different prognoses, as estimated 
by survival analysis in prospective studies.93,106-109 The classification into 
groups distinguished by their molecular patterns, as represented in Figure 2, 
not only allows for a better subclassification, leading to more accurate 
prognosis of patients with primary breast cancer, but also includes patients 
who developed metastases.  
 
Table 2 Studies Investigating Clinical Potential of Multi-Gene Factors  
Authors Tumors (n) Primary Endpoint Molecular Tool 
Genes 
(n) 
Year 
published 
Sørlie T et al. 78 Classification to outcome custom cDNA array (8,102) 427 
09/2001,106 
PNAS 
van 't Veer LJ & Dai H & 
van de Vijver M et al. 98 
Prediction of distant 
metastases 
Affymetrix, 
Hu25K 231 
01/2002,93 
Nature 
van de Vijver MJ et al. 295 Prediction of distant metastases 
Affymetrix, 
Hu25K 70 
12/2002,109 
N Engl J Med 
Chang JC et al. 24 Prediction of reponse* to chemotherapy (A) 
Affymetrix, 
HgU95-Av2 (12k) 92 
08/2003,110 
Lancet 
Ayers M et al. 42 Prediction of pCR in chemotherapy (T/FAC) 
custom cDNA array 
(31k) 74 
06/2004,111 
J Clin Oncol 
Paik S et al. 668 Prediction of distant metastases RQ-PCR 21 
12/2004,112 
N Engl J Med 
Wang Y et al. 286 Classification to outcome Affymetrix, Hu133a (22k) 76 
02/2005,113 
Lancet 
Hannemann J et al. 48 Prediction of "near" pCR in chemotherapy (AD;AC) custom cDNA (18k) -- 
05/2005,114 
J Clin Oncol 
  
* response defined as ≥75% regression of tumor 
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While these molecular classification models have been developed independently 
from the clinical parameters, they do reflect some of the clinical classifications. 
This includes, for example, the estrogen receptor positive and negative groups 
or the HER2 positive patients. However, the molecular patterns allow the 
identification of subgroups within these larger classes, and integrate a finer 
mapping of the biological setup. Prominent examples are luminal subtypes A, B 
and C, which together represent the ER positive patients, but show a varying 
prognosis and therefore benefit from different kinds of treatment.106 The 
clinical group of HER2 positive patients, on the other hand, can also be further 
subdivided into those that have a prognosis similar to some of the luminal 
subtypes and those behaving differently. This demonstrates that while 
classifications based on single genomic or protein factors alone cannot be used 
in this example, the gene expression levels incorporated for several genes are 
able to identify distinct groups of patients with a high prognostic value. 
Additional groups of patients distinguished by molecular profiling include the 
basal-like subtype that includes BRCA1/2 mutation or deregulation carriers, 
and the ER negative "normal breast-like" subtype. 
These molecular subtypes allow for a better decision regarding their different 
treatment options; e.g. only the luminal subtype A with a low expression of 
proliferative genes shows a good prognosis, therefore suggesting a successful 
treatment with endocrine therapy alone. 
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Figure 2 
 
Hierarchical clustering of patients using microarrays. Gene expression patterns of 85 samples (78 carcinomas, 
three benign tumors, four normal tissues) analyzed by hierarchical clustering using the 476 cDNA intrinsic clone set. 
(A) The tumor specimens were divided into subtypes based on differences in gene expression. The cluster dendrogram 
showing the subtypes of tumors are colored as: luminal subtype A, dark blue; luminal subtype B, orange; luminal 
subtype C, medium blue; normal breast-like, green; basal-like, red; and ERBB2+, pink. Estrogen receptor positive 
subtypes, solid brown; Estrogen receptor negative subtypes, dashed purple. (B) The full cluster diagram scaled down. 
The colored bars on the right represent the inserts presented in C-G. (C) ERBB2 amplicon cluster. (D) Novel unknown 
cluster. (E) Basal epithelial cell–enriched cluster. (F) Healthy breast-like cluster. (G) Luminal epithelial gene cluster 
containing ER. Adapted from Sorlie et al., 2001.106 
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In order to estimate a predictive score, studies integrating the prognostic 
groups, e.g. for the luminal A group, to predict the recurrence of relapse after 
tamoxifen treatment identified a capable predictor of 21 genes.112,115 In the 
case of predicting response to chemotherapy treatment protocols, several 
studies have been performed.93,110,111,113 These studies yielded gene expression 
signatures of less than 100 genes, and outperformed other clinical parameters 
in their predictive power. However, the patient sets that were included in these 
studies were either limited in number or pre-selected in their patient cohorts 
(e.g. mean age below 50 years, node-negative patients). 
The very urgent need to improve the pCR rate significantly is underlined by the 
continuous search for improvements to the existing chemotherapy 
protocols.42,96,97 However, since these are yet to prove their ubiquitous 
applicability with a significant percentage of pCR patients, the gene expression 
signatures are currently the most promising approach to reach that goal 
without a long delay. In December of the year 2006, a large phase III trial 
(planned recruitment: 6,000 patients) was initiated to assess the clinical 
relevance of the 70-gene prognosis signature, and how it compares with 
common prognostic factors for assigning adjuvant chemotherapy for patients 
with node-negative breast cancer ("Microarray In Node-Negative Disease May 
Avoid Chemotherapy", MINDACT).116,117  
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1.3. DNA Microarrays 
Over the past decade, the microarray technique has taken considerable steps 
forward. Originally, DNA microarrays had been developed from cDNA or 
genomic material, incorporated into plasmids or BACs (bacterial artificial 
chromosomes), respectively, then stored and sustained in E.coli libraries, and 
finally further amplified as PCR products before being spotted onto coated 
glass slides.118,119 Since the information, which cDNA was contained within 
each clone of the library and thus contained in each feature of the array had to 
been obtained by sequencing of the cDNA, the annotation was insufficient for 
most of the collections. 
 
The publication of the human genome sequences and those of other important 
mammalian species around the year 2001 has made detailed genomic 
information publicly available, giving commercial oligonucleotide 
manufacturers the opportunity to bioinformatically design and create specific 
oligonucleotides for each gene or genomic locus.119,120 Today, the most common 
forms of the genomic and expression profiling microarrays contain either 
probes synthesized in situ on the support material as 20- to 60-mers, or 
oligonucleotides that were synthesized in vitro, e.g. as 70-mers, and then 
deposited onto glass slides as had been done with the PCR products.120 
Advantages to the former, the in situ synthesis, are mass production with tight 
feature reproducibility, a much smaller feature size and therefore the 
possibility to analyze many samples on a vast number of DNA probes at once in 
a comparative manner. Their disadvantage is the higher production cost of the 
microarrays. Furthermore, Affymetrix' 20- to 25-mer oligonucleotide GeneChips 
require the addition of immobilized DNA probes containing single nucleotide 
mismatches to quantify unspecific hybridization events. 
Advantages of the in vitro synthesized oligonucleotides are the much simpler 
and already highly standardized synthesis that leads to a dramatically lower 
cost per probe and the inclusion of quality control for the synthesized probes 
before actually depositing them on the array.  
Common to both methods is the high consistency of the hybridization 
characteristics of the probes. This results from standardization of parameters 
like base content, length and melting temperature of the oligonucleotides, as 
 21
well as from prevention of loop structures, cross-reactivity and repetitive 
sequences, by bioinformatic design of the oligonucleotides. The uniformity is 
the major advantage of these types of arrays over their former cDNA 
counterparts. Additionally, changes in the annotation and mapping of the 
genome can be represented quickly and cost-effectively by adding new probes 
to the set. Furthermore, different splice variants of mRNAs from the same gene 
can be represented using specific oligonucleotides for common versus unique 
exons, if necessary.  
 
In cDNA arrays, the variance in DNA content of the single features is large, as 
they are subject to the amplification efficiency, consequently resulting in 
varying hybridization requirements of the individual spots. Secondly, within 
each feature, different DNA molecules have to be expected as a result of full 
length and partial length PCR products. Thirdly, since they derive from full 
length cDNA molecules, the products to be PCR amplified range from 500 to 
2,500 base pairs in length. However, longer initial cDNA molecules are more 
probable to be amplified partially.  
Additionally, for their optimal hybridization performance, longer DNA 
molecules require different reaction buffers and/or temperatures than shorter 
ones, while a higher DNA molecule content dictates a different reaction time 
than lower density spots, respectively. As all the features are hybridized 
together on a single array, they can only be incubated in a certain buffer at a 
certain temperature for a certain time. 
This heterogeneity of hybridization optima for the molecules between and 
within the features therefore leads to a deviation of results, making 
normalization a difficult yet very important process in the analysis of the raw 
data. Nevertheless, a direct comparison between single features can not be 
made without taking this aspect of heterogeneity into account. 
 
Oligonucleotide DNA microarrays have eliminated this problem almost entirely, 
since all molecules have a very tight distribution of hybridization properties, for 
example the Tm of the melting temperature usually varies only by ± 2 K. As the 
DNA quantity in each spot is the same for every feature, the hybridization 
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conditions are very homogeneous for the entire array, resulting in a much 
higher reproducibility of the gene expression measurements. 
 
The advantages of the oligonucleotide-based microarrays have lead to an 
increase of their use and thus a much higher comparability of the results 
generated, e.g. experiments performed in different laboratories or even between 
different studies. A study comparing expression profiling experiments using 
different oligonucleotide microarray platforms on patient material was 
performed to show the consistency of the results.121 
 
The workflow of obtaining tumor tissue, extracting nucleic acids from the 
tumor cells, amplifying the genetic material and generating labeled 
polynucleotides to hybridize onto microarrays is shown schematically in 
Figure 3. 
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Figure 3 
 
Schematic workflow of gene expression profiling using microarrays. (A) Extraction of tissue from tumor mass (M) 
by needle biopsy (N) under sonographic surveillance. (B) 1. Extraction and isolation of DNA and RNA from reference 
and tumor tissues*, 2. amplification and labeling of the genetic material with fluorescent dyes; 3. mixing of tumor and 
reference samples appropriately labeled for 4. competitive hybridization on DNA microarrays. (C) Spotting of cDNA or 
oligonucleotide microarrays by deposition of DNA onto glass slides. (D) Scanning of microarrays to measure intensities 
of hybridized sample molecules using Axon Microarray Scanner Model 4000B. (E) Scanned microarray image showing 
individual DNA probes hybridized with Cy3- and Cy5-labeled sample DNA (green and red, respectively). 
* Reference RNA can also be used from independent sources, e.g. cell lines. 
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1.4. Messenger RNA Amplification Methods 
Even though the sensitivity and reproducibility of DNA microarray techniques 
for expression analysis have increased, there is a certain detection limit of 
these methods. This limit is given by the technical or biochemical variances of 
comparative hybridization, fluorescent labeling and detection of the molecules 
in respect to variations between the expression levels of different genes. 
Such a limit, e.g. 1 µg of mRNA to be reversely transcribed and directly labeled 
with Cy-dye coupled nucleotides for hybridization to spotted cDNA or 
oligonucleotide microarrays, usually cannot be accomplished with small tumor 
samples, like biopsies or small cell cultures. In most applications, it is 
therefore necessary to enrich and specifically amplify the mRNA against other 
RNA types, since mRNA constitutes only 5 - 10% of the total RNA in cells on 
average. 
Several different methods have been developed to achieve the necessary 
amount of DNA or RNA that can be successfully labeled, hybridized and 
detected.122-129 These can generally be divided into two groups: Those that 
amplify linearly, mostly using in vitro transcription (IVT), and those amplifying 
exponentially, using polymerase chain reaction (PCR) based protocols. In both 
cases, the input nucleic acid is generated by reversely transcribing the mRNA 
into cDNA, firstly because the mRNA molecules can be selectively transcribed 
by making use of their poly(A) tails, secondly because they will then be 
transcribed into more stable and less digestion sensitive DNA molecules. There 
is an exception to the classification into these two groups, in that special Taq 
DNA polymerase based variants can also be used to amplify linearly.127,128 
The advantage of the exponential amplification methods based on PCR is their 
rapid and effective usage. Since PCR is a standard method in scientific 
laboratories, they can be performed with widely used enzymes and materials, 
therefore resulting in great cost and labor efficiencies. Their disadvantage, 
however, lies in the exponential amplification itself: As the ratio of two different 
mRNA molecules in a cellular sample can exceed 1000-fold easily, the 
representation of the ratio would be greatly exaggerated by the exponentially 
amplification method. This can be explained by the probability of each single 
molecule to be processed by a polymerase, which is the limiting component in 
this reaction. Additionally, with increasing length of the mRNA molecules, the 
 25
probability to receive a full-length amplification product necessary to generate 
a signal decreases. Therefore, longer mRNAs are underrepresented. Another 
bias is introduced by the initial random selection of molecules to be amplified: 
as the number of DNA molecules exceeds the number of available DNA 
polymerase proteins, the selection of amplified sequences occurs randomly. At 
the initial steps of the PCR, this selection will introduce a bias, which will be 
exaggerated by the exponential amplification. The PCR-based methods are only 
suitable to significantly detect differences, if these are either occurring in 
highly abundant mRNA molecules or if the molecules differ only slightly in 
numbers or length. Otherwise, the results of the method do not represent the 
true situation within the cells, and can only be used as a qualitative result. As 
mentioned above, exceptions to this classification are the protocol variants in 
which the amplification occurs linearly despite usage of Taq DNA polymerase. 
The advantage of linear amplification methods, mostly performed by IVT, is the 
preservation of cDNA molecule ratios independently of their original 
abundance. Their disadvantages, however, are the reintroduction of RNA 
molecules into the amplification procedure, which is less stable and prone to 
unintentional digestion, and the relatively high laborious effort. 
Since the disadvantages of the exponential PCR-based methods outweigh the 
disadvantage of the more reliable linear methods, the standard method for 
amplification of mRNA and labeling onto cDNA microarrays has become the 
IVT-based protocol, as described by the laboratories of Eberwine and Baugh 
and later optimized by Kenzelmann and co-workers.123-125 
 
With the introduction of single-stranded oligonucleotide microarrays into the 
laboratories, another disadvantage of the linear IVT-based method became 
obvious: Since the amplification step produces antisense-orientated RNA 
molecules, their labeled complementary DNA products are, of course, sense-
orientated. However, these can not hybridize onto the oligonucleotide 
microarrays with sense-orientated DNA probes, which had been designed as 
such to be used with directly labeled antisense-orientated cDNA. 
This incompatibility of IVT-based linear amplification and labeling with the use 
of sense-oriented oligonucleotide microarrays needs to be overcome in order to 
perform expression profiling studies with the oligonucleotide array technology. 
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Therefore, a novel protocol suitable for the amplification of mRNA yielding 
fluorescently labeled antisense nucleic acid and for the usage in expression 
profiling hybridization experiments with long oligonucleotide microarrays is 
required. 
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2. Aim and Procedure 
 
The aim of this dissertation was to assess the applicability of the microarray 
expression profiling technology for finding a reliable predictive set of genes from 
small tumor biopsies of female primary breast cancer patients for the response 
to the tested neo-adjuvant chemotherapy comprised of gemcitabine, epirubicin 
and docetaxel.  
Patients were considered as responders only if they had a pathological 
complete remission (pCR) after primary systemic chemotherapy. Patients with 
residual tumor cells at surgery, either resulting in pathological partial 
remission (pPR) or pathologically no change (pNC), were considered as non-
responders. 
 
For this purpose, the technique to generate 70-mer oligonucleotide microarrays 
representing transcripts of the whole human genome had to be established and 
optimized for the use with the given infrastructure in the laboratory. 
Additionally, a protocol to linearly amplify mRNA and fluorescently label the 
nucleic acids needed to be developed that could be used with spotted sense-
orientated oligonucleotide microarrays and, at the same time, had the 
necessary fidelity to analyze small tumor biopsies. 
 
After performing the genome-wide expression profiling of the tumors, an 
extensive bioinformatic analysis of the contained genes had to be performed to 
establish the gene signature predicting the classification of patients into 
responders and non-responders. For this purpose, the samples had to be split 
into two sets, one used as a training set to discover a predictive gene set, the 
other to validate its predictive power. Algorithms used to identify the genes 
were support vector machines and receiver-operator characteristic curve 
analysis. 
 
In order to elucidate the biological mechanisms of response to the 
chemotherapy, it was of great interest to investigate the genes contained in this 
signature. Therefore, further pathway and immuno-histochemical analyses of 
some of these genes were the concluding objectives of this dissertation. 
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3. Material and Methods 
 
3.1. Microarrays  
DNA microarrays were generated using oligonucleotides which had been 
evaluated earlier.130 Based upon these data, the Human Oligo Set 2.0 (Operon), 
containing 21,329 gene-specific 70-mer sequences plus controls, were 
obtained. After production and usage of microarrays with this set for the first 
group of patients, an upgrade set of 5,462 sequences was added. The new 
entire collection, containing 26,791 oligonucleotide probes (Human Oligo Set 
2.1.1), was then used for the second group of patients, in the second patient 
group of the study (see Chapter 3.3). 
 
3.1.1. Generation of Microarrays 
The technique used here to deliver small spots of DNA onto coated microscope 
slides was split pin printing. For this method, oligonucleotides were diluted in 
an appropriate spotting buffer and distributed in 384-well plates. A robot 
equipped with steel pins, which have a fine slit, dipped these into the DNA 
solution and the pins were allowed take up a small but defined volume by 
capillary force. Subsequently, the pins were brought into contact with each of 
the slides to deliver a small drop on them. Afterwards, the pins were washed 
several times and dried. This cycle was repeated until all sequences of the 
entire set were successively deposited in spots, creating an array of the 
different DNA molecules, each with a defined position on the slide. 
The oligonucleotides were delivered by the manufacturer in lyophilized form, 
600 pmol of each DNA probe in 384-well plates. To obtain a concentration of 
40 mM as recommended by the manufacturer, the sequences were dissolved in 
15 µl of buffer. As seen during the evaluation of the oligonucleotides, the 
spotting buffer "FBNC", developed by Dr. Gunnar Wrobel, proved to be most 
useful for printing oligonucleotides on glass slides.131 It contained formamide, 
aqueous betaine solution and nitrocellulose diluted in DMSO (Table 3). Along 
with its good spot versus background intensity ratio characteristic, it offered an 
important practical advantage over commonly used 3 × SSC or 3 × SSC / 1.5 M 
betaine spotting buffers, namely the minimized evaporation due to the 
components formamide and DMSO. The disadvantage of the buffer, a slightly 
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wider spread of the spots at delivery due to DMSO, was minimized by setting 
and the relative humidity of the air in the room to a maximum of 40%. 
 
Table 3 FBNC Spotting Buffer, per 10 ml 130 
  2.50 ml formamide (p.A.; Merck)   
  0.25 ml  20 mg/ml nitrocellulose (Sigma-Aldrich) in DMSO (Merck)   
  2.00 ml 2.5 M betaine hydrochloride (pH 6.0; Sigma-Aldrich)   
  5.25 ml H2O (Milli-Q)   
        
 
To print the DNA onto the epoxy-silane coated slides (Schott Nexterion), two 
spotting robots available in the laboratory were used, first the GeneMachines 
OmniGrid 100 (Genomic Solutions) with a capacity of 100 slides, later the 
VersArray ChipWriter Pro System (Bio-Rad, Figure 4), with a capacity of 108 
slides. Both were equipped with a print head capable of carrying up to 48 
SMP3 pins (TeleChem, Figure 5). The advantage of the VersArray System lay in 
its ability to process stacks of up to 4 × 13 plates, while the OmniGrid robot 
could only process one plate at a time, which required manually changing each 
plate of a set. 
 
Figure 4 
 
VersArray Microarray Spotting System. From Bio-Rad Laboratories, Inc. 
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Figure 5 
 
Microarray SMP3 split pin needle (left) and pin head holding 48 pins (right). From Telechem Inc. 
 
Another restriction of the OmniGrid was the incompatibility of its software to 
manage the required 4 × 6 pin setting, required for spotting array duplicates 
with the maximum distance between two repeat spots and maximum 
processing speed. The minimal possible distance of the spots with the FBNC 
buffer of 125 µm, limited the arrays to a maximum of 54 384-well plates in a 
4 × 4 pin configuration with this robot. To spot arrays larger than 54 plates, 
e.g. the Operon Human Oligo Set 2.0 (57 plates), a 2 × 12 pin configuration, 
had to be used, which allowed only for array duplicates with a much lower 
distance of the repeat spots to each other. On the other hand,  this setting had 
a more suitable spot-to-spot distance of 145 µm (961 spots / pin × 24 pins = 
23,064 different spots) with up to 60 384-well plates. Spotting the entire 
Human Oligo Set 2.1.1, consisting of 72 plates including the update, was 
performed solely by using the VersArray system and a 4 × 6 pin configuration, 
with a spot-to-spot distance of 130 µm, creating 27,648 different spots in array 
duplicate. 
For all spotting runs, SMP3 spotting pins were used (TeleChem, Figure 5, left 
panel), which have a take-up volume of 0.25 µl, and the robots set to a slide 
approach speed of 1 mm/s. On average, this generated spots with a diameter 
between 60 and 65 µm, so the spot-to-spot distance, e.g. for the entire Human 
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Oligo Set 2.1.1, was twice as large as the spots themselves. Each drop 
contained an estimated volume of 0.625 nl. 
After spotting, arrays were post-processed by drying the slides for 60' at 60 °C 
in an oven and cross-linking of the DNA to the coated surface by UV-radiation 
(254 nm) for 2 × 2' in a Stratalinker 2400 (Stratagene), with "Auto-Crosslink" 
setting (maximum of 120 J/cm2). Microarrays were sealed together with silica-
gel in airtight packages for keeping them dry and stored at 4 °C. 
Directly before usage, the microarrays were washed for 2' in 0.2% SDS (w/v) at 
room temperature, 2' in ddH20 at room temperature, and 10" in boiling ddH20. 
Right after that, the slides were immediately transferred to 50 ml-Falcon tubes 
and locked in to avoid evaporation of remaining water on the slides. To remove 
residual water, the arrays were centrifuged for 1' at 1000 rpm in a Heraeus 
Varifuge 3R (Kendro). 
 
3.1.2. Hybridization and Post-Processing 
Labeled and washed DNA or RNA samples (see Chapter 3.2) were diluted in 
UltraHyb buffer (Ambion), which had been pre-heated to 70 °C, to a final 
volume of 120 µl. The mix was pre-incubated for 30' (RNA) or 60' (DNA) at 
60 °C while shaking at 1,200 rpm and shielded from light. Meanwhile, the 
microarrays were mounted in a GeneMachines HybStation (Genomic Solutions) 
and pre-heated for 5' at 60 °C. Finally, the samples were heated for 10' at 70 °C 
in the same conditions as before and spun down briefly to collect condensed 
solvent. The samples were then immediately injected into the HybStation 
chambers onto the slides. 
Hybridization was performed for 16 h at 42 °C with agitation of the 
hybridization mix by the HybStation. Afterwards, each slide was washed with 
Medium Stringency Buffer (40" flow, 5' hold), High Stringency Buffer (40" flow, 
3' hold) and Postwash Buffer (40" flow, 2' hold) at 36 °C on the HybStation (see 
Table 4 for composition of the buffers). Each microarray was then dismounted, 
immediately dipped into Postwash / Tween Buffer at room temperature and 
transferred to 50 ml-Falcon tubes which were immediately locked to avoid 
evaporation. Slides were centrifuged for 4' at room temperature in the Varifuge. 
Centrifugation was started at 500 rpm and the speed was increased every 30" 
by 500 rpm, resulting in a maximum centrifugation speed of 2,000 rpm, which 
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was kept for the remainder of the time (approximately 90" to 120"). The dried 
slides were then protected from light until scanning on the same day. 
 
 
 
3.1.3. Scanning and Data Pre-Processing 
An Axon Microarray Scanner, Model 4000B (Molecular Devices), was used to 
document hybridization of the fluorescently labeled DNA or RNA samples to the 
gene-specific sequences immobilized on the array. For each channel, the 
fluorescent molecules were excited at their characteristic optimal wavelength 
with dedicated lasers, the locally emitted photons were specifically filtered by 
their wavelength and amplified via photo-multiplier tubes (PMTs) to be 
measured digitally on a 16-bit scale (maximum intensity = 65,536).  
Scanning was performed at a resolution of 5 µm, and the voltage of the PMTs 
was adjusted so that the overall rate of pixels reaching saturation did not 
exceed 0.1%. At the same time, it was assured that the distribution of 
intensities for both channels was as similar to each other as possible, as seen 
in the histogram (Fig. 6). This was necessary to compensate for different 
incorporation rates of the labeled nucleotides as well as emission and 
bleaching specifics of the used fluorescent dyes Cy3 and Cy5. 
The primary data generated from the measurement consisted of pixel intensity 
values, which had to be matched to the individual spots of DNA in the array. 
Therefore, a corresponding grid needed to be compiled, based on the table of 
the DNA sequences in the plates, using the software of the spotting robot. This 
grid was then overlaid in the scanner software GenePix Pro 5.0 (Molecular 
Devices) with the image representing each scan. This enabled averaging values 
of all pixels representing the individual DNA spots and the labeled samples 
Table 4 Microarray Hybridization Wash Buffers 
  Medium 
Stringency 
High 
Stringency Postwash 
Postwash 
/ Tween Component 
  
  0.5 x 0.05 x 0.05 x 0.05 x SSC (150 mM NaCl, 15 mM Na3-citrate, pH 7.0)   
  0.1% 0.1% -- -- SDS (w/v)   
  -- -- -- 0.05% Tween-20 (v/v)   
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hybridized to them. For each spot, pixels from the surrounding area were taken 
as a background value. Spots which could not be considered as representative 
for a gene, e.g. neighboring spots that had accidentally joined or those 
significantly too small or large were marked manually as outliers. Spots near or 
below the background intensity, which could not be faithfully taken for a 
measurement, where marked automatically by the GenePix Pro software. The 
entire dataset was then exported and saved for each scanned slide. This raw 
data table contains values for each spot consisting of its position, the number 
of pixels, the fore- and background intensity values for each channel averaged 
as arithmetic mean and median, flags representing validity of the spot, and 
other data. 
 
 
 
 
 
 
 
Figure 6 
 
Histogram of pixel intensities. Scanned images were analyzed for pixel intensities in both dye channels in an overlay. 
Relative incidence gives ratio to sum of intensities for all pixels in the respective channel of the image. Value denotes 
pixel intensity measured in arbitrary units (max. intensity, 65,536). 
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3.2. Messenger RNA Amplification and Labeling Protocol 
To successfully use microarrays generated from sense-orientated 
oligonucleotides, the sample RNA needed to be converted into labeled RNA or 
DNA with antisense-orientation. For this purpose, different protocols were 
developed and tested, partly in cooperation with Dr. Jörg Schlingemann. 
 
3.2.1. Sample and Reference RNA 
RNA used for the development of suitable amplification and labeling protocols 
for hybridization onto oligonucleotide arrays was generated from cell lines 
grown and harvested in the laboratory. Since the comparison of protocols 
included analyses concerning reproducibility and linearity of the amplification, 
two cell lines with well defined but limited genetic differences between them 
were chosen. The expression patterns of these cell lines was needed to include 
equally expressed genes as well as differentially expressed genes between the 
two, enabling analysis of various aspects for the suitability of the amplification 
protocols in question. Details of the chosen cell lines HL-60 and NU-DHL-1 are 
given in Appendix A. 
 
Culture and Harvest of Cells 
Both cell lines HL-60 and NU-DHL-1 are from myeloid origin and grow in 
suspension. Cells from frozen stocks (-80 °C or -196 °C) were quickly diluted in 
5 ml 1640 RPMI medium (GibCo) containing 20% fetal calf serum (FCS, GibCo) 
and 1% 100 x Pen-Strep Solution (10,000 U/ml Penicillin, 10,000 µg/ml 
Streptomycin; GibCo), pre-incubated at 37 °C. After 4 h of incubation at 37 °C 
and 5% CO2 (standard conditions) cells were pelleted at mild conditions (2' at 
500 rpm) to remove residual DMSO from the freezing medium. Medium 
supernatant was removed and cells were again diluted in 5-10 ml of the same 
medium as before (containing 20% FCS) and incubated overnight at standard 
conditions. This procedure of pelletting and resuspension in medium 
containing 20% FCS was repeated every 12 h until the cells had grown into 
clusters for the first time, usually after 2-4 days. Cells were then diluted 1:2 to 
1:2.5 and transferred to larger flasks, resuspending them in 20-25 ml medium 
containing 20% FCS, but changing the medium only every 24 h. When the cells 
formed clusters for the second time, they were again diluted 1:2 but now in 
 35
50 ml medium containing only 10% FCS. In this medium, the cell number 
doubled every 2-3 days on average and they were therefore diluted 1:2 to 1:4 
every 2-4 days, as necessary. During resuspension, clusters were disintegrated 
by passing the cells from the pellet through the end of a glass pipette for 
several times. 
Cells were harvested by centrifugation from 50-100 ml culture medium under 
harsh conditions (2' at 2,000 rpm). Medium supernatant was discarded and 
the cell pellet was resuspended in 10-15 ml TRIzol reagent (Invitrogen) at 4 °C. 
 
RNA Extraction 
Cells suspended in TRIzol reagent were incubated at room temperature for 5' 
and then mixed vigorously on a vortex. Chloroform, 1/5 of the volume of TRIzol 
used (2-3 ml), was added and the suspension was again mixed vigorously. To 
separate aqueous and organic phases, the tubes were then centrifuged for 
30' - 60' at 3,000 rpm and 4 °C. The upper RNA containing aqueous phase 
(approximately 60% of the total volume) was collected with a pipet, thereby 
taking care not to take up any of the other two phases. The white intermediate 
phase contains DNA and proteins, while the pink organic phase contains 
membrane lipids, DNA and insoluble cell debris. When any amount of these 
phases was taken up into the pipet tip, this volume was discarded. 
The aqueous phase was collected in a new falcon tube and mixed 1:2 with 
ethanol (p.A.). Immediately afterwards, this mixture was applied to RNeasy 
midi columns (Qiagen) at room temperature. After each loading step, columns 
were centrifuged at 3,750 rpm for 5' and the flow-through was discarded. The 
columns were washed with 4 ml buffer RW1 (Qiagen) and centrifuged for 5' at 
3,000 rpm, followed by 2.5 ml buffer RPE (Qiagen) and centrifugation for 2' at 
3,000 rpm and again with 2.5 ml buffer RPE but centrifuged for 5' at 
3,000 rpm. Each flow-through was discarded. The RNA from the columns was 
then eluted twice with 250 µl RNase-free water as recommended by the 
manufacturer. Total RNA was stored at -80 °C. 
 
Quality Control of Extracted Total RNA 
Before the first usage or after several freeze-thaw cycles, extracted total RNA 
needed to be analyzed for yield and integrity or degradation. The yield was 
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determined by photometric measurements either with UV-spectrometer Cary 
50 Bio (Varian Inc.), usually with 1:25 dilutions in RNase-free water, or 
undiluted in a ND-1000 spectrometer (NanoDrop Technologies). Measurements 
were taken at 260 and 280 nm wavelength and scans were taken from 230 to 
400 nm wavelength. For integrity and degradation analysis, the 2100 
BioAnalyzer (Agilent) with RNA 6000 Nano LabChip Kit was used as 
recommended by the manufacturer. The device works by application of high 
voltages to a current running through a matrix according to the principle of 
capillary electrophoresis. It requires only small amounts of RNA for a 
measurement (25-500 ng). The design of the RNA measurement kit is explained 
in Figure 7. 
 
Figure 7 
 
Schematic view of the Agilent BioAnalyzer RNA Nano 6000 electrophoresis chip. From Agilent Technologies. 
 
 
3.2.2. Comparative Amplification and Labeling of RNA 
Direct Labeling with Reverse Transcription (RT) 
The commonly used protocol for creating fluorescently labeled cDNA from 
mRNA takes advantage of the Reverse Transcriptase, for example from Moloney 
Murine Leukemia Virus (M-MLV). Here, the enzyme SuperScript II (Invitrogen) 
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was used, which had been genetically engineered by the manufacturer to 
reduce RNase H activity and increase thermal stability. This improves overall 
yield and incorporation of the bulky nucleotides, as they are covalently coupled 
with fluorescent Cy-dyes (Amersham). The protocol was not only the starting 
point but also the benchmark for the testing of amplification procedures. 
To ensure selective reverse transcription of messenger RNA, which contains the 
polyadenylation signal [poly(A)], an "anchored" oligo-d(T)21-VN primer was used 
(Biospring; V = any except thymine, N = any nucleotide). 
 
Table 5 Direct Labeling Protocol 
  SuperScript II RT mix, on ice! volume [µl]   
  5 x 1st strand buffer (Invitrogen) 6.00   
  0.1 M DTT (Invitrogen) 3.00   
  RT dNTP-Mix (25 mM dATP, dCTP, dGTP; 10 mM dTTP) 0.60   
  Cy-dUTP (1 mM) (Amersham) 3.00   
  RNase Inhibitor (40 U/µl) (Promega) 1.50   
  SuperScript II RT (200 U/µl) (Invitrogen) 2.00   
  total volume RT mix 16.10   
        
  RNA (2-5 µg mRNA or 40-100 µg total RNA) 0.50 - 11.90   
  Oligo-d(T)21 (1 µg/µl) 2.00   
  RNase-free water ad 13.90   
  total volume RNA / primer 13.90   
  total reaction volume 30.00   
        
  Denature 13.9 µl RNA / primer 4' @ 70 °C and chill on ice   
  add 16.1 µl RT mix    
  3' @ 25 °C    
  60' @ 42 °C    
  add 1 µl SuperScript II (200 U/µl)    
  60' @ 42 °C    
  add 15 µl 0.1 M NaOH, 2 mM EDTA    
  20' @ 70 °C    
  add 15 µl 0.1 M HCl    
        
 
At least 40 µg of total RNA are necessary as input per channel and experiment 
to successfully hybridize the generated cDNA onto a microarray with 70-mer 
oligonucleotide DNA. Assuming an mRNA content of approximately 5% in total 
RNA extracted with the TRIzol procedure, this corresponds to 2 µg of mRNA. 
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Total RNA and oligo-d(T) primer were mixed and denatured for 4' at 70 °C and 
immediately chilled on ice. The RT reagents were mixed according to Table 5 for 
each fluorescent dye separately. Denatured RNA and primer were mixed with 
the RT reagents and pre-incubated for 3' at room temperature. The reaction 
was performed for two hours at 42 °C with addition of another 1 µl (200 U) 
SuperScript II after one hour. Next, RNA was selectively degraded by addition 
of 15 µl 0.1 M NaOH / 2 mM EDTA and incubation for 20' at 70 °C, and finally 
the mix was pH-neutralized by addition of 15 µl 0.1 M HCl. 
For disposal of non-incorporated fluorescent nucleotides, very short products 
and degraded RNA, the reaction mix was passed through Microcon YM-30 
columns (Millipore), which retain molecules of at least 30 kDa molecular 
weight. This corresponds to oligonucleotides with a minimal length of 
approximately 90 DNA bases, if no fluorescent dyes were incorporated, or 100 
RNA bases. The enzymes were also retained, but denatured before by the 
incubation at 70 °C. For washing, the reaction mixes for both labelings (Cy3 or 
Cy5) of a hybridization experiment were mixed and diluted with TE buffer to a 
total volume of 450 µl, then passed through the Microcon columns by 
centrifugation at 13,000 rpm for 10' and the flow-through was discarded. This 
washing procedure was repeated twice. In the last cycle, the cDNA was washed 
with 450 µl TE containing 0.25 µg Cot-1 DNA (Roche), 0.25 µg poly(A) RNA and 
0.75 µg bovine or yeast tRNA (both Sigma-Aldrich) per 1 µg total RNA input and 
centrifuged as above, but this time until the membrane started to become dry 
in the middle, though not entirely. In this manner, the residual volume was 
reduced to approximately 10-20 µl. The Cot-1 DNA, poly(A) RNA and tRNA were 
added as blocking mix to prevent unspecific hybridization events that would 
give background signals on the array. Although the 70-mer oligonucleotides 
spotted onto the arrays are said to be designed free of repeat elements by their 
manufacturer, this blocking procedure was kept as standard. After the last 
washing step, the columns with the residual volume were inverted into a 
collection tube and centrifuged for 1' at 13,000 rpm to collect the labeled cDNA 
and blocking mix. If not used for hybridization immediately, this mix was 
stored at -20 °C in the dark. 
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In Vitro Transcription Labeling with T7-RNA Polymerase 
The most straightforward solution to the problem of limited RNA available for 
hybridization from small tissue samples included linear RNA amplification and 
simultaneously generating labeled antisense RNA. This was performed by first 
creating double-stranded cDNA from the mRNA introducing a T7 promotor, and 
then to perform the in vitro transcription (IVT) with simultaneous incorporation 
of fluorescently labeled nucleotides. If feasible, this would produce labeled 
antisense RNA, thereby amplifying the copy numbers of aRNA by repeatedly 
transcribing from the double-stranded DNA. 
Similar protocols are used both by Affymetrix in the GeneChip technique and 
by Agilent for their Linear Amplification Kit PLUS.43,132 The difference between 
the approaches proposed here or by Agilent and the protocol based on works 
by Lockhart et al. (Affymetrix) is that the latter recommend the usage of 
biotinylated RNA nucleotides. The cRNA containing these biotin labels are first 
hybridized onto the GeneChip Arrays, then in a second step detected by 
binding of streptavidin and thirdly anti-streptavidin antibodies. Consequently, 
the Affymetrix protocol allows only for detection of one channel per 
hybridization experiment, a competitive hybridization with two differently 
labeled samples is impossible. Therefore, a comparison between two tissues, 
e.g. tumor and reference, requires two different chips or arrays, and 
concentration or input deviations have to be addressed additionally. 
The downside of the approach of incorporating fluorescently labeled 
nucleotides during IVT is that the T7-RNA polymerase, which is used for in 
vitro transcription, is barely permissive for bulky or modified nucleotides, and 
therefore has only a low incorporation rate for them. In the tested protocol, we 
tried to overcome this restraint by using a high concentration of fluorescently 
labeled nucleotides, which is of course a lavish solution. 
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Table  6 In vitro Transcription (IVT) Labeling Protocol 
  1. Reverse Transcription (RT)   Promega IVT# vol [µl] Conc. OK   
  RNA/primer, on ice! vol [µl] m [µg] OK RNAse-free water 0.0   
  total RNA 4.0 0.02 - 2     5x T7 Transcr. Buffer 8.0       
  (dT)-T7 primer (100 ng/µl) 1.0 0.1     100 mM ATP 2.6 6.5 mM     
      100 mM CTP 2.6 6.5 mM     
  RT-Mix, on ice! vol [µl] m [µg]     5 mM Cy-UTP (not dUTP) 9.6 1.2 mM     
  1st strand buffer 2.0      100 mM GTP 2.6 6.5 mM     
  100 mM DTT 1.0      100 mM UTP 2.1 5.25 mM     
  10 mM dNTP-mix 0.5      T7 Enzyme Mix 4.0       
  5-8 mg/ml T4gp32 0.5 2.5 - 4     SSS resuspension 8.5       
  RNase Inhibitor 0.5      Total 40.0       
  SuperScript II (200 U/µl) 0.5          
  total 5.0       mix by pipetting and gentle vortexing   
      incubate 6h @ 37 °C in dark condition!!!   
  denature RNA/primer 4' @ 70 °C, chill @ 4 °C   mix regularly (every 15-30') by gently flicking   
  add ice cold RT-Mix, mix well      
  incubate 1 h @ 50 °C with heated lid   4. aRNA Cleanup   
  inactivate 15' @ 65 °C RLT/β-ME - mix vol [µl] m [µg] OK
  chill on ice / 4 °C forever   β-mercaptoethanol 3.5       
     water 76.5       
  2. Second Strand Synthesis (SSS)   RLT (Qiagen) 350.0       
  SSS-mix, on ice! vol [µl] m [µg] OK total 430.0   
  5x 2nd strand buffer 15.00           
  10 mM dNTP 1.50       aliquot into 1.5 ml tube 430.0       
  DNA Pol. I (9 U/µl) 2.22       add IVT product (aRNA) 40.0       
  RNase H (10 U/µl) 0.10       mix well   
  DNA Ligase (10 U/µl) 0.50       add 100% EtOH 250.0       
  RNase-free water 45.68       apply to RNeasy mini column (Qiagen)   
  total 65.00       spin 15" @ 8,000 x g (9,900 rpm)   
      discard flow-through   
  add ice cold(!) SSS-mix to RT reaction   transfer column to new 2 ml tube   
  mix well   wash with 500 µl RPE (contains ethanol)   
  incubate 2 h @ 14-16 °C in thermal cycler   spin 15" @ 8,000 x g (9,900 rpm)   
  add 10 U T4 DNA-Polymerase (3 U/µl; 3.33 µl)   discard flow-through   
  mix by flicking and gentle vortexing   wash with 500 µl RPE (contains ethanol)   
  incubate 15' @ 14-16 °C in thermal cycler   spin 2' @ 13,000 rpm   
  heat inactivate 10' @ 70 °C   discard flow-through   
  add 75 µl phenol/chloroform/isoamylalcohol (pH 8)   wash with 500 µl RPE (contains ethanol)   
  mix vigorously by pipetting   spin 2' @ 13,000 rpm   
  transfer to pre-spun PLG Heavy 0.5 ml *   discard flow-through   
  spin 5' @ 13,000 rpm / RT   transfer column to new 1.5 or 2 ml tube   
  transfer aqueous phase to prepared P-6 MicroSpin **   spin 1' @ 13,000 rpm   
  spin 4' @ 1,000 x g (3,500 rpm), recover eluate   transfer column to new 1.5 ml tube   
     add 30 µl RNase-free water onto membrane   
  3. In vitro Transcription (IVT)   spin 1' @ 8,000 x g (9,900 rpm)   
  SSS-resuspension vol [µl] m [µg] OK repeat eluting steps
  transfer eluate to 0.6 ml PCR tube   clean with Microcon YM-30   
  add LPA   5     wash with 450 µl TE   
  add 1/25 vol 5 M NaCl 3.5       wash with 500-50 µl TE§ / blocking mix   
  add 2.5 vol 100% EtOH 220.0       concentrate to ~ 10 µl and "elute"   
  mix well      
  precipitate 30-60' @ -70 °C or 2h - o/n @ -20 °C   * 30'' @ 13,000 rpm   
  spin tube 30' @ 13,000 rpm, remove s/n   ** resuspend, drain by gravity, 2' @ 3,500 rpm   
  wash pellet with 500 µl 70% Et-OH     
  spin tube 5' @ 13,000 rpm, remove s/n   
§ Optionally measure incorporation rate before adding 
mix (use 50 µl of 500 µl TE resuspension)   
  pulse spin, remove s/n completely     
  allow pellet to dry 2-3' @ room temp.   
#All reagents for IVT mix, except enzyme, must be 
used @ room temp.    
  resuspend in 8.5 µl water      
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The first steps of the protocol, reverse transcription, second strand synthesis 
and cleanup of double-stranded DNA, were adapted from Kenzelmann et al. 
(Table 6).125 In short, mRNA from 2 µg total RNA was reverse transcribed using 
a protocol modified from the Direct Labeling procedure, including a primer 
combining the promotor sequence for T7-RNA polymerase with the oligo-
d(T)21VN sequence from above to 5'-GCA-TTA-GCG-GCC-GCG-AAA-TTA-ATA-
CGA-CTC-ACT-ATA-GGG-AGA-(T)21VN-3'.123 The RNA in the resulting DNA-
RNA heteroduplex was slowly digested using low concentrated RNase H 
(Epicentre); thus it could be used to prime the second strand synthesis using 
DNA polymerase I from E. coli (Promega). Joints resulting from different 
polymerized DNA stretches were closed with DNA ligase, also from E. coli 
(Amersham). Afterwards, overhanging ends were filled ("polished") by use of 
T4 DNA polymerase (New England Biolabs). Double-stranded DNA was 
extracted from the reaction mix by use of phenol:chloroform:isoamylalcohol 
(24:25:1, Sigma) and Phase-Lock-Gels (Eppendorf) and subsequently washed 
through P-6 MicroSpin columns (Bio-Rad) buffered with TE according to the 
manufacturer's recommendations. Finally, the DNA was precipitated, using 
Linear Polyacrylamide (LPA, Ambion) as nucleation agent, and resuspended in 
RNase-free water to the appropriate volume. 
The double-stranded DNA, featuring the T7-RNA polymerase promotor 
sequence, was used for in vitro transcription, using the RiboMAX Large Scale 
RNA Production System (T7; Promega), modified from the manufacturer's 
protocol for 40 µl reaction volume and incorporation of Cy-UTPs. The resulting 
aRNA was cleaned using RNeasy mini columns (Qiagen), also modified slightly 
from the manufacturer's protocol to contain one more washing step. Analogous 
to the Direct Labeling procedure, RNA was again washed, blocking mix was 
added and the blend was concentrated using Microcon YM-30 columns. Before 
the addition of blocking mix, 10% of the TE-buffered RNA was withdrawn to 
measure dye-associated nucleotide incorporation rates for both channels. 
Fluorescently labeled and concentrated aRNA was used immediately for 
hybridization. 
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"Baugh Standard" and "Baugh + Klenow" (TAcKLE) Protocols 
 Based on protocols developed by Eberwine et al. and Baugh et al. for linear 
amplification of RNA by in vitro transcription (IVT), a protocol for amplification 
and labeling was developed that is useful in finally yielding antisense 
fluorescently labeled DNA.123,124 To obtain labeled antisense DNA from aRNA, 
their protocols were consequently reduced to a reverse transcription without 
labeled nucleotides, and a different step to transcribe sense DNA into antisense 
DNA was appended that could be used for labeling. For the enzymatic reaction 
step, a DNA-dependent DNA polymerization, the Klenow-fragment of DNA 
polymerase I (BioPrime Kit, Invitrogen) was selected. It had already been proven 
useful for generating fluorescently labeled DNA from fractionated genomic DNA 
in protocols used for Matrix- or Array-CGH.133  To compare the methods, both 
the original protocol, as adopted by Kenzelmann et al. including labeling during 
the 2nd round RT reaction, and the labeling procedure with the Klenow enzyme 
afterwards were performed and evaluated by hybridizing the products onto 
oligonucleotide microarrays. 
 The first two steps, from the first RT reaction to the beginning of the IVT, were 
the same as given in the IVT labeling (see Table 6), since both protocols were 
derived from the same sources. The IVT itself differed, since here there are no 
labeled nucleotides incorporated (Table 7). Therefore, it was only slightly 
modified from the manufacturer's recommendations, with respect to the 
reaction volume. Antisense RNA extraction and cleanup were again similar to 
the IVT labeling protocol, using RNeasy mini columns (Qiagen) as above. 
Afterwards, the aRNA was additionally precipitated, again using LPA as 
nucleation agent, but using ammonium acetate for RNA precipitation instead of 
NaCl for double-stranded DNA. 
For the "Second Round RT" reaction in the "Baugh + Klenow" protocol (later 
termed TAcKLE), a slightly different procedure than for the first RT was 
applied, with respect to its aRNA concentration of 0.25 µg/µl, the use of 
random hexamer primers (N6), SuperScript II reverse transcriptase and the 
reaction temperature profile, as given in Table 8. 
For the labeling with Klenow fragment, the enzyme and random primer 
solutions from the BioPrime Labeling Kit (Invitrogen) were used with a slightly 
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modified protocol from the recommended one, again concerning the scale of the 
reaction. 
 
  
The incubation time of 16 h was used as proposed for Matrix-CGH 
experiments.133 
Since the Klenow enzyme and random octamer primer in the reaction mix 
allowed copying one DNA strand from another regardless of sense or antisense 
orientation, this introduced an approximately 20-fold amplification of copy 
Table 7 Baugh Standard Protocol 
  3. In vitro Transcription (IVT)   apply to RNeasy Mini column   
  SSS-eluate @ RT vol [µl] m [µg] OK spin 15" @ 8,000 x g (9,900 rpm)   
  transfer eluate to 0.6 ml PCR tube   discard flow-through   
  add LPA   5     transfer column to new 2 ml tube   
  add 1/25 vol 5 M NaCl 3.5      wash with 500 µl RPE (contains ethanol)   
  add 2.5 vol 100% EtOH 220.0      spin 15" @ 8,000 x g (9,900 rpm)   
  mix well   discard flow-through   
  precipitate 60' @ -70 °C or 2 h - o/n @ -20 °C   wash with 500 µl RPE (contains ethanol)   
  spin tube 30' @ 13,000 rpm, remove s/n   spin 2' @ 13,000 rpm   
  wash pellet with 500 µl 70% EtOH   discard flow-through   
  spin tube 5' @ 13,000 rpm, remove s/n   wash with 500 µl RPE (contains ethanol)   
  spin tube 2' @ 13,000 rpm, remove s/n completely   spin 2' @ 13,000 rpm   
  allow pellet to dry 2-3' @ 20-40 °C   discard flow-through   
  resuspend in 10 µl water   transfer column to new 1.5 or 2 ml tube   
      spin 1' @ 13,000 rpm   
  Promega IVT# vol [µl] m [µg] OK   transfer column to new 1.5 ml tube   
  RNase free water 6.0       add 30 µl RNase-free water onto membrane   
  5x T7 Transcr. buffer 8.0       spin 1' @ 8,000 x g (9,900 rpm)   
  100 mM ATP 3.0       repeat eluting steps, measure RNA conc. (5 µl)   
  100 mM CTP 3.0         
  100 mM GTP 3.0       
precipitate aRNA with 1 µl LPA, 0.5 vol 7.5 M 
ammonium acetate and 2.5 vol 100% EtOH   
  100 mM UTP 3.0       wash pellet with 500 µl 70% EtOH   
  T7 Enzyme Mix 4.0       resuspend in 10 µl water   
  SSS eluate 10.0          
  Total 40.0       5. Labeling   
    RT mix, on ice! vol [µl] m [µg] OK   
  mix by pipetting and gentle vortexing @ room temp   10x Buffer RT 2.0       
  incubate 6 h @ 37 °C   RNase Inhibitor 1.0       
  mix regularly (every 15-30') by gently flicking   RT dNTP-Mix 0.4       
  (freeze @ -20 °C or proceed)   N6-primer (2 µg/µl) 3.0 6 µg     
      Cy-dUTP (Amersham) 1.5       
  4. aRNA Cleanup   Omniscript RT (Qiagen) 1.5       
  RLT / β-ME - mix vol [µl] m [µg] OK aRNA 10.0 2 - 5 µg   
  β-mercapto-ethanol 3.5       Water ad 20.0       
  RNase-free water 76.5       Total 20.0       
  RLT buffer (Qiagen) 350.0           
  Total 430.0       clean with Microcon YM-30   
      wash with 450 µl TE   
  aliquot into 1.5 ml tube 430.0       wash with 500-50 µl TE§ / blocking mix   
  add IVT product (aRNA) 40.0       concentrate to ~ 10 µl and "elute"   
  mix well      
  add 100% EtOH 250.0         
    
§ Optionally measure incorporation rate before adding 
mix (use 50 µl of 500 µl TE resuspension)   
 
# All reagents for IVT mix, except enzyme, must be 
@ room temp.     
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numbers. But as the random octamers could prime anywhere in the template 
sequences, the resulting DNA strands became shorter with every copy cycle. In 
consequence, the Klenow labeling procedure resulted in both sense and 
antisense strands comprising fluorescent nucleotides, which differ in length. 
The cleanup method, however, excluded DNA strands of 90 nucleotides or less 
as an effect of the pore size of the Microcon YM-30 columns.  
 
Table 8 Baugh + Klenow Protocol (TAcKLE) 
  5. 2nd Round RT   6. Klenow Labeling   
  RNA/primer, 4 °C vol [µl] m [µg] OK Klenow mix, 4°C vol [µl] m [µg] OK
  aRNA 4.0 1     eluted cDNA 10.0 ~ 1     
  N6-primer (0.5 µg/µl) 41.0 0.5     2.5x Random Primer 40.0       
      10x dNTP (low dTTP)# 10.0       
  RT-Mix* vol [µl] m [µg]     Cy-labeled dUTP 3.0       
  1st strand buffer 2.0       water ad 98 µl 35.0       
  100 mM DTT 1.0       mix briefly    
  10 mM dNTP-mix 0.5       Klenow fragment 2.0       
  5-8 mg/ml T4gp32 0.5 2.5 - 4     total 100.0       
  RNase Inhibitor 0.5           
  SuperScript II (200 U/µl) 0.5       mix gently but thoroughly   
  total 5.0       centrifuge 15-30"   
      incubate o/n @ 37 °C (~16 h)   
  denature RNA/primer 5' @ 70 °C   clean with Microcon YM-30   
  snap cool on ice 2'   wash with 450 µl TE   
  hold 5' @ room temp.   wash with 500-25 µl TE§ / blocking mix   
  mix well   concentrate to ~ 10 µl and "elute"   
  incubation:         
  20' @ 37 °C     * RT mix for 2nd Round RT must be @ room temp.!   
  20' @ 42 °C       
  10' @ 50 °C     
§ Optionally measure incorporation rate before adding 
mix (use 25 µl of 500 µl TE resuspension)   
  10' @ 55 °C         
  15' @ 65 °C     #10x dNTP (low dTTP) Final conc. Stock conc. µl   
  hold at 37 °C     dTTP 0.5 mM 100 mM 5   
  add 1U RNase H     ATP 2.0 mM 100 mM 20   
  30' @ 37 °C     CTP 2.0 mM 100 mM 20   
  2' @ 95 °C     GTP 2.0 mM 100 mM 20   
  4 °C forever     TE buffer (pH 8.0) ad 1000 µl 935   
                      
 
Primer-Assisted Linear DNA Amplification (PALDA) 
In addition to the abovementioned protocols of IVT-based amplification, 
protocols based on PCR amplification were also tested. As the standard 
protocol of PCR uses two primers, one at each end of the sequence in question, 
each DNA strand is doubled in copy number per cycle. Consequently, the 
amplification occurs exponentially. However, since the mRNA sequences differ 
in length from a few hundred to a few thousand bases, there is in theory a bias 
introduced by an exponential PCR amplification: the length of each cycle 
determines how many nucleotides can be polymerized in the given time. With 
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two primers, only a full length sequence will be amplified in all following cycles. 
Consequently, long sequences have a lower probability to be amplified for the 
full set of cycles as shorter sequences. 
 
 
 Table 9 PALDA Protocols (Taq versus Pfu exo-)  
  3. PCR Labeling Taq Polymerase    3. PCR Labeling Pfu Polymerase   
  SSS-eluate @ RT vol m [µg] OK SSS-eluate @ RT vol m [µg] OK
  transfer eluate to 0.6 ml PCR tube      transfer eluate to 0.6 ml PCR tube     
  add LPA   5      add LPA   5     
  add vol 5 M NaCl 3.5        add 5 M NaCl 3.5       
  add vol 100% EtOH 220.0        add 100% EtOH 220.0       
  mix well    mix well   
  precipitate 60' @ -70 °C or 2h - o/n @ -20 °C    precipitate 60' @ -70 °C or 2h - o/n @ -20 °C   
  spin tube 30' @ 13,000 rpm, remove s/n    spin tube 30' @ 13,000 rpm, remove s/n   
  wash pellet with 500 µl 70% EtOH    wash pellet with 500 µl 70% Et-OH   
  spin tube 5' @ 13,000 rpm, remove s/n    spin tube 5' @ 13,000 rpm, remove s/n   
  spin tube 2' @ 13,000 rpm, remove s/n completely    spin tube 2' @ 13,000 rpm, remove s/n completely   
  allow pellet to dry 2-3' @ 20-40 °C    allow pellet to dry 2-3' @ 20-40 °C   
  resuspend in 10 µl water    resuspend in 10 µl water   
           
  PCR mix, on ice! vol Conc. OK    PCR mix, on ice! vol Conc. OK   
  10x PCR buffer 5.00        10x PCR buffer 5.00       
  25 mM MgCl2 3.00        25 mM MgCl2 3.00       
  10 mM dATP 1.00        10 mM dATP 1.00       
  10 mM dCTP 1.00        10 mM dCTP 1.00       
  10 mM dGTP 1.00        10 mM dGTP 1.00       
  10 mM dTTP 0.88        10 mM dTTP 0.88       
  1 mM Cy-dUTP 1.25        1 mM Cy-dUTP 1.25       
  BSA (10 µg/µl) 0.50 0.1 µg/µl      BSA (10 µg/µl) 0.50 0.1 µg/µl     
  T7 PCR primer [100 µM] 25.00 50 µM      T7 PCR primer [100 µM] 25.00 50 µM     
  2nd strand cDNA 10.00       2nd strand cDNA 10.00       
  Taq Pol [5 U/µl] 1.00 0.02 U/µl      Pfu Pol exo- [2.5 U/µl] 1.00 0.01 U/µl     
  water 0.38        water 0.38       
  total 50.00        total 50.00       
           
  initital denaturing: 1' @ 95 °C      initital denaturing: 1' @ 95 °C     
  2x 50 cycles of:      2x 50 cycles of:     
  25" @ 95 °C (denature)      45" @ 95 °C (denature)     
  45" @ 65 °C (anneal)      45" @ 65 °C (anneal)     
  60" @ 72 °C (elongate)      120" @ 72 °C (elongate)     
  final elongation: 5' @ 72 °C      final elongation: 10' @ 72 °C     
  4 °C forever      4 °C forever     
  after first 50 cycles:      after first 50 cycles:     
  (take 1 µl, measure DNA content)      (take 1 µl, measure DNA content)     
  add 1µl Taq Pol [5 U/µl]      add 1µl Pfu Pol exo- [2.5 U/µl]     
  run 2nd time 50 cycles      run 2nd time 50 cycles     
           
  clean with Microcon YM-30    clean with Microcon YM-30   
  wash with 450 µl TE    wash with 450 µl TE   
  wash with 500-50 µl TE§ / blocking mix    wash with 500-50 µl TE§ / blocking mix   
  concentrate to ~ 10 µl and "elute"    concentrate to ~ 10 µl and "elute"   
              
  § Optionally measure incorporation rate before adding mix (use 50 µl of 500 µl TE resuspension)   
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To circumvent this restraint, a similar reaction which comprises only one 
primer was used, excluding the limiting factor of transcript length and thereby 
ensuring that the amplification occurs linearly. Analogous to the IVT labeling, 
the procedure was set up to incorporate the nucleotides during the 
polymerization reaction. 
Reverse transcription and second strand synthesis as well as extraction of the 
double-stranded DNA were performed as described before. Then, a PCR-like 
reaction with a single primer, containing a part of the T7 promotor sequence 
(5'-GCG-GCC-GCG-AAA-TTA-ATA-CGA-CTC-ACT-ATA-GGG-3'), was performed. 
PCR conditions were optimized for this primer. As the Taq DNA polymerase 
(from Thermus aquaticus, Amersham) has a limited tolerance for the bulky dye-
associated nucleotides, single primer PCR reactions were performed for 2 x 50 
cycles and the Taq DNA polymerase was renewed after the first 50 cycles. The 
general feasibility of incorporation of fluorescently labeled nucleotides during 
the PCR reaction had been assured by the manufacturer. In addition, the same 
protocol was also tested with another thermally stable polymerase, Pfu exo- 
(from Pyrococcus furiosus, Stratagene), which had been modified by the 
manufacturer for elimination of exonuclease activity. This modification was 
similar to a modification that the M-MLV reverse transcriptase had been 
subjected to in order to allow for incorporation of bulky nucleotide 
modifications. The washing and blocking steps were performed as described 
above. 
 
Single Primer Amplification (SPA) 
Another protocol based on amplification with Taq DNA polymerase was tested, 
which had been published just before the comparison was started.128 To be 
able to compare this published protocol with the ones introduced here, the 
reactions were modified to be used with the same enzymes and reagents 
already made use of (Table 10). In brief, mRNA from total RNA was reverse 
transcribed using oligo-d(T) - T7 primer and cDNA was complemented to 
double-stranded DNA as described before. A single primer PCR was performed 
as above, but using only unlabeled dNTPs (10 mM nucleotide mix). Amplified 
antisense DNA was then labeled using the Klenow fragment as described.  
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Table 10 SPA Protocol, using Taq Polymerase  
  3. SPA   PCR-eluate vol [µl] m [µg] OK   
  SSS-eluate @ RT vol [µl] m [µg] OK transfer eluate to 0.6 ml PCR tube 
  transfer eluate to 0.6 ml PCR tube     add LPA   5     
  add LPA   5     add 1/25 vol 5 M NaCl 3.5       
  add 1/25 vol 5 M NaCl 3.5       add 2.5 vol 100% EtOH 220.0       
  add 2.5 vol 100% EtOH 220.0       mix well   
  mix well   precipitate 60' @ -70 °C or 2h - o/n @ -20 °C   
  precipitate 60' @ -70 °C or 2 h - o/n @ -20 °C   spin tube 30' @ 13,000 rpm, remove s/n   
  spin tube 30' @ 13,000 rpm, remove s/n   wash pellet with 500 µl 70% Et-OH   
  wash pellet with 500 µl 70% Et-OH   spin tube 5' @ 13,000 rpm, remove s/n   
  spin tube 5' @ 13,000 rpm, remove s/n   spin tube 2' @ 13,000 rpm, remove s/n completely   
  spin tube 2' @ 13,000 rpm, remove s/n completely   allow pellet to dry 2-3' @ 20-40 °C   
  allow pellet to dry 2-3' @ 20-40 °C   resuspend in 10 µl water   
  resuspend in 10 µl water       
      4. Klenow Labeling   
  PCR mix, on ice! vol [µl] Conc. OK Klenow mix, on ice! vol [µl] m [µg] OK
  10x PCR buffer 10.0       eluted cDNA 10.0 1 µg     
  10 mM dNTP 2.0       2.5x Random Primer 40.0       
  BSA (10 µg/µl) 1.0 0.1 µg/µl     10x dNTP (low dTTP) 10.0       
  T7 PCR primer [100 µM] 2.0 2 µM     Cy-dUTP 3.0       
  2nd strand cDNA 5.0 0.01 µg/µl     water ad 98 µl 35.0       
  Taq DNA Pol. [5 U/µl] 4.0 0.2 U/µl     mix briefly     
  water 76.0       add Klenow fragment 2.0       
  total 100.0       total 100.0       
          
  initital denaturing: 3' @ 94 °C     mix gently but thoroughly     
  50 cycles of:     centrifuge 15-30"     
  1' @ 94 °C (denature)     incubate o/n @ 37 °C (~16 h)     
  1' @ 62 °C (anneal)     clean with Microcon YM-30     
  2' @ 72 °C (elongate)     wash with 450 µl TE     
  final elongation: 5' @ 72 °C     wash with 500-25 µl TE§ / blocking mix     
  4 °C forever     concentrate to ~ 10 µl and "elute"     
            
  clean with Microcon YM-30       
  wash with 450 µl TE     
§ Optionally measure incorporation rate before adding 
mix (use 25 µl of 500 µl TE resuspension)   
  wash with 450 µl TE           
  concentrate to ~ 50 µl and "elute"           
      
 
As this published protocol was originally created and optimized for microarrays 
generated from PCR-amplified cDNA libraries, strand specificity had not been a 
consideration of the authors. The primary product of the labeling step here, 
using Klenow fragment and the antisense SPA product as a template, was 
sense DNA. As described, antisense DNA was expected to be generated by 
Klenow fragment reactions with the labeled sense product as a new template. 
Therefore, it was tested whether this protocol produced enough labeled 
antisense DNA to be hybridized against the sense-orientated DNA on the 
microarrays, and whether the signal was sufficient despite the additionally 
created labeled sense DNA. 
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Template-Switch Single Primer Amplification (ts-SPA) 
A special feature of the M-MLV reverse transcriptase as used in the initial step 
of all protocols described here is the terminal addition of a few nucleotides to 
the cDNA transcript, mostly three cytosines. Though this represents only a 
short template, it had been shown to be sufficient for priming a 3'-extension of 
the first strand cDNA.127  
This effect had been used for switching the template from sense (second) to 
antisense (first) strand of the double-stranded DNA.129 Therefore, the single 
primer PCR could be used to amplify DNA using the elongated first strand as 
template, yielding multiple copies of the sense strand. These could then be 
replicated again, using the Klenow fragment, into labeled antisense DNA. 
The only difference in the ts-SPA reactions to ones described for SPA was the 
addition of a TS primer to the oligo-d(T) - T7 primer, during the RT reaction (TS 
primer sequence: 5'-CG-GCC-AGT-GAA-TTG-TAA-TAC-GAC-TCA-CTA-TAG-
GCG-3']. The TS primer then remained present during the second strand 
synthesis; consequently the first strand could be extended in the course of the 
reaction. For the single-primer amplification PCR, the same TS primer was 
used again to create the sense DNA. Klenow labeling reaction was performed as 
described before.  
 
PCR 
To have a benchmark for analysis using abovementioned different PCR 
amplification variants, a normal or standard PCR amplification with two 
primers and fluorescently labeled nucleotides was also performed. Since these 
bulky nucleotide derivatives were known to have a low incorporation rate, the 
protocol was modified according to the above described PALDA protocols. In 
brief, the number of cycles was also increased to 100 with intermediate 
refreshment of Taq DNA polymerase after 50 cycles, but the usage of the 
modified dCTP nucleotide derivatives instead of dUTP. The primers used for the 
reverse transcription using SuperScript II were oligo-d(T)21VN primer and the 
TS-primer (see above). Subsequently, cDNA was cleaned using Microcons 
columns as described before. Then the PCR reaction was performed on 1 µg 
cDNA with internal primers, to suppress amplifying false products, and in 
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presence of fluorescently labeled dCTP nucleotides. Amplified and labeled DNA 
was again cleaned up with Microcon columns as described. 
 
Blocking Mix 
The products of all abovementioned protocols were hybridized to microarrays in 
presence of a mix consisting of Cot-1 DNA (Roche), tRNA and poly(A)-RNA (both 
Sigma-Aldrich). These nucleotide sequences were used to inhibit binding of free 
repetitive RNA sequences or non-messenger RNA molecules, mostly in an 
unspecific manner, to probes on the microarray. Although this procedure is not 
necessary in each of the above introduced protocols, it was nevertheless 
performed in all of them for comparative reasons. 
 
Table 11 Blocking Mix  
  Blocking Mix vol [µl] m [µg] OK   
  Cot-1 DNA (1 µg/µl) 25.0 25     
  Poly(A) RNA (5 µg/µl) 5.0 25     
  tRNA (10 µg/µl) 7.5 75     
  total 37.5       
            
 
 
3.2.3. Analysis of Comparative Amplifications 
DNA and RNA Purity 
Nucleic acid purity and concentration were measured to ensure the optimum 
prerequisites for a successful hybridization event. This was performed during 
the last washing step at the end of each protocol, before the blocking mix was 
added and the volume was reduced on the Microcon columns. A small volume 
(5-10%) was taken and measured on the UV-spectrometer Cary 50 Bio (Varian 
Inc.), taking the absorption value at the peak of 260 nm (A260) for DNA or RNA 
content and applying multiplication factors (37 µg/ml, single stranded DNA; 
40 µg/ml, single stranded RNA) to estimate the nucleic acid concentration. 
Calculating the ratio of A260 over A280 was used for purity measurements, 
anticipating values for DNA of 1.8 to 2.0 and for RNA of 1.9 to 2.1 for good 
results. 
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Incorporation Rates of the Fluorescently Labeled Nucleotides 
The performance of each of the amplifying and labeling methods tested was 
evaluated by measuring and calculating the incorporation rate of labeled 
nucleotides. This was carried out together with the DNA or RNA concentration 
and purity estimations on the UV-spectrometer.  
Incorporation of fluorescently labeled nucleotides was estimated from the 
characteristic absorption maxima for Cy3 and Cy5 dyes, at 550 nm and 
650 nm, respectively. These peak values were set into relation with the nucleic 
acid concentration to determine the incorporation rate. The rates for each 
channel were compared with each other, to identify imbalances in the tolerance 
of the different enzymatic approaches to the two types of bulky nucleotides. To 
estimate the incorporation yield of the corresponding reaction of each labeling 
procedure, an approximation to the average incorporation efficiency, given as 
 
 A dye ε Nucl. Acid 
 r I =  x [1] 
 A 260 ε dye 
 
was used. Here, r I is the incorporation ratio, A is the absorbance at a specific 
wavelength in nm (550 nm for Cy3 dye and 650 nm for Cy5 dye, respectively),  
and ε is the extinction coefficient in cm-1M-1 at the absorption maximum for 
either nucleic acid or the respective dyes. Values for DNA (ε = 10,162.5 cm-1M-1) 
and RNA (ε = 10,418.75 cm-1M-1) were estimated from averages per nucleotide 
of measured and published values for any possible dinucleotide.134 Values for 
the two dyes Cy3 (ε = 150,000 cm-1M-1) and Cy5 (ε = 250,000 cm-1M-1) were 
provided by the manufacturer. The r I was additionally multiplied with 1,000 to 
calculate the average number of incorporated fluorescently labeled nucleotides 
per 1,000 nucleotides. 
 
Outlier Features 
After scanning the microarray images, the grid was placed in GenePix Pro 
Software onto the image and feature alignment as well as detection of false 
positive spots, which were flagged as outliers, were performed as described. 
Only features of good quality were used for further analyses, and the rate of 
outlier features was considered as a quality estimate. 
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Spot Homogeneity 
Each feature spot consists of some 50 to 500 pixels, which are taken as 
foreground measurement. To receive a single intensity value for the feature, 
either the median or mean of the intensities of these pixels can be used. To see 
whether the intensity distribution within the spot of a feature is homogenous, 
the ratio of mean over median was taken. Ideally, this ratio should have the 
value of one for a homogenous spot. A deviation of up to 0.2 below or 0.25 
above this quotient was considered acceptable, features with a mean to median 
ratio outside the interval were considered inhomogeneous. 
 
Feature and Background Signal Comparison 
A general assessment of the amplification and hybridization success was 
achieved when comparing the median signal intensities of features versus each 
feature's local background (the surrounding area of the DNA spot). These were 
set into relation to each other and averaged across all features of each chip to 
estimate a compatible value for the different protocols. 
 
Scatter Plots 
Scatter plots represent the intensities of the features in one dye channel versus 
the other. For this scheme, median intensity values from the raw data tables 
for each feature were plotted on a two-dimensional scale, each feature being 
represented by its corresponding logarithmic values for Cy3 and Cy5 intensity. 
To integrate dye-swap experiments, the ratios between the two channel values 
were taken for each DNA spot and transformed by natural logarithm. These 
ratios were then plotted against each other for both experiments. 
This method allowed for a more elaborate examination of the distribution for 
the following reasons: A bias, e.g. towards smaller intensities or loss of 
dynamic range, could be detected much better when looking at the 
corresponding plots as compared to looking at the images themselves or an 
average of signal to background. In this respect, the different amplification and 
labeling procedures were much easier to compare on the basis of their scatter 
plots. In addition, differential and same-versus-same hybridization results 
could be compared with each other to identify effects derived from the 
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amplification procedure but independent from the distribution of the different 
mRNA copy numbers between the two cell lines. 
 
Linear Trend of Intensity Scatter Plots 
Taking the median feature intensity values from the raw data table for each 
channel, the differences between procedures to amplify and label were also 
accountable for in measurable parameters. The distribution of these 
intensities, as seen on the scatter plots, was described by calculating the slope 
and intercept of the trend line derived from the feature intensity spots 
scattered on the plot. A deviation of the slope from the value one, which 
represents the bisecting line of the plot, could be explained by different input 
amounts. The intercept or offset on the ordinate, however, expresses a bias 
towards one of the channels, e.g. by incorporation incompatibilities of the dyes.  
 
Correlation of Gene Expression Patterns 
To account for similarity between the distributions of intensities across all 
features of a chip for both channels, the Pearson's coefficient was estimated. 
On a scale from -1 to 1, it provided an assessment of similarity between two 
data sets, or matrices representing them, independent of the slope of the trend 
line of their distribution. The grades of similarity between same-versus-same 
hybridization intensities or between repeat experiments, such as the dye-
swaps, were of particular interest in this comparison. In the case of repeat 
experiments, this value signified the reproducibility of the amplification 
procedure.  
 
The calculations described in this chapter were performed with the statistical 
software "R" [www.r-project.org], a script-based programming environment.135  
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3.3. Gene Expression Signature Predictive for Chemotherapy in Primary Breast 
Cancer  
This study was conducted to investigate whether a gene expression signature 
could be identified in tissue specimens taken from primary breast tumors of 
patients that allows for predicting the patient's outcome, or response, to a 
chemotherapy applied after taking the specimen. 
To generate this gene expression signature, the principles of the techniques 
described above were applied, extracting the RNA from the tumor samples, 
amplifying the mRNA with the chosen procedure (see chapter 4.1), labeling 
them with fluorescent dyes in the process, and hybridizing them to microarrays 
generated from the Human Oligo Set 2.0 or 2.1.1. 
 
3.3.1. Patients and Chemotherapy Protocol 
The primary breast cancer specimen used here were provided by the 
Department of Gynecology and Obstetrics of the University Hospital Heidelberg 
(Universitäts-Frauenklinik) from female patients (n=148) who participated in 
two similar studies evaluating new chemotherapy protocols, combining 
gemcitabine, epirubicin and docetaxel as anti-cancerous agents. Patients were 
recruited with their voluntary commitment, if they had no prior chemotherapy 
treatment, their tumor had a diameter of at least 2 cm, they had a maximum of 
nine metastatic local (internal) or axillary lymph nodes and no distal 
metastases (WHO classification: T2-4 N0-2 M0), among other criteria. 
The evaluation of the chemotherapy protocols concerned the treatment dosages 
and schedule. In the course of this assessment, these parameters were 
modified, resulting in two different cohorts, treated with either the "GEDoc" or 
"GEsDoc" protocols (Figure 8). The major difference between the two schedules 
was comprised of the sequential application of docetaxel. 
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Figure 8 
 
Patients enrolled in clinical study evaluating GEDoc or GEsDoc chemotherapies. Patients participated in one of 
either studies of neoadjuvant chemotherapy protocols administering gemcitabine, epirubicine and docetaxel in the 
Clinic for Gynecology and Obstetrics, University of Heidelberg. After therapy, surgery of the residual tumor was 
performed and the response to chemotherapy was estimated by pathology (pCR, pathological complete remission; pPR, 
pathological partial remission; pNC, pathological no change). Modified after A. Schneeweiß, University of Heidelberg. 
 
 
3.3.2. Tumor Samples and Reference 
Tumors were sampled by taking core cut biopsies with a 14-gauge needle 
under surveillance of sonographic life-imaging. Up to five of these biopsies, 
each yielding a tissue sample with a maximal size of 20 × 2 × 2 mm, were taken 
from each tumor at the time of diagnosis, before chemotherapy treatment of 
the patient. One or two of these samples per patient were available for gene 
expression measurements with the microarray technique. These tissue samples 
were locked in cryo tubes and shock frozen in liquid nitrogen (-196 °C) within 
10’ after being taken from the tumor and were kept at -80 °C until processing. 
The total number of investigated tumor samples was 174, taken from 148 
patients. 
 
Extraction of RNA 
Deep frozen tumor tissue samples were cooled in liquid nitrogen to -196 °C and 
quickly transferred from the cryo tubes to polytetrafluoroethylene (PTFE or 
Teflon®) containers (NeoLab) suitable for ball milling, which had been pre-
cooled in liquid nitrogen as well. The containers containing the tissue sample 
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were then equipped with the appropriatly pre-cooled tungsten balls (5 mm 
caliber, NeoLab), locked and again cooled in liquid nitrogen to ensure that the 
sample remained deeply frozen. Then the sample was milled in the container 
with a dismembrator (B.Braun) at 3,000 rpm for 10", if necessary for several 
times with intermediate cooling of sample, ball and container in liquid nitrogen, 
until the tissue sample was completely ground to powder. After another cooling 
cycle, the tissue powder was collected into a 15 ml-Falcon tube which had been 
prepared to contain 5 ml of TRIzol solution at 4 °C. The mix was vigorously 
shaken and left for 5' to equilibrate at room temperature. Then, 1 ml of 
chloroform was added and the suspension was again vigorously shaken and 
mixed on a vortex. Centrifugation and obtaining of the aqueous phase 
containing the RNA was carried out as described before (Chapter 3.2.1). After 
mixing of the aqueous phase 1:2 with ethanol (p.A.), it was applied to RNeasy 
mini columns (Qiagen) and centrifuged at room temperature for 4' at 8,000 rpm 
(6,000 × g) in a bench-top Biofuge fresco (Kendro). The columns were washed 
as recommended by the manufacturer with the buffers provided, and the RNA 
was eluted twice with 30 µl RNase-free water. After taking 5 µl of the elution for 
RNA yield and quality assessments, the remaining total RNA dilution was 
stored at -80 °C until used for amplification and labeling. The yield and purity 
were measured in 1:25 dilution of the RNA (3 µl in 75 µl total volume) as 
described on the UV-spectrometer and the quality was assessed by application 
of the "Lab-on-a-chip" system (Agilent) as described before (Chapter 3.2.1). 
 
Reference RNA 
For clinical and ethical reasons, only a restricted amount of non-cancerous 
tissue of the mammary was available and could not be used as source for 
reference RNA. The RNA chosen was Human Universal Reference RNA 
(Stratagene), consisting of total RNA from a mixture of ten cell lines of different 
cancer origin. Since expression levels of different tumor classes between each 
other were compared here, namely those from patients with complete remission 
versus those with partial remission or no change, the origin of the reference 
RNA could be neglected. 
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3.3.3. Amplification of mRNA from Samples and Reference RNA 
The Baugh + Klenow protocol, also named TAcKLE (see chapters 3.2, 4.1 and 
5.1) was chosen for amplification and labeling of the tumor mRNA. To avoid 
introducing a bias between RNA extracted from the tumor specimens and the 
reference RNA, the latter was also amplified using this procedure. Since tumor 
samples were recruited consecutively, reference RNA was amplified in bulk and 
the c*DNA was pooled before labeling the aliquots as needed. 
The RNA extracted from tumor samples was precipitated using LPA, 
ammonium acetate and ethanol as before for aRNA cleanup during the TAcKLE 
procedure, and suspended to a concentration 0.5 µg/µl. Such prepared RNA 
was amplified in two different aliquots with a maximum of 2 µg total RNA input 
each, and the sense-orientated c*DNA was copied, including labeling using 
Cy3- and Cy5-modified dUTPs, respectively, to perform color switch repeat 
experiments. Each labeled tumor sample was then mixed with adversely 
labeled reference RNA sample, washed on Microcon columns and 
complemented with blocking mix containing 25 µg Cot-1 DNA (Roche), 25 µg 
poly(A) RNA and 75 µg tRNA (both Sigma-Aldrich). These combined sample-
reference mixes, ready for hybridization, were stored at -20 °C for a maximum 
time of two weeks, if they were not applied to the microarrays on the same day. 
 
3.3.4. Hybridization to Microarrays and Data Pre-Processing 
Labeled tumor and reference sample mixes were hybridized to the 
oligonucleotide microarrays generated on the HybStation as described. The 
hybridized microarray slides were scanned using the Axon 4000B scanner at 
5 µm resolution with adaptation of the optimal settings for the PMT voltages to 
correct for different incorporation rates and bleaching characteristics of the 
different Cy-dyes attached to the dUTP nucleotides.  
Raw data tables were generated by imposing the appropriate grid on the 
microarray images, inspecting and flagging degenerated resulting spots and 
saving the data set to the computer. Since all tumor RNA samples had been 
amplified and labeled with both Cy3- and Cy5-modified nucleotides, the entire 
data set for each patient contained two of these raw data tables. Together with 
the clinical data relevant for analysis of the gene expression signatures, these 
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raw data were uploaded into a database (ChipYard), developed and maintained 
by Grischa Tödt from the Division of Molecular Genetics.  
 
3.3.5. Data Analysis 
The pre-processing and data analysis described in this chapter were performed 
in collaboration with Grischa Tödt from the Division Molecular Genetics. 
In a first step, the raw data tables from the microarrays were inspected for 
aspects of quality concerning the hybridization experiment, the amplification 
and the integrity of the underlying RNA input. These quality assessments were 
achieved by (i) plotting the median intensity values for both channels in scatter 
plots, (ii) box plots showing average, upper and lower 25% percentiles for each 
microarray and channel, (iii) screening of the averages for red and green 
intensities per spot versus their log ratio (M/A plots) and (iv) plotting the 
distribution of the spot background intensities according to spot localization. In 
the course of this quality examination, repeat hybridizations with switched dye 
assignments were compared with each other for estimating reproducibility. 
Based on these analyses, experiments showing low quality of RNA, improper 
amplification or hybridization results were identified and excluded from further 
processing and analysis. Data sets for patients with excess RNA, whose low 
quality outcome could not be explained by low RNA quality as evaluated with 
the BioAnalyzer, where highlighted. If possible, for these both dye swap 
experiments were repeated from the beginning of the amplification procedure, 
even if only one of the experiments showed low quality in the assessment of the 
raw data. This guaranteed prevention from a bias introduced by different 
experiments within dye-swap pairs. 
 
Individual spots were scored for homogeneity by calculating mean over median 
of the raw intensity values, and for dynamic range (signal-to-background 
intensity ratio) by calculating corresponding median fore- over background 
intensity ratios. As a third component, the standard deviation of intensity 
ratios (before normalization) between replicate spots within one microarray was 
also calculated. The scores of these three feature quality measurements were 
combined by multiplication, features were ranked and the lower 30% of them 
were eliminated.  
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After choosing the data sets for experiments with sufficient reliability, the 
values for median spot intensities were normalized to balance out the different 
dynamic ranges between individual microarrays. For this purpose, the variance 
stabilizing normalization (vsn) method was applied.136 In the course of this 
calibration, the median intensities (x) were transformed by 
 
 h (x) = arsinh (a + bx) [2] 
 
The parameters a and b describe the onset and magnitude of contraction of 
small intensities (near the detection limit) towards zero in comparison with the 
logarithmic conversion and are estimated iteratively by the vsn function. Large 
intensities, on the other hand, are affected by this contraction to a much lesser 
extent and therefore coincide with a natural logarithmic transformation. For 
this reason, the variance stabilizing normalized values h could be used for 
building ratios between intensities in the same manner as logarithmically 
transformed values, meaning that while 
 
 logn (xi,red / xi,green) = logn (xi,red) - logn (xi,green) [3], 
 
the logarithm was in this case substituted with the vsn transformation h (x) to 
 
 logn (xi,red / xi,green) ≈ h (xi,red) - h (xi,green) [4]. 
 
This derivation of the logarithmic transformation, however, required caution 
when considering ratios resulting from low intensity values. 
After normalization, repeat spots within one microarray and corresponding 
values for color-switch repeat experiments were averaged. If, according to the 
filtering that had been performed before, individual features had been removed 
from one array, the matching dye swap partner had to be eliminated as well. 
 59
3.3.6. Identification of the Gene Expression Signature 
The data analysis described in this chapter was performed in collaboration 
with Grischa Tödt from the Division Molecular Genetics and Dr. Patrick Warnat 
from the Division Theoretical Bioinformatics. 
To detect the most relevant genes to distinguish between patients with a 
complete response to chemotherapy (pCR) and patients with a partial response 
or no change in tumor growth (pPR or pNC, respectively), the genes had to be 
ranked according to their predictive power. The ranking of genes was 
performed in the process of learning to classify the patients by usage of the 
Support Vector Machines (SVM) algorithm on the training subset (GEsDoc 
patients) with five times repeated five-fold cross-validation.137 Afterwards, the 
most predictive genes were chosen and the predictive power of the set of genes 
was estimated. To test independently whether the prediction based on the 
ranked genes is accurate, the expression data were divided into two sets, one to 
identify the predictive gene subset (training set), and the other data set to test 
the predictive power (test set).  
To minimize the number of genes, the Recursive Feature Elimination (RFE) 
algorithm was applied.138 The RFE approach recursively reduces the number of 
genes used in the predictor function by removal of those genes with lowest 
weights and re-fitting of the SVM algorithm using the remaining genes. In the 
first step, the number of genes used is reduced to the highest power of two that 
is smaller than the total number of genes. In each following step of the RFE 
procedure, half of the genes are eliminated from the predictor model until only 
one gene is left. The minimal number of used genes with a predictive value of at 
least 0.8, which was set as a threshold, was the constraint of this selection. 
Finally, the RFE approach was applied once on the training set to generate a 
final predictive model with the optimal number of genes as determined in 
cross-validation. Microarray data for patients receiving GEDoc therapy (48 
patients) were used as a test set for independent validation of this gene 
expression based predictor of pCR. The final predictive model generated a 
predictor score for every patient in the test set. Sensitivity and specificity, 
resulting from different cut-off values, were visualized by a Receiver Operating 
Characteristic (ROC) graph. A ROC graph shows how sensitivity and specificity 
vary together as the cut-off value (that determines the class prediction for a 
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given sample) on the output of a prediction function for a given test set of 
samples is varied between the extremes of the prediction function output. The 
cut-off value yielding a maximal Youden's Index (sensitivity + specificity - 1) 
was used to determine the binary classification of the test set into pCR and 
non-pCR cases. 
 
 
3.4. Real-time Quantitative PCR 
To validate the results from the microarray data for gene expression, a real-
time quantitative PCR (RQ-PCR) was performed on reverse transcribed mRNA 
from all patients with sufficient RNA after performing the microarray analysis, 
for selected genes. The selection was comprised of genes belonging to the 
signature predicting the patient's outcome, plus two genes (ESR1, HER2) which 
belong to markers classically used in immuno-histochemical pathology and 
another two genes (DCTN2, GALNAC4S-6ST) which were used as reference 
genes. The references were chosen from the genes on the microarray by 
analyzing the results of these for minimal differential expression between the 
two patient groups (responder versus non-reponders), minimal standard 
deviation across patients within these groups, and functional ontology in the 
sense of metabolic and/or structural activity within living cells. This was 
necessary to ensure that the results were unbiased for tumor cell activity, since 
these standard genes were used to normalize between individual patients and 
across all genes of interest (target genes). 
 
3.4.1. Reverse Transcription 
The Reverse Transcription (RT) reaction to create cDNA, and the following 
RQ-PCR reaction mix to measure the content of each specific gene transcript 
were carried out as given in Table 12. For estimation of amplification efficiency, 
the cDNA generated from of Universal Reference RNA (Stratagene) was diluted 
in seven serial 1:4 dilution steps, starting with cDNA corresponding to 512 ng 
total RNA. 
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 Table 12 RQ-PCR Protocol  
Reverse Transcription for RQ-PCR 
RNA/primer mix amount [ng] vol [µl] OK 
d(T)21VN primer, 1 µg/µl 300 0.30   
total RNA, 2 µg/µl 3,000 1.50   
dNTP, 10 mM   0.60   
ddH2O   5.40   
mix, 5' @ 65 °C, snap cool on ice, spin down   
add 5x 1st strand buffer   2.40   
add DTT, 0.1 mM   1.20   
mix and incubate 2' @ 42 °C   
add SuperScript II, 200 U/µl   0.60   
total volume: 12.00   
incubate 50' @ 42 °C   
incubate 15' @ 70 °C   
dilute by 1:1.25 to 0.01 µg/µl cDNA (≈ 5% of total RNA), 
add 3 µl H2O 
  
RQ-PCR 
2x SYBR Mix (Thermo Scientific) 10.00   
upper primer, 5 mM   0.20   
lower primer, 5 mM   0.20   
template cDNA, 0.01 µg/µl 32 3.20   
ddH2O   6.40   
  
total volume: 20.00   
 
  
 
 
3.4.2. Primer Design 
For each of the measured genes, at least two primer pairs were designed. For 
exclusion of quantitative bias resulting from amplification of genomic DNA 
during the PCR reaction, the two primers of each pair were located within 
different exons of the gene with the largest possible intron, or more than one 
intron embedded between them, to create a minimum genomic distance of 2kb. 
The maximal distance on the mature mRNA between the two primers, however, 
was limited to a size of 100 to 400 bases, so the amplicon could be optimally 
duplicated during each round of PCR, as given by the distinct elongation time. 
To ensure a uniform annealing performance, all primers were designed to have 
a Tm of 60 °C, and the resulting amplicon was required to have a minimum Tm 
of 78 °C (both estimated with standard PCR conditions of 50 mM Na+ and 250 
pM primer concentration). 
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Each primer pair was tested for optimal results with templates of 25, 50 and 
100 ng of total RNA from the reference RNA to estimate correct efficiency, 50 ng 
of genomic DNA to exclude amplification of genomic templates and "no 
template control" to exclude primer dimerization products. Primer pairs with 
efficiency outside 1.7 to 2.05 or products with a crossing point (CP) larger than 
40 cycles were neglected, and a new primer pair was generated for the 
respective gene. Primer pairs were also neglected if their product's melting 
curve, as measured with the RQ-PCR thermocycler by fluorescence, did not 
match with the estimated melting temperature characteristics. For resulting 
primer sequences, see Appendix C. 
 
3.4.3. RQ-PCR Measurements and Analysis 
Measurements of real-time quantitative PCR were performed on an ABI PRISM 
7700 Sequence Detection System (Applied Biosystems) in triplicates; using 
10 µl of 2x SYBR Mix (Thermo Scientific), cDNA derived from 32 ng of total RNA 
and a concentration of 50 nM of each primer in a total volume of 20 µl per well 
(Table 12). Only one 384-well plate per gene was used, and all control RNA 
dilutions and samples were measured on the same plate to eliminate plate-to-
plate variance bias within genes. 
 
Analysis was performed using algorithms based on the efficiency of the PCR 
reaction for each tested gene. This efficiency estimation [5] uses the slope of the 
CP values versus the logarithmic input for the dilution series of the reversely 
transcribed control RNA.139 
 
 Ε = 10 [–1/slope] [5] 
 
The difference of expression levels of each gene in question (target genes) 
between cDNA from the control RNA and sample RNA were then normalized to 
the differences between controls and samples for the reference genes [6], 
resulting in a normalized ratio of expression in samples versus control. 
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      [6] 
 
These normalized expression ratios for each gene of interest (target gene) 
against the two different reference genes were averaged to further lower any 
bias produced by different expression levels of these reference genes. This 
average was used as the final expression ratio and compared between the 
groups of patients either completely responding to the chemotherapy (pCR) or 
not completely responding (pPR and pNC combined) to validate the microarray 
expression data. 
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3.5. Antibody Generation 
To create a monoclonal antibody, it was necessary to produce recombinant 
protein of interest and isolate it to a very high grade. This was performed for 
the BAMBI protein, a TGF-β receptor - like protein residing in the plasma 
membrane of certain epithelial cells. Due to its nature as a plasma membrane 
protein and its considerable amino acid sequence similarity to the TGF-β 
receptor family protein BMP-receptor type 1b, only the cytosolic parts of the 
protein not homologous to BMPR1B were expressed for generating an antibody 
against (BAMBI cytosolic fragment). For later testing of the generated antibody 
serum candidates, BAMBI full length and BMPR1B proteins were expressed 
both in eukaryotic and prokaryotic settings.  
 
3.5.1. Preparation of cDNA and Cloning into Expression Vectors 
 To obtain vectors for prokaryotic and eukaryotic expression of BAMBI protein, 
the mRNA was first reversely transcribed into cDNA, as described above and in 
Table 12. Then the BAMBI coding sequence (CDS) was isolated using a PCR 
with gene-specific primers and a low cycle number (n=15). Using agarose gel-
electrophoresis to identify and excise the correct DNA strands, and Rapid Gel 
Extraction Protocol (Marligen Bioscience) to clean them up, excess cDNA was 
discarded. In a second step PCR reaction, primers were used which 
additionally contain the necessary sequences for enzymatic restriction and re-
ligation into the expression vectors pBCHGs and pQC-His, using the sites for 
Bam HI and Hind III. 
 As a negative control for later experiments, the same procedure was also 
conducted for BMPR1B protein. However, for the successful isolation of the 
BMPR1B coding sequence, the PCR had to be performed using nesting primers, 
containing locus-specific sequences outside of the actual coding sequence. 
After agarose gel-electrophoresis and clean-up of this longer PCR product, the 
second PCR was performed again using primers containing the gene-specific 
sequences and the additional restriction sites. Primer sequences are given in 
Table 13. 
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 Table 13 Primers used for Cloning from Reversely Transcribed mRNA  
Gene Position Use Sequence (5'- … -3') 
upper cDNA ATG-GAT-CGC-CAC-TCC-AGC-TAC-ATC 
lower cDNA TCA-TAC-GAA-TTC-CAG-CTT-CCC-GTG 
upper cloning GAG-AGA-GGA-TCC-ATG-GAT-CGC-CAC-TCC-AGC-TAC-ATC 
lower cloning GAG-AGA-AAG-CTT-TCA-TAC-GAA-TTC-CAG-CTT-CCC-GTG-C 
upper sequencing GGC-GGA-TCC-ATG-GAT-CGC-CAC-TCC 
BAMBI 
lower sequencing GGC-AAG-CTT-TCA-TAC-GAA-TTC-CAG-CTT-CCC 
upper cDNA, nesting 
CAG-CCG-CGG-GGT-GGA-GTT 
lower cDNA, nesting 
TGA-TGT-CTT-TTG-CTC-TGC-CCA-CAA 
upper cloning GAG-AGA-GGA-TCC-ATG-CTT-TTG-CGA-AGT-GCA-GGA-AA 
lower cloning GAG-AGA-AAG-CTT-TCA-GAG-TTT-AAT-GTC-CTG-GGA-CTC-TGA-C 
upper sequencing TCA-GAG-TTT-AAT-GTC-CTG-GGA-CTC-TGA-C 
middle 1 sequencing GAA-GTG-GAT-CAG-GCC-TCC-CTC-TG 
middle 2 sequencing CGA-GTT-GGC-ACC-AAA-CGC-TAT-ATG 
BMPR1B 
lower sequencing ATG-CTT-TTG-CGA-AGT-GCA-GGA-AAA 
pQC-His plasmid, 40bp 
upstream of Bam HI site sequencing 
CGG-ATA-ACA-ATT-TCA-CAC-AG 
  
pBCHGs plasmid, 60bp 
upstream of  Bam HI site sequencing 
GGT-CCT-TCT-TGA-GTT-TGT-AAC-AG 
 
  
 
 Afterwards, gel-electrophoresis and clean-up was performed again for both 
constructs to isolate the correct length CDS / restriction site product and 
discard excess primers, nucleotides and polymerase. DNA concentration was 
determined using spectrometric measurements and the DNA was stored at 
-20 °C. To ensure that no mutations had been introduced during the previous 
PCR reactions, a small aliquot of 500 ng was used for sequencing. 
 
Vector DNA for pBCHGs and pQC-His was provided by the laboratory of Prof. 
Dr. Hanswalter Zentgraf from the DKFZ. 100 µl of E.coli bacterial cells of strain 
XL1-Blue (Stratagene) were transformed with 1 - 10 ng of the vector DNA 
[retransformation], harboring an ampicillin resistance gene (β-lactamase), and 
the competent bacterial cells were plated in 1/5 and 4/5 aliquots onto two LB-
agar plates each, containing 100 µg/ml ampicillin. Cells were grown overnight 
(12-16 h) at 37 °C, then stored at 4 °C. 
For each preparation, up to six isolated bacteria clones from these plates were 
picked and used to inoculate LB-Amp mini-cultures (5 ml LB containing 
100 µg/ml ampicillin). Again, these cultures were grown overnight (12-16 h) 
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and plasmid DNA was harvested with Plasmid Mini kits (Qiagen) according to 
the manufacturer's protocol. The DNA was checked for concentration by 
photometric measurement on a NanoDrop spectrometer and for plasmid purity 
by electrophoresis on 1.2% agarose gels. 
The plasmids and cDNA inserts were then each digested using both restriction 
enzymes Bam HI and Hind III (Roche) in a combined restriction reaction, using 
SureCut buffer B (Roche) according to the manufacturer's protocol. Linearized 
plasmid DNA was then separated by agarose gel electrophoresis, excision, 
clean-up as above and concentration measurement. 
Afterwards, the linearized vector strands were processed with shrimp alkaline 
phosphatase (Roche) according to the manufacturer's protocol to 
dephosphorylate the 5'-phosphate from the DNA. This optional step was 
performed to limit the number of unspecifically re-ligating vectors. 
Ligations of plasmids with insert constructs were performed using T4 DNA 
ligase (Roche) according to the manufacturer's protocol, but with 4 U of enzyme 
in 40 µl reaction volume. Input DNA used were 60 ng for pQC-His and 100 ng 
for pBCHGs, and exactly three times more molecules, as calculated by the 
number of basepairs, for each PCR product (BAMBI cytosolic fragment, 
15 ng / --; BAMBI full length CDS, 42 ng / 50 ng; BMPR1B, 80 ng / 94 ng; for 
ligations with pQC-His / pBCHGs, respectively). Ligation reactions were 
performed for 10 h at 12 °C followed by 4 h at 8 °C. The vector charts for the 
ligated products are given in Figure 9. 
After ligation, 20 µl of the reaction volume were directly used for 
transformation of E.coli XL-10 gold strains and seeded on LB-Amp agar plates 
to select for re-ligated colonies, as described above. Of each of the ligation 
constructs, clones were picked to conduct a colony PCR as well as grow a mini 
culture (10 ml LB-Amp medium). The remainders of the ligation reactions were 
stored at 4 °C for a few days or at -20°C for long term, while the LB-Amp plates 
were stored at 4 °C. 
If the colony PCR proved the plasmids positive for inserts, 2 ml of the 
corresponding mini cultures were harvested and the remainder was used to 
seed maxi cultures (400 ml). The harvested bacteria were used to isolate the 
DNA, again using Plasmid Mini kits (Qiagen) and the DNA was sequenced to 
check for mutations. After confirming the correct sequence, the plasmid DNA 
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was harvested from the maxi cultures with Plasmid Maxi kits (Qiagen), using 
the manufacturer's recommendations but with 30 ml of each buffer P1 - P3 
and adjusting the protocol accordingly. 
 
Figure 9 
 
Vector charts. Eukaryotic pBCHGs and prokaryotic pQC-His vectors were subcloned to contain the respective coding 
sequences (CDS) of BAMBI cytosolic fragment, BAMBI full length CDS or BMPR1B full length CDS. 6x His, tag 
consisting of 6 subsequent histidine amino acids for purification purposes; Amp (R), ampicillin resistance gene β-
lactamase. Charts were generated using Vector NTI software (Invitrogen). 
 
 
3.5.2. Protein Expression in the Prokaryotic System and Isolation 
For the expression of proteins in E.coli, BL21 CodonPlus (DE3)-RIL Competent 
Cells (Stratagene) were transformed with pQC-His construct plasmids bearing 
coding sequences of BAMBI cytosolic fragment, BAMBI full length protein or 
BMPR1B full length protein. These cells had been engineered to allow for a 
higher protein yield than normal XL-Blue or XL-Gold strains, and easy 
induction of the T7 RNA polymerase-driven expression by the manufacturer. 
Transformation was carried out with 50 µl of cells and 100 ng of plasmid DNA 
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each. Cells were kept 15' on ice, then heat-shocked for 3' at 37 °C and cooled 
again 3' on ice before adding 400 µl of LB medium and incubating at 37 °C for 
45' in a shaker at 600 rpm. Cells were then plated on LB-Amp agar, incubated 
overnight, and clones were picked for each construct and transferred to mini-
cultures (5 ml) as described above. 
E.coli mini cultures were diluted in a rich medium (TB-Amp) to a final volume 
of 30 ml and grown under periodical surveillance of growth at OD600 on the 
spectrometer until an optical density of 0.6 was reached. Then, isopropyl β-D-
1-thiogalactopyranoside (IPTG, dioxane-free, Fermentas) was added to a final 
concentration of 1 mM for induction of desired gene expression. Cells were 
continuously grown at 37 °C and 200 rpm. After 6 h of incubation, cells were 
harvested by centrifugation at 2,000 rpm in a Heraeus Varifuge 3.0 and the 
medium supernatant was discarded. 
Depending on the purification of protein with native or denaturing protocol, 
cells were resuspended in 10 ml of the appropriate lysis buffer, as 
recommended by the Ni-Agarose manufacturer, sonified three times for 30' 
with intermediate cooling on ice, and the lysed cells were incubated overnight 
at 4 °C. 
After pelletting the cell debris for 90' at 4 °C and 4,300 rpm (4,000 x g) in the 
Heraeus Varifuge, the supernatant containing the protein was decanted into a 
new tube. 5 ml of the solution were mixed with 4 ml of Ni-Agarose slurry 
(Qiagen) and the protein purification protocol was continued according to the 
manufacturer's protocol, but with 3 x 2 ml aliquots per washing step. Cleared 
protein fractions were stored at 4 °C. 
 
To check for the protein content, 20 µl of the mini culture, lysis supernatant as 
well as each of the fractions were mixed with 10 µl Laemmli gel loading buffer, 
incubated for 15' at 96 °C and loaded onto a 15% polyacrylamide gel 
(containing SDS, Bio-Rad). Size marker used for direct staining was Unstained 
Protein Molecular Weight Marker and for subsequent blotting PageRuler 
Prestained Protein Ladder (both Fermentas). Electrophoresis was performed for 
approximately 2 h with 20W constant electrical current per mini gel, until the 
front of the loading buffer reached the end of the gel. 
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For immediate results, gels were stained with Coomassie Blue for at least 60' or 
overnight, destained with 20% isopropanol / 7% acetic acid (v/v) until the 
staining of background had diminished, and fixed in 7% acetic acid (v/v) for at 
least 30' or overnight. For long term storage, stained gels were spread on 
Whatman paper and dried under vacuum at 80 °C for 105'. 
 
3.5.3. Immunization of Mice and Generation of Hybridoma Cells 
The generation of antibodies from mice hybridoma cells was carried out in 
cooperation with the laboratory of Prof. Dr. Hanswalter Zentgraf, DKFZ 
Heidelberg. 
In brief, mice of strain BALB/c, 8-12 weeks old, were injected subcutaneously 
with 20 µg of soluble protein as immunogen. The preparation of the 
immunogen included a nonspecific immunogenic stimulator (Freund's 
Adjuvant) containing mineral oils. This procedure is administrated for the 
primary immunization to enhance the immune response of the animals and 
protect the immunogen from rapid catabolism. Primary immunization of the 
mice was performed with a conjugate made of BAMBI cytosolic fragment with 
keyhole limpet hemocyanin (KLH) by thiol-coupling according to Sawin and co-
workers.140 Second and third immunizations, in two weeks intervals, were 
performed with 20 µg of the antigen alone to boost the specific immune 
response against the BAMBI cytosolic fragment. Three days later, spleen cells 
from the immunized mice were fused with cells of the myeloma line 
P3x63Ag8.65 3 using polyethylene glycol as described.141 Cell culture 
supernatants were screened for antibodies by ELISA and immunoblotting. 
Positive cell lines were subcloned by limited dilution. 
 
3.5.4. Validation by Western Blotting 
For testing of antibodies, prokaryotic expression of proteins and PAGE were 
performed as described above, but with BAMBI full length protein as well as 
BMPR1B protein, on 15% polyacrylamide gels. 
Gels were blotted using polyvinylidene fluoride (PVDF) membrane (Millipore) in 
a standard mini-gel tank-blotting apparatus (Bio-Rad) according to 
manufacturer's instructions. The buffer used for transfer was Tris/Glycine 
based but without SDS and contained 20% methanol (v/v). Blots were then 
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washed, blocked and incubated with antibodies. Transfer and washing buffers 
were prepared and used according to protocols given in the "QIAexpress 
Detection and Assay Handbook for Anti·His Antibodies" (Qiagen). The only 
exception to these recommendations was the blocking mix, for which 5% milk 
powder (w/v) and 3% BSA (w/v) in TBS-Tween buffer containing 0.05% 
Tween-20 (v/v) were used. 
Hybridoma cell supernatants were used undiluted to test antibodies. For 
positive controls, anti-P53 antibody was used on the blots against P53 protein 
(both kindly provided by Hanswalter Zentgraf), which was additionally loaded 
onto the acrylamide gels. As negative controls, antibodies against either P53 or 
BRWD3 protein (the latter provided by Magdalena Schlotter) were used against 
whole cell lysate. All controls were performed at concentrations recommended 
by the provider. 
 
 
3.6. Pathway Analysis 
For the identification of cellular signaling pathways involved in the course of 
the disease, as characterized by the classification between responders and non-
responders with the gene expression signature, the contained genes were 
analyzed using designated software and tools. 
The most comprehensive and best known database is Gene Ontology (GO). 
Since GO and its use are public, other tools use it to integrate the information 
for providing statistical analyses (AmiGO, FatiGO)142,143 or graphical 
illustrations of the interplay (KEGG)144 between proteins or lists of genes and 
proteins. To identify pathways deregulated or altered between the responder 
and non-responder groups of breast cancer patients, the FatiGO and KEGG 
analysis tools and databases were used, as well as the raw information 
published and stored in the GO database and information collected in the Gene 
and Pubmed databases of the National Center for Biotechnology Information 
(NCBI), which belongs to the United States National Institutes of Health (NIH). 
 
 
 71
3.7. Immuno-Histochemistry 
To validate results from the gene expression data acquired by microarray and 
RQ-PCR measurements, the translation of the deregulated genes into proteins 
was assessed by immuno-histochemical measurement in sections of breast 
tumor samples from the same patients. These formalin-fixed and paraffin-
embedded tissue samples as well as the sections thereof were provided by Prof. 
Hans-Peter Sinn from the Department of Pathology at the Hospital for 
Gynecology and Obstetrics of the University of Heidelberg. In total, 80 patients 
from both GEDoc and GEsDoc studies were available for immuno-
histochemical experiments, with four consecutive sections per patient, cut at 
5 µm thickness. 
 
Deparaffination and Antigen Retrieval 
Embedded tissue sections were deparaffinated and antigen retrieval was 
carried out by incubation of the pre-processed tissue section slide by boiling for 
25' in either citrate buffer (10 mM citric acid, 0.05% Tween-20, pH 6.0) or 
EDTA buffer (10 mM Tris, 1 mM EDTA, 0.05% Tween-20, pH 9.0) and left to 
cool down at room temperature for another 25' (Table 14).145-147 For each 
antibody, the optimal retrieval method was tested on excess sections and the 
optimal protocol was then applied to the sections from tumor specimen of the 
breast cancer patients from the GEDoc and GEsDoc study cohorts.  
 
Table 14 Preprocessing of Paraffin Sections  
Incubate in xylol, 3x 5' 
Incubate in 100% EtOH, 2x 5' 
Incubate in 95% EtOH, 2x 5' 
Incubate in 80% EtOH, 2x 2' 
Incubate in aqua dest., 1' 
Incubate in Tris-EDTA (pH 9.0) / citrate (pH 6.0) buffer, 25' @ 97 °C 
  
25' cool down at room temperature 
 
  
 
Immuno-Staining Reactions 
Antibodies against BAMBI, BMP4, BRCA1, LMO4, SMAD3 and SRC proteins 
were purchased and used as given in Table 15. Washing of the sections, 
incubation with the antibody dilutions and staining with chromogens was 
carried out on a TechMate Horizon (Dako) using protocol MSIP and the 
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solutions provided, as recommended by the manufacturers. Double-stains 
(BAMBI/SRC and BMP4/SMAD3) were performed sequentially using NovaRed 
chromogen first and SG chromogen (both Vector) second, and in accordance 
with deparaffination method and subcellular location compliance of the two 
antigens. Counterstaining with hematoxylin & eosin solution was performed 
during the first staining run and substituted with Washing Buffer 4 during the 
second staining run. 
 
 Table 15 Antibodies and Dilutions  
Target 
Protein Antibody No. Manufacturer Clonality 
Origin 
Species Dilution Chromogen 
BAMBI a H00025805-M01 Abnova monoclonal Mouse 1:150 NovaRed (red, Vector) 
BMP4 b NCL-BMP4 NovoCastra monoclonal Mouse 1:50 NovaRed (red, Vector) 
BRCA1 ab16780 Abcam monoclonal Mouse 1:100 NovaRed (red, Vector) 
LMO4 sc-11120 Santa Cruz polyclonal Goat 1:100 DAB (red, Dako) 
SMAD3 b ab28379 Abcam polyclonal Rabbit 1:100 SG (grey, Vector) 
  
SRC a ab32102 Abcam monoclonal Rabbit 1:150 SG (grey, Vector)  
a,b Double stains performed on the same sections. 
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4. Results 
 
In the presented study, the discovery of a gene expression signature based on 
RNA samples from small tissue biopsies, obtained from primary tumors of the 
breast, was elucidated. As the RNA yield was very small, the appropriate 
method for amplification of mRNA to be used with long gene-specific 
oligonucleotide microarrays had to be developed. Then, the amplification 
procedure was applied to a large set of biopsies from breast cancer patients, 
and whole-genome gene expression experiments were performed to identify a 
gene signature predicting response of the patients to chemotherapy. The 
prediction performance of the obtained gene expression signature was then 
tested for significance in an independent set of patients, who received 
chemotherapy with the same drugs. Genes contained in the predictive gene 
signature demonstrating biological relevance of the corresponding pathways 
were selected to confirm the microarray expression results using RQ-PCR and 
to further investigate these pathways by immuno-histochemical staining of 
tumor biopsy sections from the same patients. 
 
4.1. Messenger RNA Amplification Protocols 
To overcome restrictions imposed by the strand incompatibility of the sense-
orientated oligonucleotide DNA probes of the microarray with established 
mRNA amplification protocols yielding sense orientated labeled DNA samples, 
six different procedures and additional variations thereof to amplify nucleic 
acids were developed or introduced and tested in collaboration with Dr. Jörg 
Schlingemann. In order to have a direct comparison and minimize bias, the 
protocol steps that were shared between the individual methods were 
performed correspondingly, e.g. using the same enzymes and concentrations of 
reagents. Then, various measurements were made to estimate the performance 
of these methods like fluorescent dye incorporation, microarray signal 
intensity, reproducibility, and others. The source material used for testing was 
generated from two different cell lines, HL-60 and NU-DHL-1, which both are 
from myeloid origin but represent different genetic alterations (see Appendix A). 
For a short summary of the different amplification methods, see Figures 10-12. 
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Figure 10 
 
Schematic view of Direct Labeling and In Vitro Labeling protocols. ssDNA, second strand DNA, complementary 
strand of cDNA; aRNA, antisense RNA. Sense and antisense refer to the orientation of mRNA. 
 
 
Figure 11 
 
Schematic view of Baugh Standard and Baugh + Klenow protocols. ssDNA, second strand DNA, complementary 
strand of cDNA; aRNA, antisense RNA; c*DNA complimentary sense DNA. Sense and antisense refer to the orientation 
of mRNA. 
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Figure 12 
 
Schematic view of PALDA and ts-SPA protocols. ssDNA, second strand DNA, complementary strand of cDNA; c*DNA 
complimentary sense DNA. Sense and antisense refer to the orientation of mRNA. 
 
4.1.1 Incorporation of Fluorescently Labeled Dyes 
The first step in evaluating the performance of the different protocols for 
amplifying nucleic acid material was comparing the rate of incorporated 
fluorescent dyes per 1000 nucleotides. Since the Cy dyes are covalently bound 
to the nucleotides, resulting in a much higher molecular weight and surface 
area, this rate of incorporation depends on the different enzymes that are used 
to polymerize the nucleic acids. Some of the enzymes had been modified 
accordingly by their manufacturers, e.g. by reducing the proof-reading capacity 
or modifying the size of the grooves for nucleotide entry and polynucleotide 
exit. For unmodified enzymes, the tested protocols had been adapted to 
increase the ratio of labeled to normal nucleotides, thereby increasing the 
probability to incorporate the labeled ones (PALDA Taq / Pfu and IVT Labeling). 
The Primer-Assisted Linear DNA Amplification (PALDA) protocols did not 
incorporate these bulky nucleotides well (Figure 13), although the used Pfu 
DNA polymerase with the lowest incorporation rate (below 2 per 1000 
nucleotides) has a decreased exonucleoase activity (exo-). PALDA using the Taq 
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DNA polymerase as well as In Vitro Transcription (IVT) labeling performed 
significantly better (7.3 and 10.1 per 1000 nucleotides, respectively), but their 
incorporation rates were considerably low when compared to the other 
protocols. Using the Klenow fragment of DNA polymerase I, as in Baugh + 
Klenow and the two Single Primer Amplifications (SPA) protocols, performed 
substantially better (24.3, 49.9 and 52.3 per 1000 nucleotides for Baugh + 
Klenow, ts-SPA and SPA, respectively). 
Figure 13 
 
Incorporation rates for fluorescently labeled nucleotides. Bars represent labeled nucleotides per 1000 nucleotides 
as a result of the different protocols for amplification, estimated by photometric measurements after amplification. 
 
Another very important aspect in evaluating the incorporation rates of the 
labeled nucleotides is the ratio between the two different fluorescent dyes. As 
these have different molecular weights and surface areas, a difference in their 
incorporation into the nucleic acids was expected, especially for the 
incorporating enzymes with low processivity for these bulky nucleotides. 
However, the only protocol showing a dramatic bias towards one of the dyes 
was the IVT Labeling protocol (1.99 for Cy3 over Cy5, Figure 13 & 14). The RNA 
polymerase II, which was used in this protocol with the labeled nucleotides, 
showed a strong discrimination in its processivity between the dyes, as the Cy5 
dye has the bulkier fluorescent molecule group and therefore requires more 
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space to be integrated. The enzyme with the lowest dye bias was the Pfu exo- 
polymerase, although it had a very limited total incorporation. The protocols 
using the Klenow fragment, as well as the PALDA Taq method, had a moderate 
bias for the benefit of Cy3 dye (1.24 to 1.38). 
Figure 14 
 
Biased incorporation of fluorescently labeled nucleotides between dye channels. For different amplification 
protocols, the ratio of Cy3 over Cy5 incorporation rates after amplification was calculated. 
 
4.1.2 Performance of Amplified Messenger RNA on Oligonucleotide Microarrays 
After evaluation of the dye incorporation, the second but even more critical 
aspect of the amplification protocols was to investigate their performance on 
the oligonucleotide microarrays. In order to obtain valuable data, the 
experiments were performed at least in duplicates. For comparison, directly 
labeled cDNA as well as DNA amplified and labeled with the Klenow standard 
protocol and by PCR were also included. Since the PALDA protocol with Pfu 
exo- enzyme did not yield sufficient fluorescent labeling, this protocol was not 
pursued anymore. 
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Signal Intensity 
Beyond the general incorporation as estimated above, the amount of 
fluorescently labeled nucleic acid actually available for hybridization to the 
DNA probes on the microarray was analyzed. To obtain this measure, the total 
intensity of each feature, representing hybridized sample molecules, was 
calculated versus its local background of the surrounding area and averaged 
for all valid features. These ratios were compared for the different protocols 
(Figure 15). 
Figure 15 
 
Signal to background ratio. Intensity values from feature foreground (signal) to local area surrounding feature 
(background) were averaged for both dye channels of microarray experiments, and the ratio was calculated. 
 
Compared to the direct labeling procedure used as benchmark (signal to 
background ratio of 56.7), only one method showed superior signal to 
background ratio, the IVT Labeling (237.8). Next closest to the direct labeling, 
but lower, is the Baugh + Klenow method. Even though the input amount of 
total RNA was modified (0.5, 1.0 and 2.0 µg), the protocol yielded higher signal 
to background ratios than the next best method (18.9, 26.7 and 24.2, 
respectively). Both SPA and template-switch SPA yielded relatively low ratios 
when compared with the direct labeling (12.8 and 16.2, respectively), while the 
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other protocols (Baugh Standard, 8.0; PALDA Taq, 3.1; PCR, 3.0) did not yield 
sufficient signal to background ratio. 
 
Same-versus-same (Equivalent) and Differential Expression Correlation 
To analyze whether the signals received from the microarray hybridizations 
were gene-specific and reproducible, expression ratios from hybridizations of 
same-versus-same (referred to as equivalent) experiments as well as from 
experiments with the two different cell lines (differential) were compared. 
Unfortunately, the PALDA Taq protocol did not yield enough labeled product to 
perform same-versus-same hybridizations, so only differential experiments 
could be carried out. The Pearson's Correlation for all valid features was 
calculated both in equivalent and differential experiments, to evaluate 
reproducibility or difference (Figure 16). While most protocols show good 
reproducibility, as shown by high values for the equivalent comparisons, the 
Baugh Standard, SPA and PCR methods have low or no correlation. The PALDA 
Taq protocol could not be evaluated in this aspect. In the differential 
experiments, a medium (0.5) to slightly elevated (0.65) correlation was 
expected, as the two cell lines have some, but not high similarities. However, 
the Direct Labeling, PALDA Taq and ts-SPA methods have a higher than 
expected correlation, while the SPA protocol shows very low correlation.  
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Figure 16 
 
Squared Pearson's correlation coefficient. Repeat hybridizations in same-versus-same (equivalent) or differential 
hybridizations between cell lines HL-60 or NU-DHL-1 were compared across all valid features of the respective 
microarrays. 
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Outlier Features 
The GenePix software detecting the hybridized microarray features, as guided 
by the manual inspection of the user, was used to identify features without 
hybridization as well as spots representing artificial or otherwise false positive 
signals. The proportion of these so-called outlier features could be determined 
for each protocol (Figure 17). A certain extent of missing features was expected, 
since not all genes are expressed in one or both of the cell lines. A very high 
percentage of outlier features was seen in amplifications with the PCR (50.1%) 
and the PALDA Taq (28.5%) methods, while the SPA and ts-SPA protocols 
showed an elevated percentage (18.6% and 16.1%, respectively), when 
compared to the remaining protocols (11.5% - 14.2%). 
 
Figure 17 
 
Percentage of non-valid features (outliers). Outlier features were identified by microarray scanning software or 
manually flagged by user inspection, and set in relation to total number of spots per microarray. 
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Linear Trend of Intensity Scatter Plots 
By spreading the median intensities of all spots on the microarrays on scatter 
plots, either in same-versus-same (equivalent) or differential hybridizations, 
and calculating the linear trend of the resulting data points, the slope and 
intercept of the trend line could be used to describe key features of the 
amplification performance and hybridization to the probes on the microarrays. 
The intercept of this line expresses a bias of the corresponding dye intensity, as 
the scanner was set to a higher PMT voltage in the corresponding channel to 
compensate for the intensity loss. Such a bias is seen as a very high intercept 
of the trend in IVT labeling (1885.5), and as an elevated intercept in the PCR 
protocol (608.3). 
 
Figure 18 
 
Ordinate intercept points of the linear trend. Linear models were fitted to the scatter plots of feature intensities 
between both dye channels, Cy3 and Cy5, and the ordinate intercept was calculated. 
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Spot Homogeneity 
The homogeneity of the spots was another factor used for evaluation of the 
amplification protocols. Spots with inhomogeneous pixel intensities have to be 
dismissed, as they do not represent a substantial intensity value. Therefore, 
the percentage of homogeneity outlier features was used as a measure of 
intensity validity, accepting features for data analyses if the ratio of mean to 
median was between 0.8 and 1.25. The percentage of the features with a ratio 
outside this interval was estimated for each protocol (Figure 19). With a 
homogeneity outlier percentage above that of the PCR amplification (40.9%), 
the Baugh Standard (63.6%) and PALDA Taq protocols (61.6%) showed very 
high values. IVT labeling showed an elevated homogeneity outlier percentage of 
27.6%, while the Baugh + Klenow protocols (11.6% - 19.1%) and the SPA 
methods (ts-SPA, 14.3%; SPA, 14.9%) were within acceptable range of the 
Direct Labeling protocol (17.2%). 
 
Figure 19 
 
Homogeneity outlier percentage. Valid features with a mean to median ratio of feature intensity pixels outside the 
acceptable interval of 0.8 to 1.25 were calculated in respect to total number of valid features. 
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Based on the results shown, it was evident that the protocol for amplification of 
messenger RNA to be used for small amounts such as those obtained from 
clinical biopsies to be used together with the oligonucleotide microarray 
technology was best met with the Baugh + Klenow method. In all aspects 
measured and displayed, it performed best or second to best and showed good 
reliability in laboratory practice. Since its denomination was derived from the 
original author and the enzyme nickname that was used for its additional 
extension, it was finally entitled "T7-based Amplification of cDNA and Klenow 
Labeling for Expression Analysis", abbreviated TAcKLE Analysis. 
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4.2 Gene Expression Signature Predictive for Chemotherapy in Primary Breast 
Cancer 
A total of 148 patients had been enrolled in two combined clinical phase II 
studies to determine the efficacy and dosage compatibility of a neoadjuvant 
chemotherapeutic regimen of gemcitabine, epirubicin and (or sequentially 
followed by) docetaxel, termed GEDoc and GEsDoc, respectively, for therapy of 
patients with primary breast cancer at the Clinic for Gynecology and Obstetrics 
of the University of Heidelberg. This protocol includes the addition of the drug 
gemcitabine, a nucleoside analog like fluorouracil, to the combination therapy 
of an anthracycline (epirubicine) and a taxane (docetaxel). The addition of 
gemcitabine promised an improvement of the response of the tumors to 
established chemotherapy regimens, resulting in an increase in both the 
number of patients with a complete response (no residual tumor) and the 
number of patients with a partial response (decreased tumor size).47,104  
 
To supplement these studies, an accompanying trial was conducted at the 
German Cancer Research Center (Deutsches Krebsforschungszentrum) in 
Table 16 Patient Characteristics  
GEsDoc GEDoc   
n % n % 
No. of patients 52 100 48 100 
Age [median (range)], years                    45 (29 to 65) - 49 (30 to 65) - 
Tumor size by US  [median (range)], cm   3.5 (2.1 to 8.0) - 3.5 (2.1 to 10.0) - 
Histology, ductal / lobular / other 45 / 4 / 3 87 / 8 / 6 37 / 7 / 4 77 / 15 / 8 
Histological grade, 1 / 2 / 3 / n.a. 2 / 22 / 25 / 3 4 / 42 / 48 / 6 2 / 19 / 23 / 4 4 / 40 / 48 / 8 
Clinical nodal status, N0 / N+ 31 / 21 60 / 40 20 / 28 42 / 58 
Hormone receptor expression, ER or 
PGR score ≥ 1 / ER & PGR score 0 37 / 15 71 / 29 35 / 13 73 / 27 
HER2 expression, 0 / 1+ / 2+ / 3+ 40 / 2 / 1 / 9 77 / 4 / 2 / 17 33 / 3 / 1 / 11 69 / 6 / 2 / 23 
KI67 expression, ≤ 50% / > 50% / n.a. 34 / 18 / 0 65 / 35 / 0 37 / 8 / 3 77 / 17 / 6 
P53 expression, ≤ 20% / > 20% 39 / 13 75 / 25 38 / 10 79 / 21 
BCL2 expression, 0 / 1+ / 2+ / 3+ 21 / 10 / 12 / 9 40 / 19 / 23 / 17 29 / 4 / 10 / 5 60 / 8 / 21 / 10 
Clinical response after 6 weeks of PST, 
CR / PR / NC / PD / n.a. 
1 / 28 / 21 / 0 / 
2 
2 / 54 / 40 / 0 / 
4 
0 / 30 / 18 / 0 / 
0 
0 / 63 / 38 / 0 / 
0 
Pathologic response at surgery   
pT0 / pTis / pT1-4 12 / 3 / 37 23 / 6 / 71 5 / 4 / 39 10 / 8 / 81 
pN0 / pN+ / n.a. 19 / 32 / 1 37 / 62 / 2 34 / 14 / 0 71 / 29 / 0 
pCR breast (pT0 and pTis) 15 29 9 19 
pCR breast+axilla [(pT0 or pTis) & pN0] 13 25 9 19 
  
CR, complete remission; ER, estrogen receptor; n.a., not available; N, nodal status; NC, no change; PD, progressive 
disease; pN, pathologically determined nodal status; PGR, progesterone receptor; PR, partial remission; PST, primary 
systemic chemotherapy; pT, pathologically determined tumor status (is, tumor in situ); US, ultrasound 
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Heidelberg to establish and test a gene expression signature that allows the 
prediction of the response of patients to this chemotherapy. 
To conduct the necessary experiments, core needle biopsies of the primary 
tumor were taken from the patients under sonographic surveillance at the 
clinic and one to two of these tumor specimens were subjected to microarray 
analysis in our laboratory as described. For the number of 100 patients, the 
mRNA could be successfully extracted, amplified and analyzed on the 
oligonucleotide microarrays. A detailed overview of the characteristics of this 
cohort of patients is given in Table 16. 
 
4.2.1. Identificaton of the Gene Expression Signature 
In order to obtain statistical significant genes predicting the response of the 
patients to the chemotherapy, two preconditions had to be set. First, the 
patients needed to be classified as responders or non-responders. According to 
the clinical behavior of the patients, only those who achieved a pathologically 
confirmed complete remission of their tumor, defined as the disappearance of 
all viable tumor cells in the specimen at surgery after chemotherapy, termed 
pathological complete remission (pCR), were classified as responders. All other 
patients were classified as non-responders. Secondly, to minimize overfitting 
bias of the algorithms identifying the classifier, the total number of 100 
patients had to be divided into two cohorts of similar size. One of these sets 
was used as a training set to discover the gene signature, while the other 
completely independent set was exclusively used to test the gene signature and 
estimate its predictive power. As the patients had enrolled in two slightly 
different studies, of which almost identical numbers of patients were 
successfully analyzed, these were used as training and test sets. For the 
training set, the GEsDoc study patients were chosen, as they had the larger 
proportion of responders (29%) and thus the greater probability to establish a 
significantly predicting gene signature. The GEDoc study patients were then 
used to test the gene signature. 
 
Of the initially 21,329 gene-specific oligonucleotides contained on the 
microarray, 15,355 were expressed and passed quality checks in at least 80% 
of the patients. Therefore, only these genes were considered for the 
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establishment of the gene signature. Applying the Support Vector Machines 
algorithm, the training set was used to discriminate the predictive power of 
these genes. Subsequently, the number of genes was halved stepwise by 
Recursive Feature Elimination, and each time the predictive power of the 
subset of genes, given as misclassification error, was estimated by cross-
validation (Figure 20). On the basis of the minimal misclassification error, the 
selected gene signature contained the 512 (29) most predictive genes. The list of 
the genes contained in the signature is given in Appendix D. 
Figure 20 
 
Misclassification error. The sum of false positives and negatives, estimated by cross-validation depending 
on the number of genes of the model within the training set of patients. In collaboration with P. Warnat. 
 
Using the Receiver-Operator Characteristic graph, in combination with the 
Youden's Index (Sensitivity + Specificity - 1), the predictive characteristics of 
the chosen gene signature was calculated on the test set (Figure 21). For the 
optimal Youden's Index of 0.68, the parameters sensitivity (true positive rate, 
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estimated within observed pCR cases), specificity (true negative rate, estimated 
within observed non-pCR cases), positive predictive index (PPV, observed 
within estimated pCR cases), negative predictive index (NPV, observed within 
estimated non-pCR cases) and overall accuracy (PPV + NPV) were calculated 
(Table 17). With a total of seven correctly predicted pCR cases, sensitivity was 
78% and the positive predictive value was 64%. Non-pCR patients were 
correctly classified by the predictor in 35 cases, yielding a specificity of 90% 
and a negative predictive value of 95%. In total, the accuracy was 88%, with 42 
cases correctly classified. Due to the small number of pCR cases, the 
confidence interval of sensitvity and PPV are high.  
Figure 21 
 
Receiver-Operator Characteristics graph. Displayed are the dependencies of the selected 
classification model between true positive rate (sensitivity) and false positive rate (1 - specificity), as 
estimated by cross-validation of the training set of patients. The optimal balance between low false 
positive rate and high true positive rate is marked by the blue arrow. In collaboration with P. Warnat. 
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Table 17 Patient Prediction Characteristics (test set)  
predicted 
  
pCR non-pCR total 
pCR 7 2 9 
non-pCR 4 35 39 
ob
se
rv
ed
 
total 11 37 48 
  cases percentage 95% C.I. 
sensitivity 7 of 9 78% 40% to 97% 
specificity 35 of 39 90% 76% to 97% 
PPV 7 of 11 64% 31% to 89% 
NPV 35 of 37 95% 82% to 99% 
accuracy 42 of 48 88% 75% to 95% 
 
C.I., confidence interval; NPV, negative predictive value; 
pCR, pathologic complete remission; PPV, positive predictive value  
 
 
When comparing the predictive power of the gene signature with the best 
clinical factors in multivariate analysis, it shows superior predictive power, as 
calculated by the Odds Ratio (Table 18). The Odds Ratio describes the relative 
risks of patients in the respective classes for the predicted negative outcome of 
not reaching a pathological complete remission. Of the clinical factors, only 
HER2 (Score 0-2 versus Score 3) has a significant predictive power in the 
tested patient cohort. With p-values lower than 0.25 demonstrating factors to 
be not statistically relevant trends, as the low grading of the tumors for positive 
outcome as well as smaller tumors for negative outcome, the other factors, 
estrogen and progesterone negativity as well as the clinical tumor response 
after six weeks of therapy, are statistically irrelevant. 
 
Table 18 Penalized Logistic Regression of Signature and Clinical Factors  
Factor Odds Ratio 95% C.I. p 
Signature (Predicted negative vs. positive) 38.3 2.43 - 6560 0.01 
Grading (G1, G2 vs. G3) 0.2 0.00 - 2.75 0.23 
HER2 (0-2 vs. 3) 10.5 1.26 - 151 0.03 
ER/PgR (ER 0 & PgR 0 vs. ER >0 or PgR > 0) 0.5 0.03 - 8.19 0.64 
Response after 6 weeks PST (PR, CR vs. NC, PD) 0.6 0.02 - 10 0.70 
  cT max (cT 2-5 cm vs. cT >5 cm) 6.9 0.33 - 1128 0.22  
  
C.I., confidence interval; CR, complete response; cT, clinical tumor size; ER, estrogen receptor; 
NC, no change; PgR, progesterone receptor; PR, partial response; PST, primary systemic chemotherapy   
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4.2.2. Genes and Pathways of the Predictive Signature 
In order to understand the biological implications of response to chemotherapy 
in breast cancer patients, it was of biological interest to investigate the genes 
contained in the gene expression signature in further detail. For this purpose, 
the Gene Ontology entries of the genes in the signature, which had an 
annotation, were studied in respect to cellular localization and molecular 
function (249 and 292 genes, respectively). As these numbers of genes were 
large, they were first depicted in their corresponding groups (Figure 22). Only a 
very small percentage of genes codes for proteins located in the extracellular 
matrix (2%), while the proportion of proteins in the nucleus is relatively large 
(36%), as the cellular components graph (upper panel) illustrates. The 
molecular function graphic (lower panel) shows a large proportion of genes 
coding for proteins involved in catalytic activity (35%) and nucleic acid binding 
(25%), binding of other molecules (21%) and proteins (20%) as well as signal 
transducing (14%) and transcriptional regulation (12%) activities. 
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Figure 22 
 
Analysis of genes contained in the predictive expression signature. Genes are grouped according to their 
annotation in Gene Ontology for cellular localization and molecular function. Due to missing annotations, only 249 
and 292 genes could be categorized, respectively. Pies amount to more than 100% as genes may have entries in 
multiple categories. 
 
In a second step, the GO annotation terms of the genes from the signature 
were analyzed for statistically significant enrichment when compared with all 
genes represented on the microarray using Fisher test (Table 19). Genes 
significantly associated with the metabolic pathways directly targeted by the 
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chemotherapeutic agents gemcitabine and epirubicin were grouped as 
nucleotide metabolisms (yellow), and genes targeted by docetaxel belong to the 
functional groups of microtubular depolymerization and regulation of spindle 
apparatus during the mitotic phase (pink). Protein farnesylation/ prenylation, 
associated with Ras proteins, showed a very high significance (orange), as did 
the significant genes from the TGF-β pathway subfamily of bone remodeling 
proteins (blue) and DNA damage response genes (green). 
 
 Table 19 Significantly enriched GO Terms  
GO ID GO Term p value 
GO:0018343 protein farnesylation 0.0015 
GO:0018347 protein amino acid farnesylation 0.0015 
GO:0018342 protein prenylation 0.0141 
GO:0018346 protein amino acid prenylation 0.0141 
  
GO:0007265 Ras protein signal transduction 0.0347 
 
GO:0045669 positive regulation of osteoblast differentiation 0.0391 
GO:0030501 positive regulation of bone mineralization 0.0391 
GO:0046852 positive regulation of bone remodeling 0.0391 
  
GO:0045778 positive regulation of ossification 0.0391 
 
GO:0009117 nucleotide metabolism 0.0209 
GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism 0.0330 
GO:0009134 nucleoside diphosphate catabolism 0.0391 
  
GO:0046939 nucleotide phosphorylation 0.0391 
 
GO:0009132 nucleoside diphosphate metabolism 0.0087 
GO:0006014 D-ribose metabolism 0.0391 
GO:0009191 ribonucleoside diphosphate catabolism 0.0391 
GO:0046785 microtubule polymerization 0.0391 
  
GO:0045842 positive regulation of mitotic metaphase/anaphase transition 0.0391 
 
GO:0000718 nucleotide-excision repair, DNA damage removal 0.0391 
 
GO:0042769 DNA damage response, perception of DNA damage 0.0391 
 
  
 
A more detailed inspection of the signature genes was performed using the 
KEGG database of genes or proteins, which illustrates the grouping of the 
proteins by their participation in signaling or metabolic cellular pathways. 
Moreover, using the NCBI database of genes, detailed annotations of the genes 
and the function of the encoded proteins were allocated and functional or 
signaling connections between them were identified, as described in 
chapter 5.3. 
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4.3 Validation of Microarray Results by Real-time Quantitative PCR 
In order to validate the results yielded by the TAcKLE amplification method in 
combination with the oligonucleotide gene expression microarrays, and to gain 
more detailed insights into the molecular pathways involved with the prediction 
of chemotherapy response, four genes from the signature were chosen to be 
analyzed for their expression by real-time quantitative PCR (RQ-PCR). 
As discussed in chapter 5.3, the genes selected from the signature were 
DAPK2, BAMBI, LMO4 and SRC for their associations with the DNA damage 
response or TGF-β pathway. Additionally chosen genes for RQ-PCR were 
SMAD3, coding for a transcription factor interconnecting signaling between 
BAMBI and LMO4, as well as ESR1 and HER2, two genes for which the 
corresponding protein levels had been measured for all patients in the clinic. 
The results were averaged for all patients in the corresponding responder class 
(pCR/non-pCR) and the averages set into relation, both in the microarray and 
RQ-PCR data sets (Figure 23). 
 
Figure 23 
 
Comparison of gene expression results as measured by Microarray and RQ-PCR techniques. Displayed here are 
the ratios between expression values averaged for patients with pCR or non-pCR to chemotherapy. 
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When comparing these data, it became evident that for all genes except SRC, 
the expression differences between classes relate well between RQ-PCR and 
microarray results. However, the ratios between the patient classes had in 
these cases higher absolute values for the microarrays as compared to the 
RQ-PCR, except for HER2. Genes downregulated in pCR patients as compared 
to non-pCR patients were estrogen receptor (ESR1) and the TGF-β/bone 
morphogenic pathway (BMP) signal transducer SMAD3. BAMBI, the negatively 
regulating pseudoreceptor of the TGF-β/BMP signaling family, as well as 
LMO4, a transcription regulator associated with suppression of TGF-β target 
genes, were both upregulated in tumors pCR patients as compared to the 
tumors of non-pCR patients. Another gene upregulated in tumors of pCR 
patients is the death-associated protein kinase DAPK2, which is thought to 
induce apoptosis. The epithelial growth factor receptor gene HER2 did not show 
significant regulation differences between tumors of pCR and non-pCR patients 
on the transcription level by both methods. 
 
For the proteins estrogen receptor 1 (ESR1) and HER2, the averages of 
immuno-histochemical staining scores of the tumor biopsies (Figure 24) were 
included into the comparison by taking the natural logarithms of the ratios 
between patients from the different response classes (pCR over non-pCR). 
These log-ratios amount to -2.0 for ESR1, given as pCR (average score 1.0) 
versus non-PCR (7.4), and 1.0 for HER2 (pCR, 1.06 versus non-pCR, 0.38), 
respectively. While the protein expression value corresponds very well in case 
of ESR1 to the RQ-PCR and microarray values, it does not reflect transcript 
data for HER2. It should be noted, however, that the HER2 protein expression 
levels were scored on a scale of 0 to 3, and while their means result 1.06 and 
0.38 for pCR and non-pCR, repectively, the medians of the scores have the 
value of 0 in both classes. 
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Figure 24 
 
Immuno-histochemical evaluation of tumor biopsies. Tumor sections from patients participating in GEDoc and 
GEsDoc studies were scored for protein expression of estrogen receptor (ESR1) and HER2/NEU, respectively. 
Maximum score is 12 for ER expression and three for HER2 expression. Scores were averaged for pCR and non-pCR 
patient classes. Data was provided by the Clinic for Gynecology and Obstetrics, University of Heidelberg. 
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4.4 Generation of Antibody using Mouse Hybridoma Cells 
One of the genes contained in the signature discriminating between patients 
classified as responders or non-responders in respect to the chemotherapy was 
the BAMBI gene. It was considered an important protein, as it negatively 
regulates the TGF-β signaling cascade, which was significantly enriched in the 
gene signature. For this reason, it was decided to measure the protein 
expression of BAMBI to reveal insight into its role in breast cancer 
chemotherapy response. Since there was no antibody available at the time the 
signature was discovered, it was necessary to generate one against BAMBI 
protein that would be suited for Western blot analysis and immuno-
histochemistry. In collaboration with the laboratory of Prof. Hanswalter 
Zentgraf at the DKFZ, such antibodies were aimed to be developed. 
 
Figure 25 
 
Antibody sensitivity test. Western blot strips containing BAMBI full length protein (1-1 to 4-2), isolated from whole 
cell lysates of E.coli cells overexpressing the protein, or TP53 protein (4-3 and 4-4) with His-tag attached were stained 
by immune reaction with antibody containing conditioned cell media from different hybridoma cell clones, α-His 
(Qiagen) antibody for positive or TBS buffer for negative control. TP53-His was kindly provided by Prof. Hanswalter 
Zentgraf. 
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Conditioned media of the generated hybridoma cell clones were used for testing 
of the antibodies on Western blots (Figure 25). The sensitivity of the antibodies 
contained in the conditioned media was very high in samples 11, 17, 55, 92, 
118 and 123, but very low in samples 215 and 225. Specificity is low in 
samples 11, 17 and 118, as seen by their detection of other bands. TBS control 
was negative, showing only overshadowing of very strong signal from α-His 
control, and TP53 positive controls are also positive. Samples with the best 
balance of high sensitivity and specificity were 123, 138, 153, 167 and 189. 
 
In order to validate the specificity of the antibodies produced by the hybridoma 
cells, the antibody containing media needed to be tested against whole cell 
lysates containing either BAMBI or BMPR1B proteins in their native form. To 
do such a test, it was therefore necessary to express these proteins in 
mammalian cell lines. However, it proved impossible to generate such cells: 
While transfection of cells was successful with the "empty" pBCHGs vectors, as 
seen by positive fluorescence of GFP protein, the cells transfected with either 
pBCHGs containing GFP-BAMBI or GFP-BMPR1B fusion genes showed no 
significant fluorescence (data not shown). To exclude any cell-type specific 
effects of GFP-BAMBI or GFP-BMPR1B overexpression, the transfection method 
was evaluated with cell lines from different tissue origins, as e.g. epithelial cells 
(MCF-7, HeLa), osteosarcoma cells (U20S), hepatocellular carcinoma cells 
(HEPG2) or embryonic cells (HEK-293). However, even though all of these cells 
incorporated the DNA vectors, none of them produced sufficient amounts of 
fluorescent fusion proteins of GFP with BAMBI or BMPR1B to be used for 
testing with immuno-histochemical methods. 
Some of the tested cell lines did produce very rarely a faint signal of GFP fusion 
proteins, but the signal was too weak. The transfection with GFP-only vectors 
had an efficiency of 60-70%, depending on cell type (data not shown). At this 
point, a commercial monoclonal antibody against BAMBI protein had become 
available, and the development of an antibody was not pursued. 
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4.5 Immuno-Histochemical Analysis of Patients 
With the identification of genes, of which the expression in the tumors of 
primary breast cancer patients allows classification of these patients into 
responders or non-responders to the tested chemotherapy, candidates for 
corresponding marker proteins were identified. 
To test some of these markers for clinical applicability, sections of paraffin-
embedded tumor biopsies were obtained from the Clinic for Gynecology and 
Obstetrics of the University Heidelberg, from 80 of the 100 patients that were 
included in the final microarray analysis. Unfortunately, only four sections per 
patient were available, limiting the number of possible tests. 
Antibodies against six different proteins were selected for their involvement in 
pathways enriched in the gene expression signature (BAMBI, BMP4, LMO4, 
SMAD3, SRC) or for the known responsibility for hereditary predisposition to 
develop breast cancer (BRCA1). Four of these proteins were used in double-
stains, and two solitary in single stains. These proteins were chosen Following 
the recommendations of the manufacturer, the double stains were performed 
with the use of NovaRed and SG (dark grey) chromogens. However, the 
applicability of the technique was limited, as strong and therefore dark red 
stains obscured weaker grey staining (Figure 26). For that reason, the results 
of the staining against SMAD3 and BRCA1 were evaluated with caution. 
The staining for the different proteins was assessed by scoring of the tumor 
cells in the tissue biopsies only. Scoring was performed both in respect to 
staining intensity (scores 0-3) as well as percentage of stained cells. 
Localization of the cell staining was not accounted for. 
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Figure 26 
 
Immuno-histochemical double-staining. Example of breast cancer tissue samples stained with both BMP4 (red) and 
SMAD3 (grey) chromogens. A. Image representing a tissue sample with good discrimination between both stainings 
(yellow arrows). B. Image showing a tissue sample with dark red and/or grey stainings that were difficult to 
discriminate between (green arrows). 
 
 100 
Figure 27 
 
Box plots showing protein expression of markers. Marker expression was measured by immuno-histochemical 
staining, in tumors from patients of the different response groups. Tumor cells in three different fields of sight were 
evaluated at 10x magnification. Boxes represent values within 1st to 3rd quartile of patients, red lines indicate medians 
of patients and whiskers represent minimum and maximum value within statistical significance. Outlier values, 
representing not statistically significant tumor staining percentages, are represented by circles. KI67 and TP53 
measurements were performed in the Clinic for Gynecology and Obstetrics of the University of Heidelberg. 
 
For statistical analysis, box-plots of the percentages were performed with 
regard to the classification of the patients into responder and non-responder 
patients (Figure 27). Additionally, all different combinations of linear 
dependencies between the staining patterns as well as between them and 
important clinical markers were analyzed using linear models for the 
estimation of probabilities (Table 20). Probability values lower than 0.01 are 
marked by green fields and bold italic writing, while p-values between 0.01 and 
0.05 are marked by yellow fields and bold writing. The upper panel A shows the 
dependencies of the markers as measured by immuno-histochemistry, among 
each other. The lower panel B shows also dependencies of these with the 
clinical markers, as well as therapy (GEDoc versus GEsDoc), patient response 
(pCR versus non-pCR) and pathological status of their tumors (pCR, pPR and 
pNC). The input denotes the percentage value that was used for the 
classification of the scored other variables (output). 
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Table 20 Probability Values for Dependencies Based on Linear Models *  
Input (Percentage of Stained Tumor Cells) A 
BAMBI % BMP4 % BRCA1 % LMO4 % SMAD3 % SRC % TP53 % KI67 % 
BAMBI   0.119 0.004 0.353 0.064 0.412 0.466 0.903 
BMP4 0.145   0.514 0.106 0.058 0.449 0.662 0.720 
BRCA1 0.004 0.398   0.441 0.517 0.121 0.423 0.394 
LMO4 0.182 0.026 0.075   0.693 0.157 0.615 0.248 
SMAD3 0.134 0.078 0.255 0.167   0.068 0.527 0.308 
SRC 0.113 0.023 0.366 0.155 0.386   0.536 0.047 
TP53 0.972 0.720 0.664 0.117 0.472 0.631   0.174 
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KI67 0.674 0.574 0.340 0.319 0.378 0.964 0.003   
  
Input (Staining Intensity Score / Factor) 
B Re-
sponse 
The-
rapy 
Gra-
ding ER PgR HER2 BCL2 
BAM-
BI BMP4 
BRCA
1 LMO4 
SMAD
3 SRC 
Response   0.385 0.040 0.000 0.000 0.012 0.052 0.557 0.472 0.944 0.101 0.332 0.548 
Therapy 0.385   0.610 0.901 0.745 0.701 0.311 0.001 0.600 0.560 0.920 0.654 0.009 
Grading 0.123 0.563   0.025 0.037 0.050 0.000 0.374 0.441 0.507 0.490 0.331 0.908 
ER 0.000 0.823 0.008   0.000 0.099 0.005 0.507 0.644 0.688 0.307 0.679 0.405 
PgR 0.000 0.409 0.050 0.000   0.048 0.054 0.312 0.811 0.399 0.743 0.468 0.786 
HER2 0.029 0.637 0.056 0.058 0.162   0.491 0.585 0.922 0.358 0.591 0.217 0.711 
BCL2 0.040 0.436 0.001 0.010 0.023 0.621   0.151 0.352 0.020 0.866 0.482 0.397 
BAMBI 0.781 0.005 0.133 0.560 0.969 0.498 0.768   0.076 0.000 0.711 0.222 0.016 
BMP4 0.593 0.557 0.495 0.013 0.035 0.548 0.356 0.157   0.818 0.041 0.026 0.139 
BRCA1 0.116 0.443 0.838 0.466 0.060 0.653 0.025 0.000 0.803   0.716 0.140 0.028 
LMO4 0.262 0.862 0.453 0.426 0.192 0.595 0.804 0.835 0.010 0.876   0.956 0.236 
SMAD3 0.563 0.901 0.712 0.598 0.355 0.290 0.978 0.808 0.110 0.223 0.509   0.534 
SRC 0.708 0.033 0.830 0.101 0.175 0.374 0.411 0.005 0.220 0.024 0.085 0.214   
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Pathol. 
Status 
0.000 0.377 0.122 0.000 0.000 0.042 0.153 0.030 0.628 0.189 0.153 0.428 0.394 
  
 
Response (pCR/non-pCR); Therapy (GEDoc/GEsDoc); Grading (G1/G2/G3); ER, estrogen receptor score (0-12); 
PgR, progesterone receptor score (0-12); Pathol. Status, pathological status at surgery (pCR/pPR/pNC); 
all other markers scored 0-3. Data for ER, PgR, HER2, BCL2, TP53, KI67 as well as clinical factors provided by the 
Clinic for Gynecology and Obstetrics, University of Heidelberg. 
* P-values below 0.01, green; p-values between 0.01 and 0.05, yellow. 
 
 
 
In some cases, a strong reciprocal dependency was detected, e.g. for BAMBI 
with BRCA1 or ER with PgR. However, there are cases that show unidirectional 
dependencies, as for example SRC depending on BMP4 percentage but not vice 
versa. 
According to these linear models, the pathological status (pCR/pPR/pNC) was 
highly associated with ER and PgR status, and HER2 and BAMBI protein 
expression showed good association. Response to chemotherapy (pCR/ 
non-pCR), a slightly different classification, was highly associated with ER and 
PgR status. HER2 protein expression showed good association, but there was 
no significance in expression of BAMBI. Notably, the type of therapy given was 
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associated with BAMBI protein expression, although the therapies were 
administered after aquisition of the samples. 
Between the different marker proteins, the linear models showed strong 
associations of BAMBI and BRCA1, KI67 and TP53, and good associations 
between both LMO4 or SRC and BMP4, respectively. 
One clinical marker, the grade of the tumors, was strongly associated with 
BCL2 score and showed significant association with ER, PgR and HER2 status. 
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5. Discussion 
 
5.1. Messenger RNA Amplification and Labeling Protocol 
The use of oligonucleotide microarrays for expression analysis of small biopsies 
from tumor material from female patients set the task of developing an 
appropriate protocol for amplification of the messenger ribonucleic acids. Since 
the established protocols could not be applied per se to be used with sense-
orientated oligonucleotides spotted on arrays for complementarity reasons, the 
known protocols needed to be either adapted or entirely substituted. 
Several different methodologies were tested for this purpose, and evaluated 
with respect to amplification rate, dye incorporation efficiency in total and in 
comparison of both dyes used, linearity of the amplification across different 
mRNA molecule sizes and applicability to the oligonucleotide microarray 
technology. Additionally, the usefulness from the economic and laboratory 
handling standpoints were also taken into consideration for the decision of the 
most appropriate protocol. 
 
The first analysis, the incorporation rate in total and in comparison between 
both fluorescent dye nucleotide types (Figures 13 and 14), shows a strong 
disadvantage of the PALDA and IVT methods. As the Primer-Assisted Linear 
DNA Amplification (PALDA) uses Taq or Pfu exo- DNA polymerases for 
integration of fluorescently labeled dyes, a low incorporation rate was initially 
expected. To overcome this restraint, a high concentration of labeled dyes was 
used initially, and the amplification procedure was performed for 2x 50 cycles 
to reach the necessary amplification efficiency. Nevertheless, the yield of 
fluorescently labeled DNA was very low in comparison with the other protocols. 
The IVT labeling protocol, designed to integrate fluorescently labeled RNA 
molecules during in vitro transcription, was also expected to have a low 
incorporation rate and thus was started with a high concentration of the 
labeled nucleotides. Although the efficiency of fluorescent nucleotide 
incorporation is not comparable with the best methods in this respect, it is 
significantly better compared to the PALDA protocols and sufficient for 
hybridization to the microarrays. However, the incorporation was shown to 
have a strong bias, supposedly from a preference of the RNA polymerase used 
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in this protocol towards Cy3-labeled nucleotides. This effect, seen as a Cy3:Cy5 
ratio of approximately two, is significantly higher in IVT labeling than all other 
tested protocols, which have a maximum ratio of 1.4. 
 
While the yield and incorporation ratio were measured on the amplified nucleic 
acids directly and in total, the following analyses were performed with amplified 
and labeled nucleic acids actually hybridized to the oligonucleotides on the 
microarrays. As a benchmark for the comparison of the protocols, the direct 
labeling protocol was performed and evaluated along with the amplification 
procedures. 
Consecutive to the yield measurements was the issue of what proportion of 
amplified molecules effectively participated in the hybridization, or to which 
extent the amplified material was an interfering side-product. To answer this 
question of amplification specificity, analyses of signal-to-background intensity 
ratios of the array features were performed (Figure 15). The IVT labeling 
method results in a very high signal-to-background ratio of more than 200, 
approximately 4-fold higher than the direct labeling method with a ratio of 
approximately 57. Not surprisingly, and probably resulting from both the 
fractionation and the strand non-specificity of the Klenow enzyme used in 
these protocols, the Baugh + Klenow (TAcKLE) as well as Single Primer 
Amplification (SPA) methods yielded approximately 50% or 30% of the ratio of 
direct labeling, respectively. However, these results were acceptable, whereas 
the results of the PALDA and Baugh Standard protocol were not. 
 
Continuing with specificity, the results of repeat experiments were analyzed 
both in the same-versus-same (equivalent) and differential hybridization setting 
by estimating correlation coefficients across all valid features of the 
microarrays (Figure 16). Unfortunately, the correlation could not be calculated 
between two differentially hybridized samples for all protocols. In general, the 
correlation allows elucidating, whether the measured signal intensities are 
really specific for the genes. Sufficient reliability was seen for Baugh + Klenow 
(TAcKLE), IVT, ts-SPA and direct labeling, with correlation coefficients of 0.9 or 
higher for R2. Baugh Standard and SPA performed poorly, while for PALDA this 
analysis was not possible due to the very limited yield. On the other hand, 
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results from differential hybridizations showed a limited decrease of correlation 
in case of the direct labeling protocol, as compared to the value for the 
equivalent hybridizations. This is also the case in ts-SPA, while the 
Baugh+Klenow (TAcKLE) shows a strong decrease to approximately 60% of the 
R2 of equivalent hybridizations. 
 
While in the microarray analyses for the performance of amplification methods 
above only valid spots were taken into consideration, the percentage of spots 
not valid for analysis was of great interest too. Figure 17 depicts the ratio of 
these so-called outlier spots, averaged for the arrays of each protocol. Outliers 
are those spots that either have no intensity and were therefore flagged as such 
by the software or those that were manually flagged as false positives by the 
user. The PCR protocol, which was used for negative control, had an extremely 
high percentage of such outliers (50%), and the PALDA protocol (28.5%) also 
had a significantly high proportion. The other PCR-based methods had 
tolerable, but higher percentages than direct labeling (18.6% and 16.1% for 
SPA and ts-SPA, respectively), while the Baugh Standard and Baugh + Klenow 
methods performed similar to direct labeling (12.2%-14.2%). The IVT labeling 
had the lowest outlier percentage (11.5%). 
 
Another view taken on the performance of the amplification and nucleic acid 
labeling was the analysis of linear trend lines from scatter plots of feature 
intensities. This trend should ideally be close to the bisecting line of the plot, 
as the total raw intensity distributions from the two dye channels should be 
similar. Irregularities were displayed by the slope and intersection point on the 
ordinate of this trend. Significant deviations of the slope between the 
intensities for both channels from one or deviations of the intersection on the 
ordinate from the origin were considered hazardous. However, as the slope also 
varies with the amount of input mRNA, slight variations seen with all tested 
methods were considered acceptable. Apart from the PCR method, used as a 
negative control, the slopes were all within 1 ± 0.25 (data not shown). The 
interception on the ordinate showed a very strong variation for the IVT labeling, 
reflecting the differences in the incorporation between Cy3- and Cy5-modified 
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nucleotides (Figure 18). All other protocols considered for amplification were 
well within the acceptable range of 0 ± 500. 
 
Finally, the quality of the valid features was assessed by estimating the 
homogeneity, averaging all ratios of mean to median for each spot per array. 
This parameter is generally used for filtering of features in microarray analysis 
and was therefore an important determinant of data validity. To normalize for 
the different numbers of valid spots, the percentage of valid features outside 
the accepted homogeneity interval was calculated (Figure 19). As the threshold 
for filtering microarray features with this parameter varies between 20% and 
30% in final data analysis, the IVT labeling protocol and PALDA method were 
considered as too erratic.  
 
In summary, the amplification procedure best applicable and most stable in 
the comparison of the protocols was the Baugh + Klenow method, which had 
been based on studies by Eberwine et al., Baugh et al. and Kenzelmann and 
co-workers. It was later named "T7-based Amplification of cDNA and Klenow 
Labeling for Expression Analysis", or TAcKLE analysis. 
The second most appropriate procedure, which had been considered for 
multiple reasons, was the template-switch Single Primer Amplification, or ts-
SPA. This method was based on works of Ena Wang et al. and Matz and co-
workers.127,129 The advantages mainly comprised laboratory handling and 
economic rationales, as the fewer reaction steps are also very commonly used 
and cost-effective. However, the lack of discrimination between differentially 
hybridized samples was the major objective to disregard the method, along with 
its weaker overall performance, e.g. signal-to-background ratio and outlier 
feature percentage. 
 
The TAcKLE analysis procedure was therefore chosen as the method of choice 
to amplify and label mRNA from core needle biopsy samples for subsequent 
hybridization to oligonucleotide microarrays. 
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5.2. Gene Expression Signature Predictive for Chemotherapy in Primary Breast 
Cancer 
 
The study investigated and presented here aimed at the identification of a gene 
expression signature, which allows for the classification of patients according 
to their response to GE(s)Doc chemotherapy. For female primary non-
metastatic breast cancer patients receiving a neoadjuvant triple chemotherapy 
consisting of the regimen gemcitabine, epirubicin and docetaxel, this classifier 
should allow prediction of reaching the pathologically proven complete 
remission of their tumor at time of surgery with high sensitivity and accuracy. 
 
The patients were enrolled in two slightly different clinical studies, designated 
GEDoc and GEsDoc, which differ in their administration schedule and dosage 
(Figure 8). While the GEDoc cohort received all three therapeutics in parallel, 
the GEsDoc cohort received the third therapeutic, docetaxel, sequentially after 
gemcitabine and epirubicin treatment. As both clinical studies yielded the 
same percentage of pathological complete remission (pCR) of 26%, and all other 
parameters remained similar, they were considered to be comparable also on 
the molecular biology level.47,104 The GEsDoc cohort of patients was used as 
training set to identify the gene expression signature, while the GEDoc cohort 
was used as independent test set to estimate predicive power of this signature. 
The patients agreed to contribute to the microarray study with a core biopsy 
taken from their tumor, from which RNA was extracted, amplified, labeled and 
hybridized to the microarrays using the TAcKLE analysis procedure. 
 
As the threshold for the sensitivity of the prediction classifier was set to be at 
least 80% or 12 of 15 patients in the training group to prove its clinical 
applicability, the number of genes necessary for prediction was 512. Although 
it is possible to deduce a ranking of these genes in respect to their 
discriminating power, it is important to point out that in the theory of the used 
algorithm, the Support Vector Machines (SVM), none of the genes has a higher 
importance than the others. Each of the genes used for the classification has 
the same weight, and is therefore as necessary to make the prediction as the 
other genes. 
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When comparing the predictive power of the gene expression signature with the 
clinical predictive factors for chemotherapy to date, e.g. tumor grading, HER2 
expression, hormone receptor status or clinical response after six weeks of 
therapy, the signature proved to be of superior predictive value (Table 18). In 
the test patients group, only the HER2 score (0-2 versus 3) shows a significant 
independent predictive value, but with a lower predictive power than the 
signature. Other proposed candidates, e.g. clinical response after 6 weeks of 
treatment, do not have any statistically significant predictive values, while 
tumor size (smaller than 5 cm) and grading (G1/2 versus G3) only show a 
predictive trend. 
 
For comparison of the gene expression signature with other clinically relevant 
expression data published in respect to breast cancer and the usefulness of 
microarrays, these have to be divided into three groups:95,105,148,149 
(a) Prognostic molecular profiles, using unsupervised clustering of all or only 
pre-selected subsets of genes, were aimed at molecular classification or the 
prospective classification of disease-free and overall survival or metastasis. 
These data sets, as those of Sorlie et al., van 't Veer et al., Perou et al. and 
others following since, provide valuable information about the patient's tumors 
genetic setup, and have helped to understand and interpret the heterogeneity 
of the clinical course of patients.93,105,106,150 However, these studies are not 
related with the type of treatment, and thus cannot be compared with this 
study. 
(b) Predictive molecular profiles that are aimed at long-term effects of 
(adjuvant) treatments, e.g. tamoxifen, trastuzumab and others, or at the 
prediction of chemo-resistance had been done in retrospective manner. These 
studies need long follow-up monitoring of the patients, as the effects of 
treatment or resistance can only be seen after five or more years. Therefore, 
results are not available yet for comparison. 
(c) Predictive molecular profiles that identify gene expression signatures for 
chemotherapy, ideally in the neoadjuvant setting, are the only studies that the 
gene expression signature presented here can currently be compared to, if the 
therapy settings are relatively comparable. 
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The latter group of studies is aimed at identifying gene expression patterns or 
signatures predicting response to chemotherapy. This topic is an intensely 
investigated research field, and a number of studies have already been 
published since the start of this thesis (Table 21). It is necessary to define the 
clinical setting that can be effectively compared with the study introduced here. 
Two of these recent trials, by Hannemann et al. and Sorlie et al., completely 
failed to find a predictive gene signature, possibly due to their definition of 
response. Although other studies (Chang JC et al., Iawo-Koizumi K et al., 
Dressman HK et al., Paik S et al.) with a similar definition of response 
succeeded in making predictions based on gene expression, endpoints other 
than pathological complete remission have been shown to be only weakly 
associated with patient overall or disease-free survival.98,101 The two most 
comparable of those (Chang, Dressman) also do not show any gene overlap in 
Table 21 Studies of Gene Signatures Predicting Chemotherapy Response  
Authors Tumors (n) 
Prediction 
Endpoint 
Molecular 
Tool 
Genes 
(n) Publication 
08/2003, 110 
Chang JC et al. 24 Response* in (A) Affymetrix HgU95-Av2 (12k) 92 Lancet 
06/2004,111 
Ayers M et al. 42 pCR in (T+FAC) custom cDNA array (31k) 74 J Clin Oncol 
01/2005,151 Iawo-Koizumi K 
et al. 70
§ CR in (D) ATAC-PCR (2,453) 85 
J Clin Oncol 
05/2005, 114 Hannemann J 
et al. 48 
"near" pCR in (AD 
vs. AC) 
custom cDNA 
(18k) -- J Clin Oncol 
08/2005,152 
Rouzier R et al. 82 (22b) pCR in (T+FAC) Affymetrix U133A -- (61b) 
Clin Cancer Res 
10/2005,153 
Gianni L et al. 89; 82¶ pCR in (AT+T); (T+FAC) 
RQ-PCR (384); 
Affymetrix U133A 
(14k) 
86 (79) 
J Clin Oncol 
02/2006,154 Dressman HK 
et al. 37 
Clinical Response# 
in (AT) 
Affymetrix U133 
Plus 2.0 (38.5k) 38 Clin Cancer Res 
08/2006,115 
Paik S et al. 424 Response
† in 
(Tam+CMF/MF) 
RQ-PCR (21) 21 
J Clin Oncol 
11/2006,155 
Sørlie T et al. 81 PR in (A vs. FMi) custom cDNA (8k A / 30k FMi) -- Mol Cancer Ther 
12/2007,156 Bonnefoi H 
et al. 66; 59
¶ pCR in (FEC); (D+ED) 
Affymetrix X3P 
(38.5k) NA Lancet Oncol 
A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; D, docetaxel; M, methotrexate; Mi, mitomycin; 
T, paclitaxel; Tam, tamoxifen; CR, complete response; pCR, pathological complete response; PR, partial response 
 
* defined as ≥75% regression of tumor; § primary or locally recurring breast cancers; b basal-like patient subgroup; ¶ two 
differently treated patient cohorts; # defined as absence of pos. lymph nodes; † defined as freedom of distant recurrence 
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their predictive signatures. This could be due to the facts that both studies 
used a very limited number of patients, and without validating their signatures 
in an additional patient set. The studies by Iawo-Koizumi as well as Paik and 
respective co-workers were performed on pre-selected gene sets, and are thus 
not comparable to any of the other studies, including the one performed here. 
 
A limited number of patients (n=42) was also the basis for the analysis Ayers et 
al. performed on chemotherapy comprised of sequentially administering 
T (paclitaxel) and triple therapy with FAC (5-fluorouracil, doxorubicin, 
cyclophosphamide). Nevertheless, the authors split the patients into two 
groups to independently build and then test their signature classifier. While all 
other parameters differed only insignificantly between their training and 
validation cases, the percentage of patients reaching pathologic complete 
remission was significantly higher in the validation group (39%) versus the 
training group (25%). The overall accuracy of their 74-gene classifier in the test 
group was 78%, with a sensitivity of 43% and a specificity of 100%. When 
compared to the present study, the focus of Ayers et al. on the high specificity 
becomes evident, making sure to select only patients that would benefit from 
the therapy. In contrast, the focus of the study discussed here was put on the 
highest overall accuracy (88%), resulting in a much higher sensitivity (78%) but 
accepting a comparably lower specificity (90%). 
Patients receiving the same chemotherapy regimen as in Ayers and co-workers 
study were analyzed in a trial performed by Rouzier et al. In their investigation, 
the authors decided to differentiate the patients first by usage of the "breast 
cancer intrinsic gene set", previously published by Sorlie et al. in 2001.106 
Then, using the four different molecular subtypes of patients they received, 
these were subjected separately to the identification of gene expression 
signatures. As the resulting patient subgroups were again very small, and two 
of them had a very low to no percentage of pCR patients, only the HER2+ and 
basal-like subsets could be used. As a benefit, these two subsets had a higher 
pCR patient percentage (45% in both) than the entire collective. However, only 
for the basal-like subset a gene signature predictive for pCR could be identified, 
containing 61 genes. Due to the pre-clustering of patients, the results of the 
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Rouzier study cannot be compared with the outcome of the study presented 
here. 
Gianni et al. also included patients receiving T/FAC as chemotherapy 
treatment. However, these authors first performed the gene expression 
signature identification on a different set of patients, who received doxorubicin 
and paclitaxel followed by another paclitaxel regimen (AT+T; INT-Milan cohort). 
After identification of the gene signature, it was then tested on patients treated 
with T/FAC (MDACC-Houston cohort). Adding to this complication, the INT-
Milan group was assessed using RQ-PCR to identify a predictive gene subset 
out of 384 pre-selected genes, yielding an 86-gene signature classifier. This 
signature was then tested on the MDACC-Houston cohort, which had been 
profiled using gene expression microarrays, to validate its performance within 
that dataset. Only 79 of the 86 genes were represented in the microarray 
dataset, and 24 of these showed an association with pCR in the MDACC-
Houston dataset of p ≤ 0.05. Again this study cannot be directly compared to 
the investigation here, due to Gianni et al. limiting the number of investigated 
genes for identification of the signature. 
In the most recent study in the field, performed by Bonnefoi and co-workers, 
gene signatures identified by cell culture experiments to be predictive for 
resistance against single chemotherapy agents were used in a combinatorial 
approach. Both investigated patient cohorts, treated either with FEC (5-
fluorouracil, epirubicine and cyclophosphamide) or D+ED (docetaxel 
sequentially followed by epirubicine and docetaxel, published "TET"), were used 
to validate gene expression signatures deduced from cell line experiments for 
the single chemotherapy agents in an earlier study.157 The investigated patients 
of this study, however, were pre-selected to be ER-negative. Although it is also 
not comparable with the study performed in this thesis, the work of Bonnefoi et 
al. is very interesting the way it may lead into the future, as it successfully 
integrated separate gene signatures for each chemotherapeutic drug on a 
bioinformatic level. If this procedure of identifying signatures for single drugs 
and applying them in a combinatorial fashion to patients receiving multi-drug 
therapies proves successful in general, it could facilitate the urgent solution to 
tailor the chemotherapy to each patient's best benefit. 
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In summary, most of these trials, which were published in the four years since 
the presented study was started, are not comparable with it. Often the 
investigators lacked the necessary accuracy in defining the clinically relevant 
study endpoint, a pathologically assured complete remission (response) of the 
tumor after chemotherapy. Additionally, the datasets are often strongly biased, 
either by a pre-selection of genes based on literature research and historical 
presumptions, by the pre-selection of patients to increase the response rates of 
the investigated cohorts artificially, or both. 
The study that can be best compared with the one presented in this thesis is 
the one performed by Ayers et al. Unfortunately, the authors took a different 
perspective on the focus of the statistical analysis, in terms of sensitivity versus 
specificity, than this study. The overlap of genes from their 74-gene signature 
classifier and the 512-gene signature identified here amounts to three genes 
only (APOE, NME2, SCARA3). Taken into consideration that the gene 
expression methods, statistical approaches and most importantly the 
chemotherapeutical treatment for the patients used differ largely, this is not 
surprising. 
 
Whether the signatures derived from all these studies, including the one 
presented here, are specific to the chemotherapeutic regimens used to treat the 
patients, provide a general applicability with any chemotherapy, or a mixture 
thereof remains to be determined. But as the two studies that can be best 
compared directly show very little overlap, a general applicability seems to be 
more unlikely. A more standardized approach to the clinical endpoints as well 
as the molecular methods would be necessary to address this question for 
different studies. However, some of the research groups that investigated gene 
expression signatures for prediction in breast cancer mixed different 
methodologies even within the same study. A truly comparative clinical trial, 
evaluating patients receiving different treatments with the same biological 
methods and statistical approach, is therefore essential to find a definitive 
answer. 
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5.3. Genes and Pathways involved in Prediction of Chemotherapy Response 
The genes of which the expression levels enable to discriminate between 
patients fully responding to the chemotherapy and those not fully responding 
were identified and ranked according to their discriminating power by 
statistical analysis. Of these, the top 512 genes had been determined to be 
necessary for a predictive classification into responders and non-responders 
with a prediction sensitivity of ~80% and thus ensure its significance, as 
proven by multivariate logistic regression testing. 
Most generally, bioinformatic tools to identify gene or protein associations rely 
on the correct annotation of genetic information with the function of their 
corresponding proteins and the interplay they have in a body or cell. This 
information, which is gathered by the scientific community and made known 
through their publications, is collected and stored in databases, which are 
maintained by bodies of scientific consortia. The 512 genes of the signature 
presented here were analyzed using databases incorporating Gene Ontology 
annotation data (GO and FatiGO), revealing functional and signaling 
interconnections of encoded proteins (KEGG) and harboring published 
functional and protein interaction information (NCBI Gene and Pubmed 
databases).142-144 
 
A Fisher test was used to identify statistically significant enrichments of genes 
within the gene signature as compared to all genes represented on the 
microarrays, determined by Gene Ontology (GO) terms (Table 19). According to 
these, the gene signature represents a number of genes that could be 
associated with the chemotherapeutic action of the regimen the patients 
received, consisting of gemcitabine (a cytidine nucleoside analogue to which no 
other nucleoside can be attached), epirubicine (a DNA-intercalating 
anthracycline additionally producing free radicals in the cells) and docetaxel 
(stabilizing GDP-bound β-tubilin and thus preventing depolymerization of 
microtubules). However, groups of genes could be shown to be active in other 
pathways that were not directly associated with the action of the 
chemotherapeutics (Table 22). These include genes associated with RAS 
signaling and the related protein farnesylation metabolic pathway, the TGF-β 
signaling and associated bone remodeling pathways as well as gene involved in 
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DNA damage perception or response and genes playing a role in apoptotic 
pathways. 
 
 Table 22 Signature Genes Related to Pathways or Cellular Processes  
rank gene gene description 
Regulation of TGF-β / EP300 pathway 
19 LMO4 LIM domain transcription factor LMO4 (LIM-only protein 4) (LMO-4) (Breast tumor autoantigen). 
23 BAMBI BMP and activin membrane-bound inhibitor homolog precursor (Putative transmembrane protein NMA) (Non-metastatic gene A protein). 
24 EP300 E1A-associated protein p300 (EC 2.3.1.48). 
97 BMP4 Bone morphogenetic protein 4 precursor (BMP-4) (BMP-2B). 
98 CREB3 Cyclic AMP-responsive element-binding protein 3 (Luman protein) (Transcription factor LZIP-alpha). 
107 SMURF2 Smad ubiquitination regulatory factor 2 (EC 6.3.2.-) (Ubiquitin-protein ligase SMURF2) (Smad-specific E3 ubiquitin ligase 2) (hSMURF2). 
171 SRC Proto-oncogene tyrosine-protein kinase Src (EC 2.7.1.112) (p60-Src) (c-Src). 
222 TRIP6 Thyroid receptor interacting protein 6 (TRIP6) (OPA-interacting protein 1) (Zyxin related protein 1) (ZRP-1). 
325 TGIF2 Homeobox protein TGIF2 (TGFB-induced factor 2) (5'-TG-3' interacting factor 2) (TGF(beta)-induced transcription factor 2). 
RAS pathway 
2 RASAL1 RasGAP-activating-like protein 1. 
30 A-RAF A-Raf proto-oncogene serine/threonine-protein kinase (EC 2.7.1.37) (A-raf-1) (Proto-oncogene Pks). 
48 DAB2IP DAB2 interacting protein isoform 2. 
133 RAB32 Ras-related protein Rab-32. 
142 RRAGC Ras-related GTP binding C. 
227 RAB5A Ras-related protein Rab-5A. 
298 RASL11B RAS-like family 11 member B. 
307 RASA3 Ras GTPase-activating protein 3 (GAP1(IP4BP)) (Ins P4-binding protein). 
396 RASSF1 Ras association domain family 1 (Ras association, RalGDS/AF-6, domain family 1). 
412 RHEB GTP-binding protein Rheb (Ras homolog enriched in brain). 
456 MRAS Ras-related protein M-Ras (Ras-related protein R-Ras3). 
484 RSU1 Ras suppressor protein 1 (Rsu-1) (RSP-1). 
Regulation of apoptosis 
1 DAPK2 Death-associated protein kinase 2 (EC 2.7.1.37) (DAP kinase 2) (DAP- kinase related protein 1) (DRP-1). 
58 DIP death-inducing-protein 
99 KIAA1303 Regulatory-associated protein of mTOR (Raptor) (P150 target of rapamycin (TOR)-scaffold protein). 
168 BAK1 Bcl-2 homologous antagonist/killer (Apoptosis regulator BAK) (BCL2- like 7 protein). 
181 MRPS30 Mitochondrial 28S ribosomal protein S30 (S30mt) (MRP-S30) (Programmed cell death protein 9) (BM-047). 
208 MRPL37 Mitochondrial ribosomal protein L37 
274 MRPL30 Mitochondrial ribosomal protein L30 isoform a. 
360 FRAP1 FKBP-rapamycin associated protein (FRAP, mTOR) (Rapamycin target protein). 
DNA damage response 
88 BRAP BRCA1-associated protein (EC 6.3.2.-) (BRAP2) (Impedes mitogenic signal propagation) (IMP) (RING finger protein 52). 
346 TP53BP1 Tumor suppressor p53-binding protein 1 (p53-binding protein 1) (53BP1). 
355 CHEK2 Serine/threonine-protein kinase Chk2 (EC 2.7.1.37) (Cds1). 
446 TP53RK TP53 regulating kinase (EC 2.7.1.37) (p53-related protein kinase) (Nori-2). 
 
487 RAD51C DNA repair protein RAD51 homolog 3. 
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Genes contained in the signature from these functional groups cannot be 
considered to act independently, as the analysis of protein function of the 
respective relevant genes from these pathways reveals. Signature genes are 
highlighted by blue letters in the following. 
 
RAS Signaling Pathway 
Analysis of genes in the signature using Fisher's test identified protein 
farnesylation as a highly significant metabolic pathway in the Gene Ontology 
terms. The corresponding genes in the signature are members of or closely 
related to the Ras superfamily of proteins, which is well known as potential 
target for oncogenic transformation of cells. Many of the small GTPases, 
including the Ras, Rho and Arf subfamilies of these proteins are post-
translationally modified by covalent addition of a farnesyl group, an isoprenoid, 
which anchors these proteins in the plasma membrane. This modification step 
is administered by an enzyme called farnesyl-transferase. Due to the oncogenic 
potential of Ras, the application of farnesyl-transferase inhibitors (FTI) for 
therapeutical use is currently under investigation in clinical trials.158 
The genes belonging to the Ras signaling pathway or related to it, that were 
contained in the gene expression signature predicting the response, were 
MRAS, a homologue to the main signaling kinase HRAS. MRAS was initially 
found in muscle cells but is now known to be expressed also e.g. in epithelial 
cells, A-RAF, coding for a downstream effector kinase of Ras proteins as well as 
genes coding for other Ras-associated proteins like e.g. RHEB, RRAGC or 
RASAL1, that are held responsible for GTP recruitment or GDP/GTP exchange. 
The latter are necessary for RAS and RAF proteins to perform their 
phosphorylating enzymatic function or for recycling the GTP molecules. 
Muscle RAS oncogene homolog (MRAS), one of the genes of the Ras family, was 
reported to be engaged in regulating cell-cell adhesion via intracellular 
adhesion molecules (ICAMs).159 It was reported to bind to different downstream 
effectors of the RAF subfamily, leading to the inhibition of activation of the 
transcription factor FOS in a competitive manner.160 Mutant MRAS was more 
recently reported to induce epithelial-mesenchymal transition (EMT) and 
tumorigenesis.161 
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The downstream effector of RAS proteins, v-raf murine sarcoma viral oncogene 
homolog (A-RAF) activates the MAP kinase kinase MEK1 in epidermal growth 
factor-stimulated HeLa cells in the classical RAS signaling cascade.162 
Additionally, A-RAF was shown to bind directly to phosphatidylinositol 
3-kinase (PI3K), thus the A-RAF kinase also interacts with the G-protein 
coupled receptor signaling pathway.163 As a third role, A-RAF was also reported 
to interact specifically with two novel human proteins, referred to as hTOM and 
hTIM, which are similar to components of mitochondrial outer and inner 
membrane protein-import receptors from lower organisms.164 A-RAF was 
detected in purified mitochondrial fractions of cells, suggesting that a 
proportion of A-RAF is present in the inner matrix compartment of 
mitochondria. While a current hypothesis exists that the major effector kinase 
RAF1 is involved in apoptotic signaling through its association with BCL2 and 
mitochondrial outer membrane, a similar mode of action for A-RAF could be 
implied by the finding. 
 
TGF-β Signaling Pathway 
The general TGF-β signaling pathway includes TGF-β receptor proteins, which 
tetramerize upon binding of their ligands (BMP or TGF-β) and activate R-SMAD 
transcription factors by phosphorylation. Activated R-SMADs dimerize with Co-
SMAD proteins to form a transcription factor that is able to enter the nucleus 
and bind DNA (Figure 28).165 The transcription is further regulated by site-
specific co-factors as well as co-activator and co-repressor proteins that bind to 
the SMAD-DNA complex and mediate or inhibit the transcription of target 
genes. Members of TGF-β signaling family protein genes were identified to be 
significantly over-represented in the signature, e.g. the bone morphogenic 
ligand BMP4, the pseudo-receptor "BMP and activin membrane-bound inhibitor 
homolog precursor" (BAMBI), the inhibitory downstream regulator "Smad 
ubiquitination regulatory factor 2" (SMURF2) as well as the TGF-β -induced 
transcription factor 2 (TGIF2), the co-factor LMO4, and the co-activators of 
transcription EP300, CREB and the proto-oncogene SRC. 
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Figure 28 
 
Basic TGF-β pathway. Receptor-regulated SMAD transcription factors (R-SMADs) require transforming growth factor-
beta (TGF-β) -induced phosphorylation to assemble transcription regulatory complexes with partner SMADs (co-
SMADs). R-SMADs can move into the nucleus on their own but, to be accessible to membrane receptors, R-SMADs are 
tethered in the cytoplasm by proteins such as SARA (SMAD anchor for receptor activation). Receptor activation occurs 
when TGF-β induces the association of two type I and two type II receptors. Both receptor components have a 
serine/threonine protein kinase domain in the cytoplasmic region. In the basal state, the type I receptor is kept 
inactive by a wedge-shaped GS region, which presses against the kinase domain, dislocating its catalytic centre. In the 
ligand-induced complex, the type II receptor phosphorylates the GS domain and this activates the type I receptor, 
which catalyses R-SMAD phosphorylation. Phosphorylation decreases the affinity of R-SMADs for SARA and increases 
their affinity for co-SMADs. The resulting SMAD complex is free to move into the nucleus and competent to associate 
with transcriptional co-activators or co-repressors. SMADs can contact DNA, but effective binding to particular gene 
regulatory sites is enabled by specific DNA-binding co-factors. R-SMADs that move into the nucleus may return to the 
cytoplasm, but their ubiquitylation- and proteasome-dependent degradation in the nucleus provide a way to terminate 
TGF-β responses. From J. Massague, 2000.165 
The transforming growth factor TGF-β plays a dual role in its mode of action, 
as it can both act as mediator of transformation as well as an inhibitor of 
proliferation. Its dual role is mainly cell-type dependent, and it has been shown 
to have tumor suppressor activity in early stages of tumorigenesis, while 
operating as a promotor of tumor cell invasiveness and metastasis in advanced 
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tumors.165-167 The tumor suppressor activity includes the arrest of the cell cycle 
in epithelial, endothelial and hematopoetic cells at the early G1 phase via 
SMAD protein-mediated transcriptional regulation of critical regulators of the 
cell cycle, e.g. by transcriptionally inhibitory promotor elements leading to 
repression of c-Myc and CDK4, maintenence of Rb in hypo-P state as well as 
control of cell-cycle inhibitors (CKIs) such as p15 (Ink4) and p21/p27/p57 
(Cip/Kip family) proteins. 
TGF-β is also known to induce the epithelial-mesenchymal transition (EMT) in 
an oncogenic manner, thus enhancing proliferative, migratory, invasive and 
metastatic potential of the cells. TGF-β thereby acts in an autokrine loop, 
sustaining its acivity on the invasive cells. On the contrary, closely related BMP 
proteins fail to elicit EMT, and higher levels of BMP proteins inhibit TGF-β from 
inducing EMT. BMPs have been shown to be able to reverse EMT and lead to 
MET. Therefore, the ratio between BMP and TGF-β in tumor cells may be of 
importance in the decision of migration potential and invasiveness. However, in 
a cooperative manner, active RAS/RAF signaling further enhances the 
establishment of EMT, as do PI3K and Rho GTPase signaling. 
 
The transcriptional co-activators or -repressors present in the nucleus facilitate 
and determine the mode of action of the activated SMAD dimers. 
Transcriptional activators include CREB binding proteins, EP300 and 
repressors include TGIFs like TGIF2, among others. The repressors bind 
histone deacetylases (HDACs), while activators generally act as histone 
acetyltransferases (HATs). In general, TGIFs bind to SMAD2 and SMAD3 in a 
competitive manner to EP300, so the relative levels of these transcriptional 
regulator proteins determine the activating versus repressing mode of action of 
TGF-β. Thus, TGF-β signaling leads to inactivation of gene expression in many 
cases.168 Additionally, there is evidence for cross-talk between RAS/MAP-
kinase and the TGF-β pathway in that TGIF2 was shown to be phosphorylated 
in response to EGF signaling. Another known debranching from the classical 
TGF-β pathway leads to a cross-talk with the MAP kinase pathways on the level 
of Jun-amino-terminal kinase (JNK, MAPK8) associated transcription factors, 
also known as AP-1 family.169 It was shown that TGF-β harbors the ability to 
increase the activity of AP-1 (JUN-FOS) complexes through phosporylation by 
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JNK or the activity of ATF2 transcription factor (which also contains HAT 
activity) binding to CREB complexes, either resulting in an activation of AP-1 or 
CREB target genes (Figure 29). 
Figure 29 
 
Crosstalk between the SMAD and mitogen-activated protein kinase pathways. The three principal MAPK 
pathways in mammalian cells may affect the SMAD pathway through various mechanisms. The Ras–MEK–ERK 
pathway can decrease TGF-β receptor levels by controlling expression, attenuate SMAD accumulation in the 
nucleus by phosphorylating SMADs in the linker region and increase the level of the SMAD corepressor TGIF by 
stabilizing this protein. The MKK4/JNK and MKK3/p38 pathways, which can be activated by various cytokines, 
enhance the activity of Jun and ATF2 transcription factors that may cooperate with SMADs through direct physical 
contacts. In certain cell types and conditions, the MKK4/JNK and MKK3/p38 pathways are reportedly activated by 
TGF-β itself, and the proteins XIAP, HPK1 and TAK1 might be involved in this link. The direct nature and 
physiological relevance of these interactions remain to be established. (ATF2, activating transcription factor 2; ERK, 
extracellular-signal-regulated kinase; GRB2, growth factor receptor-binding proteins 2; JNK, Jun amino-terminal 
kinase; XIAP, Xenopus inhibitor of apoptosis; HPK1, haematopoietic progenitor kinase 1; TAK1, TGF-β -activated 
kinase; MAPK, mitogen-activated protein kinase; MKK, MAPK kinase; R-SMAD, Receptor-regulated SMAD 
transcription factors; sos, son of sevenless; TGF-β, transforming growth factor-beta.) From J. Massague, 2000.165 
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The receptor protein BAMBI acts as a negative regulator in the TGF-β signaling 
pathway. It is located in the plasma-membrane of cells, has high homology to 
the BMP receptor BMPR1B, but lacks an intracellular serine/threonine kinase 
domain required for signaling. As the BMP receptor proteins are required to 
tetramerize upon BMP or TGF-β signaling to perform their activating 
phosphorylation function, the BAMBI protein acts as a so-called pseudo-
receptor, inhibiting downstream signaling. Expression of BAMBI was described 
by Sekiya et al. to be upregulated by TGF-β/BMP signaling-mediated activation 
of the transcription factor SMAD3/4 dimer, thus acting in a negative feedback 
loop.170 BAMBI expression was also found by the authors to be elevated in 
colorectal and hepatocellular cancers. 
In 2001, Visvader et al. explored a role for LMO4, initially described as a 
human breast tumor autoantigen, in developing mammary epithelium and 
breast oncogenesis.171 The gene was expressed predominantly in the 
lobuloalveoli of the mammary gland during pregnancy. Consistent with its role 
in proliferation, forced expression of this gene inhibited differentiation of 
mammary epithelial cells. Overexpression of LMO4 mRNA was observed in 5 of 
10 human breast cancer cell lines. Moreover, in situ hybridization analysis of 
177 primary invasive breast carcinomas revealed overexpression of LMO4 in 
56% of specimens. Immuno-histochemistry confirmed overexpression in a high 
percentage (62%) of tumors. These studies implied a role for LMO4 in 
maintaining proliferation of mammary epithelium and suggested that 
deregulation of this gene may contribute to breast tumorigenesis. 
LMO proteins act as transcription factor regulators, do not bind to DNA directly 
but associate with other transcription factors (CLIM1 and especially CLIM2 for 
LMO4). LMO4 expression was also reported to be associated with a worse 
prognosis and overexpression in mammary glands of mice led to inhibition of 
mammary gland development, hyperplasia and intraepithelial neoplasia.172,173  
Identifying LMO4 as a transcription regulation factor that does not bind 
directly to DNA but other transcription factors, Ning Wang et al. recently 
identified BMP7 protein (a BMP4 homologue) as one of the highly significant 
target genes of LMO4 regulation through recruitment of the histone deacetylase 
HDAC2 to the binding site.172,174 Other upregulated genes include e.g. AKT1, 
RHOB, SMAD5 and TGFBRAP1 while among the downregulated genes were e.g. 
 121
MBD1 (methyl-CpG binding domain protein 1), RERG (RAS-like estrogen-
regulated growth inhibitor) and RRAS. Markedly, the only statistically 
significant Gene Ontology process enriched in the set of deregulated genes was 
apoptosis. In the study presented by Ning Wang et al., BMP7 decreased 
proliferation and induced apoptosis. In 2003, a different role for LMO4 was 
suggested by Sutherland and co-workers as a BRCA1-interacting protein, 
repressing its transcriptional activity.175 The authors concluded that the high 
expression of LMO4 in sporadic breast cancers may alter the stoichiometry of 
BRCA1 expression, leading to an inhibition of its tumor-suppressing function. 
 
Regulation of Apoptosis 
Among the genes contained in the signature, apoptosis regulation seemed to 
play a particular role in classifying patient response groups. While cells that 
undergo apoptosis can be triggered for the programmed cell death by either of 
two pathways, it seemed striking that only those of the mitochondria-related 
apoptosis mechanism were contained, but not genes from the mechanism 
regulated by the caspase protein signaling cascade. 
The signature genes involved in apoptosis regulation included the death-
associated protein kinase 2 (DAPK2), death-induced protein (DIP), BCL2-
antagonist/killer 1 protein BAK1 and other mitochondrial proteins as well as 
the rapamycin-associated protein genes KIAA1303 (RPTOR) and FRAP1. 
Whether DAPK proteins regulate the activation of mitochondrial apoptosis 
program via BAX and BAK1 upon TGF-β signaling, as proposed by Pardali and 
Moustakas (Figure 30), remains unclear.167 However, a direct interaction of the 
TGF-β pathway with the proteins of the AKT/mTOR pathway was 
demonstrated by association of SMAD3 with FRAP1 (also called mammalian 
target of rapamycin, mTOR), in which FRAP1 suppresses the phospho-
activation of SMAD3.176 The authors proposed a model of an AKT kinase-
dependent inhibition of SMAD3 through FRAP1, and a resulting loss of tumor 
suppression by TGF-β in cancer. In 2007, Creighton discovered a link between 
gene expression patterns derived from overexpression of AKT in mouse-models 
and human breast cancer gene expression studies by meta-analysis.177 Genes 
upregulated by AKT and dependent on FRAP1 activity were associated with 
poor prognosis in these studies. 
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Figure 30 
 
The apoptotic response program. TβRII in the TGF-β receptor complex directly binds DAXX, which recruits HIPK2 
and becomes phosphorylated by HIPK2, leading to activation of MKK3/4/7. The same kinases can be activated by 
TAK1 which is activated by Smad7 (I-Smad) bound to the receptor complex. MKKs then phosphorylate and activate 
JNK or p38 MAPKs. JNK activates the AP-1 transcriptional complex, leading to induction of pro-apoptotic genes (red 
circular nodes) in cooperation with Smads. p38 activates caspase-8 (Cas8), which activates the pro-apoptotic factor 
Bid, leading to cytochrome C (cyt C) release and activation of the apoptosome (cyt C/Apaf1/Caspase-9 (Cas9) complex), 
which activates caspase-3 (Cas3) and executes apoptosis. The TGF-β receptor complex signals by unknown mechanism 
(?) to mitochondrial ARTS, which inhibits XIAP, the inhibitor of caspase 3, leading to apoptosis. The activated nuclear 
Smad complex induces transcription of pro-apoptotic genes such as Bim, DAPK, GADD45β, TIEG1, and SHIP. Bim 
activates the pro-apoptotic Bax, which leads to cytochrome C release and caspase activation. DAPK modulates the 
action potential of the mitochondrial membrane and induces apoptosis via yet unknown molecular mechanisms (?). 
GADD45β interacts with and activates MKK4, thus activating the p38 pro-apoptotic pathway. TIEG1 is a transcription 
factor that regulates additional pro-apoptotic genes, but it is not clear whether these include those listed in the figure 
(?). SHIP inhibits PI3K. Smad3 can directly interact and inhibit the activity of Akt/PKB in addition to transactivating 
pro-apoptotic target genes. Activated Smads also induce expression of the pro-survival factor FLIP, which exits the 
nucleus and activates the transcriptional activity of NF-κB, thus inducing the expression of other anti-apoptotic 
factors. Growth factors signaling via receptor tyrosine kinases (RTK) activate the Ras/PI3K/Akt/PKB pathway. Akt 
phosphorylates the pro-apoptotic protein Bad, thus activating the anti-apoptotic protein Bcl-xL, which blocks 
cytochorome C release. Akt also activates FRAP1 (mTOR), which inhibits R-Smad phosphorylation by the TGF-β 
receptor complex, and directly inhibits the pro-apoptotic JNK, while activating the pro-survival NF-κB pathway. In 
addition to NFκB Akt phosphorylates the pro-apoptotic transcription factor FoxO3a, leading to its cytoplasmic 
retention and transcriptional inactivation of its target pro-apoptotic genes such as Fas ligand (FasL). All pro-apoptotic 
events are shown in dark red and all pro-survival events are shown in green. From Pardali & Moustakas, 2006.167 
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DNA Damage Response 
Although representing a smaller group of genes in the signature as the others 
described before, the gene activities involved in perception and regulation of 
DNA damage appeared to be significantly altered (Table 19). Signature genes 
belonging to these pathways were BRAP and RAD51C, two genes associated 
with the BRCA1 protein, TP53BP1 and TP53RK, which are both associated with 
the tumor suppressor TP53, and CHEK2, a cell cycle regulator important for 
checking DNA damage before entering replication. 
The BRCA1-associated protein BRAP was identified by its ability to bind to the 
nuclear localization signal of BRCA1 and to regulate nuclear targeting by 
retaining proteins with a nuclear localization signal in the cytoplasm. In 2004, 
a direct association of BRAP (also named IMP) with the RAS pathway was 
reported and its function as an ubiquitin E3 ligase for a RAF/MEK1 complex 
inhibitor was discovered.178 Whether the interaction of BRCA1 with BRAP has 
to do with its transcription factor or the DNA-damage dependent function of 
BRCA1 is not known. 
RAD51C is known to be involved in the homologous recombinational repair 
pathway of damaged DNA and in meiotic recombination. However, the gene 
coding for this protein is located on a region of chromosome 17q23 where 
amplification occurs frequently in breast tumors. It is therefore unclear, which 
effect is causal for the finding of highly expressed RAD51C transcript.  
Tumor protein p53 binding protein 1, TP53BP1, is clearly associated with 
activation of ATM in response to DNA double strand breaks.179 It binds to ATM 
as well as to TP53 protein. TP53RK, or TP53 regulating kinase, is known to 
activate TP53, but apart from one report claiming a binding of the protein to 
HER2, very little is known about its upstream signaling.180 
 
Expression of the Signature Genes in Perspective of Pathways 
In order to evaluate the measured expression in the female breast cancer 
studies in respect to the response of the patients to the chemotherapy given, it 
was necessary to define the view point of the gene expression regulation 
between the two response classes. Here, the expression ratios between pCR 
and non-responder patients were estimated, and should be taken as up- or 
downregulated in pCR patients versus non-pCR patients (Table 23). 
 124 
As the non-responder patients were comprised of patients with pathologically 
no change as well as partial remission, and the latter in a much larger number, 
these ratios should not be taken as absolute truth. However, it was expected 
that the genes could provide valuable information about the differences and 
maybe even the cause of response to chemotherapy. 
 
Table 23 RNA Expression of Signature Genes and BRCA1  
Gene 
Symbol 
Oligo 
ID logn (pCR)
logn 
(non-pCR) 
logn 
(pCR/non-pCR) 
A-RAF OL006360 -0.56 -0.18 -0.378 
MRAS OL020413 1.81 1.39 0.416 
RASAL1 OL014803 0.67 0.10 0.577 
  
RHEB OL017532 -0.71 -1.04 0.325 
  
BAMBI OL006551 -0.93 -1.59 0.657 
BMP4 OL005655 -1.49 -0.94 -0.550 
SMURF2 OL014622 0.48 -0.07 0.554 
CREB3 OL009199 0.20 0.24 -0.035 
EP300 OL003498 0.36 0.55 -0.194 
SRC OL014799 0.84 0.58 0.265 
  
LMO4 OL000848 1.32 0.39 0.932 
  
DAPK2 OL012804 2.32 1.88 0.441 
FRAP1 OL019848 -1.04 -0.83 -0.212 
RPTOR OL002920 -0.33 -0.16 -0.173 
  
BAK1 OL010567 0.19 -0.10 0.292 
  
BRAP OL012396 -0.73 -0.79 0.053 
RAD51C OL001998 -1.16 -1.50 0.341   
BRCA1 OL014601 -1.94 -2.03 0.086 
  
TP53BP1 OL007925 -0.45 -0.34 -0.112 
TP53RK OL017620 -0.38 -0.26 -0.120   
CHEK2 OL013553 -0.71 -1.07 0.359 
  
  
 
As the literature proposed, it may be suggested that the major difference 
between patients not responding to the chemotherapy to the responders is 
given by the fact that activation of RAS was shown to induce EMT. In the 
patients investigated here, the effector kinase MRAS shows a higher expression 
in the responders, leading to the conclusion that responder patients might 
have a higher induction of tumor cell transformation. However, the signal 
transducing protein A-RAF shows the direct opposite expression ratio, with a 
higher expression in the non-responder patients. It is therefore unclear, 
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whether a stronger activation of the Ras pathway and consequently a higher 
induction of EMT in responder patients could be reasoned by these results. 
 
The transcription regulator LMO4, acting most probably as inhibitor of 
differentiation, is strongly upregulated in responder patients, which would fit 
very well to the fact that undifferentiated cells are more likely to respond to 
chemotherapy due to their proliferative turnover, which is targeted by the 
chemotherapeutic regimen. As the interactions of the TGF-β signaling and Ras 
signaling were described, the combination of the findings here would lead to 
the conclusion that the responder patients had tumors cells which were 
proliferating more and had a lower grade of differentiation. This is very well in 
accordance with the KI67 measurements, as seen by IHC (Figure 27), and with 
the findings in the literature that LMO4 maintains cells in a proliferative state, 
and tumors with high LMO4 expression have a worse prognosis. 
While the stronger activation of BMPs was seen as generating the opposite 
effect and rather maintain cells in the differentiated state according to the 
literature, the finding that BMP4 was also upregulated in responder patients 
must not be in disagreement. It is possible to postulate that the highly 
proliferative cells try to find the balance and thus counteract by expressing 
BMPs. The results of a higher expression of BAMBI and SMURF2 in the 
responder tumors, both representing inactivating feedback loops in the TGF-β 
signaling, supports this idea. 
 
As Pao et al. reported, the activating co-regulators of TGF-β -induced 
transcription EP300 and CREB interact with BRCA1 and activate its 
transcription.181 Here, a clear difference in the expression of these coactivators 
could not be seen between response classes, and there were also no differences 
in the expression of BRCA1. However, the highly probable dependencies 
between BAMBI and BRCA1, as well as between SRC and BRCA1, as seen in 
the linear model analysis, imply a strong positive association of the TGF-β 
pathway signaling with the mechanism of DNA damage response. 
 
The upregulation of the DNA damage-related genes RAD51C and CHEK2 
measured in responder patients could not be explained by a more proliferative 
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tumor tissue. It may be possible that due to high proliferation or other 
mechanisms, the DNA of these tumor cells is unstable. However, for TP53BP1 
and TP53RK, the proteins associated with the tumor suppressor TP53, the 
gene expression were measured as slightly downregulated in responder 
patients, again supporting the idea of a more proliferative tumor tissue in these 
patients. 
 
Concerning the genes differentially regulated between patient classes in the 
apoptosis pathways, it is difficult to decide, whether the DNA and microtubule 
damages triggered by the chemotherapy drugs have an additive effect to the 
pre-therapeutic results presented here or not. However, as the transcription of 
DAPK2 and its possible downstream pathway molecule BAK1 showed a very 
clear differentiation between both patient groups, with an upregulation in 
responder tumors, it is explainable that these cells can be killed more 
effectively by chemotherapeutic intervention. 
 
The results presented here for FRAP1 (mTOR), and the associated scaffolding 
protein KIAA1303 (RPTOR) do not conform well to the published data. As 
FRAP1 activation was reported to repress TGF-β -dependent tumor 
suppression, and a dependence of genes predicting poor prognosis on the 
activation of FRAP1 was shown, it is unclear how the downregulation of both 
proteins in responder patients could be matched with these reports. 
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5.4. Antibody Generation using Mouse Hybridoma Cells 
As there was no antibody available against the BAMBI protein at the time when 
the gene expression signature was compiled, a validation of the genetic results 
on protein expression was impossible. However, as the protein seemed to be an 
interesting candidate for a more detailed analysis, a good antibody was 
required. In order to generate it, a truncated form of the BAMBI protein was 
expressed in E.coli cells, containing only the unique cytoplasmatic and 
transmembrane protein domains, and isolated using a His-tag. 
Hybridoma cells, generated using plasma cells from mice vaccinated with this 
truncated BAMBI, were grown in cell culture, and conditioned media of 
different cell clones were tested. These antibody containing media were shown 
to have a sufficient sensitivity for detection of BAMBI, as tested by staining of 
Western blots containing the full length protein, again generated using E.coli 
cells (Figure 26). For a thorough test of the specificity of these antibodies and 
evaluating them in the native state, an expression of the BAMBI protein was 
necessary in eukaryotic cell cultures. 
However, it was not possible to express this gene in such cells in culture, 
although they showed sufficient transfection efficiencies with the vectors 
containing GFP control protein. When human culture cells from different tissue 
origins were transfected with either GFP-BAMBI or GFP-BMPR1B (negative 
control) fusion proteins, they showed no fluorescence and an elevated 
apoptosis rate, so the expression could not be observed (data not shown). 
Therefore, it was impossible to test for specificity of the antibodies from the 
conditioned media, and an appropriate antibody could not be obtained. At this 
point, a commercially produced monoclonal antibody had become available, 
and the generation of an antibody against BAMBI protein was abandoned. 
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5.5. Immuno-histochemical Analysis of Tumors 
In order to validate the results that were generated with gene expression 
profiling on microarrays and with RQ-PCR, a suitable number of genes was 
selected to be analyzed with immuno-histochemical staining on tissue sections 
from the same patient tumor samples. For this purpose, four consecutive 
tumor sections of 80 patients could be obtained. As the number of selected 
proteins was six, however, two of these sections were required to be stained 
with two antibodies each. 
For data analysis, sections for each patient and antibody were interpreted in 
staining intensity (score 0-3) and the percentage of tumor cells, for three 
representative areas, if available. Data for ER and PgR scores, TP53, KI67, 
HER2 and BCL2 were provided by the pathology department of the university 
clinic. The generated data were then analyzed for the patient classes. Using a 
linear model prediction algorithm, the immuno-histochemical stainings were 
analyzed for associations among each other and in comparison with clinical 
data of the patients: tumor grading, pathological outcome and response of the 
patients, as well as the therapy administered to the patients.  
Due to the small sample size, these associations were considered statistically 
significant only if the p-value was below 0.01, even though a p-value below 
0.05 was considered an association. As expected, significant associations were 
seen between ER and PgR scores. Very good associations were also seen 
between response (pCR versus non-pCR) and both ER and PgR, BCL2 and 
tumor grading (G1-2/G3), BRCA1 and BAMBI as well as BAMBI and therapy 
(GEDoc/GEsDoc). The latter seemed not explainable, as the therapy was 
administered after the acquisition of the tumor biopsies analyzed here and as 
both therapies were considered equally effective. However, due to the small 
sample size especially in the case of pCR patients in both therapy studies, such 
a finding might be explained by minor accidental differences between patients, 
or the ability of the linear model algorithms to detect small but consistent 
differences between the groups. However, as the majority of other parameters 
and stainings were far from such a highly significant p-value, a connection 
between differences in the patients achieving pCR concerning the BAMBI 
expression levels of their tumors and the therapy schedule administered 
cannot be ruled out. 
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Statistically not as significant associations were shown between LMO4 and 
each of BMP4, SMAD3 or SRC proteins, but as these belong to the same 
signaling pathway, this was considered a probable result. More astonishing in 
this respect seemed the fact that LMO4 was exclusively associated with BMP4, 
but none of the other TGF-β proteins. 
The protein markers best associated with the response of patients were ER, 
PgR, HER2, BCL2 and LMO4, in decreasing order. 
 
To illustrate the extent of relative differences in the protein expression, 
according to their IHC staining percentages, these were depicted as box-plots 
(Figure 27). In case of TP53, the box plot seems misleading:  Due to the fact 
that patients either showed a very high or low (or no) expression of TP53 
protein, the statistical analysis here was restricted by the different sizes of the 
response groups. As the non-pCR group was large (n=52), the relatively few 
highly TP53-positive patients appear as outliers, while the much smaller pCR 
group (n=17) appears to have a wider dynamic range, thus the high percentage 
tumors are represented as the 3rd quartile. In fact, only one patient shows 
intermediate expression of TP53 (40%), while the others show values of either 
≥90% or ≤20%. This circumstance is represented by the medians in both 
groups, which show similar values. 
In general, for most protein stainings, the box plots showed only lesser 
differences between the patient classes, except for KI67 and LMO4. This 
reflects the results from the microarray gene expression study only in part, as 
some genes show a markedly higher difference in their RNA expression levels, 
as in the cases of BAMBI and BMP4 (Table 23). A significant difference between 
IHC staining and gene expression data, as measured both by microarrays and 
RQ-PCR (Figure 23), is seen in the lower median expression of LMO4 protein in 
the pCR group. However, it should be taken into consideration that only 
samples from 80 patients were available for IHC staining as compared to the 
microarrays (n=100), that the number of pCR patients was small in respect to 
the non-pCR group, that the staining of SMAD3 and BRCA1 were preliminary 
due to double staining evaluation difficulties and that the protein expression 
could be regulated post-transcriptionally as well as post-translationally. 
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The deviations seen for some factors between the protein expression, as 
measured by IHC, and the gene activity, as measured by microarray and 
RQ-PCR, seem to make the interpretation of the results uncertain. However, 
given the fact that for all but one of the gene expression values, these 
correspond very well between RQ-PCR and the microarray results, these can be 
considered absolutely valid. Therefore, the RNA expression experiments used 
for the prediction of therapy response and pathway analysis are validated and 
undisputed.  
The differences between the protein expression and the RNA expression, as 
seen in this study, could be explained: Firstly, the mechanisms of post-
transcriptional regulation, like e.g. RNA transport from the nucleus, 
modifications to or even degradation of the mRNA (editing, silencing and 
interference mechanisms) as well as the translation into proteins have long 
been known.2,182 Secondly, such differences between the expression levels of 
RNA and protein, especially in cancer, have been reported, for example by the 
oncogenic deregulation of RNA translation into protein by phosphatidylinositol-
3-kinase (PI3K), which has been identified as required for the transformation 
cells to and has been reported to be dependent on mTOR and RHEB.183 
Whether the proteins of the genes, for which a deregulation between RNA 
expression and protein expression in this study is seen, are activated or 
deactivated by such a mechanism, could not be elucidated here. A much more 
detailed protein analysis, which also includes analysis of post-translational 
modifications such as phosphorylation, would be needed for this question to be 
answered. 
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6. Outlook 
In the thesis presented here, the method of microarray expression profiling 
analysis using long oligonucleotide DNA probes was applied for the 
identification of a gene signature predicting response to chemotherapy in 
breast cancer, starting from small tumor biopsies taken at time of diagnosis. 
For this aim, a novel procedure to amplify and label mRNA from small RNA 
sources for hybridization to oligonucleotide microarrays had to be developed 
and introduced, and had also proven applicable. However, the input minimum 
of 2 µg of total RNA limits its usefulness, and thus has been improved to 
500 ng in the meantime. Further improvements to the minimum input amount 
are currently only possible through a repetition of the amplification steps, 
resulting in a further fragmentation and shortening of the labeled nucleic acid 
chains yielded and therefore a loss of dynamic range of the expression profiles. 
Protocols using two-round amplification are currently being investigated for the 
exploitation of microdissected cells retrieved from freshly frozen or paraffin-
embedded tissue sections to be used for oligonucleotide microarrays. A further 
reduction of total RNA input amounts in a single round amplification, below 
500 ng, could improve the quality of the results obtained in such experiments 
and at the same time make more patient samples available for investigation 
using whole-genome expression analysis with long oligonucleotide microarrays. 
 
The signature identified for prediction of the pathologic complete remission of 
primary breast tumors after neoadjuvant application of gemcitabine, epirubicin 
and docetaxel in a tri-fold chemotherapy regimen is comprised of 512 genes, 
and displays a higher sensitivity and specificity than the classical markers 
currently used in the clinic. 
In a new study pursuing the one presented here, other chemotherapy regimens 
for the neoadjuvant therapy of primary female breast cancers are tested in the 
same manner to identify such predictive gene expression signatures. This 
study is comprised of two different treatment arms, is performed in a double-
blind setup, and contains a similar number of patients in each arm as in the 
study presented here. In addition to the task of providing predictive gene 
signatures for each of the treatment arms, the new study will also allow for an 
evaluation of the gene signature presented here in its general applicability of 
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predicting response of female breast cancer to chemotherapy treatment. In this 
way, the genes responsible or predictive for a general response to 
chemotherapy may possibly be identified as well as the genes predictive or 
responsible for the individual chemotherapeutic drugs. The recent finding of 
Bonnefoi et al., who successfully combined genes into a predictive signature 
based on individual gene signatures derived from cell culture experiments with 
single drugs, encourages this point of view.156 Such cell line experiments could 
also be performed for comparison with the gene signatures presented here and 
identified in the pursuing study. 
 
Some of the genes within the predictive signature, that classifies patients 
according to their therapy response as discussed in this thesis, were identified 
to be functionally related. Upon analyzing these genes for possible pathway 
interactions, several genes from the TGF-β and Ras signaling pathways as well 
as genes involved in DNA damage response and apoptosis were identified. 
These genes could possibly represent pathways that are not only functionally 
related to the response of the patients, but also to the development of breast 
cancers and its different tumor types. A closer investigation of the relationships 
between these pathways and the development of breast tumors might be very 
helpful in understanding the heterogeneity of breast cancer patients. 
Additionally, they could provide new drug targets and be good candidates for 
further improvements of existing targeted therapies. As some of these had 
already been identified as genes or proteins related to breast cancer, as e.g. 
BAMBI and LMO4, they should be investigated in greater detail. 
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ʺWhat we observe is not nature itself,  
but nature exposed to our method of questioning.ʺ 
 
Werner Heisenberg   
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8. Appendix 
 
A. Cell Lines HL-60 and NU-DHL-1 
  NU-DHL-1 HL-60 
Cell type human B cell lymphoma human acute myeloid leukemia 
DSMZ N° ACC 583 ACC 3 
Origin 
established from the left inguinal lymph node of a 73-
year-old Caucasian man with B-cell Non-Hodgkin 
lymphoma (B-NHL, diffuse large cell lymphoma, non-
cleaved cell type) in 1982 
established from the peripheral blood of a 35-year-
old woman with acute myeloid leukemia (AML FAB 
M2) in 1976; cells can be used for induction of 
differentiation studies; described to be responsive to 
DMSO, phorbol ester TPA and other reagents and to 
carry amplified MYC gene; present cells are 
apparently tetraploid derivates of hypodiploid original 
where MYC was amplified in dmin (instead of hsr) 
References Epstein et al., Int J Cancer 35:619-627 (1985);
184 
Winter et al., Blood 63:140-146 (1984).185 
Collins et al., Nature 270:347-349 (1977);186 
Gallagher et al., Blood 54:713-733 (1979);187 
Dalton et al., Blood 71:242-247 (1988);188 
Collins, Blood 70:1233-1244 (1987, review).189 
Depositor Dr. A. L. Epstein, USC, Los Angeles, CA, USA Dr. E. Porfiri, The Royal Free Hospital, Department of Haematology, London, UK 
DSMZ Cell Culture Data 
Morphology single, round to polymorph cells growing in suspension round, single cells in suspension 
Medium 80-90% RPMI 1640 + 10-20% FBS 90% RPMI 1640 + 10% FBS 
Subculture 
split saturated culture 1:2 to 1:4 every 2-3 days; 
seed out at ca. 1.0 x 106 cells/ml; maintain at ca. 
0.5-1.0 x 106 cells/ml; recommended to start culture 
in a 24-well-plate and with 20% FBS 
maintain at 0.5-1.0 x 106 cells/ml, split 1:2 to 1:5 
every 1-2 days; seed out at about 1 x 106 cells/ml 
Incubation  at 37 °C with 5% CO2 at 37 °C with 5% CO2 
Doubling time ca. 50 hours ca. 25 hours 
Harvest cell harvest of ca. 1.5 x 106 cells/ml maximal density of 1.5-2.0 x 106 cells/ml 
Storage frozen with 70% medium, 20% FBS, 10% DMSO at about 5 x 106 cells/ampoule 
frozen with 70% medium, 20% FBS, 10% DMSO at 
about 4-5 x 106 cells/ampoule 
DSMZ Scientific Data 
Mycoplasma negative in microbiological culture, PCR assays negative in DAPI, microbiological culture, RNA hybridization, PCR assays 
Immunology 
CD3 -, CD10 -, CD13 -, CD19 +, CD20 +, CD34 -, 
CD37 +, CD38 -, CD79a +, cyCD79a +, CD80 -, 
CD138 -, HLA-DR +, sm/cyIgG -, sm/cyIgM +, 
sm/cykappa -, sm/cylambda + 
CD3 -, CD4 +, CD13 +, CD14 -, CD15 +, CD19 -, 
CD33 +, CD34 -, HLA-DR - 
Fingerprint fluorescent nonaplex PCR of short tandem repeat markers revealed a unique DNA profile 
multiplex PCR of minisatellite markers revealed a 
unique DNA profile 
Species confirmed as human by cytogenetics and species PCR confirmed as human with IEF of MDH, NP 
Cytogenetics 
human hyperdiploid karyotype with 4% polyploidy 
51(46-53)<2n>XY, +5, +8, +9, +12, +12, 
t(3;8)(p25;q24), i(5p), dup(7)(q21.3q31.1), 
der(8)t(3;8)(p25;q24), i(9p), del(12)(q11), i(12p), 
der(14)t(14;18)(q32;q21)x1-3 
sideline with dup(2)(p2?1p2?4) 
carries t(3;8) and t(14;18) effecting respective 
rearrangements of MYC and IGH-BCL2 
resembles published karyotype 
human flat-moded hypotetraploid karyotype with 
hypodiploid sideline and 1.5% polyploidy 
82-88<4n>XX, -X, -X, -8, -8, -16, -17, -17, +18, +22, 
+2mar, ins(1;8)(p?31;q24hsr)x2, 
der(5)t(5;17)(q11;q11)x2, add(6)(q27)x2, 
der(9)del(9)(p13)t(9;14)(q?22;q?22)x2, 
der(14)t(9;14)(q?22;q?22)x2, 
der(16)t(16;17)(q22;q22)x1-2, add(18)(q21) - 
sideline with: -2, -5, -15, del(11)(q23.1q23.2) - c-myc 
amplicons present in der(1) and in both markers 
Viruses EBV -, HBV -, HCV -, HIV -, HTLV-I/II - ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV -, HTLV-I/II - 
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B. Manufacturers of Chemicals and Laboratory Material 
 
Agilent 
Agilent Technologies, Inc. 
5301 Stevens Creek Blvd 
Santa Clara , CA 95051 
USA 
Millipore 
Millipore 
290 Concord Rd. 
Billerica, MA 01821 
USA 
Ambion 
Applied Biosystems 
850 Lincoln Centre Drive 
Foster City, CA 94404 
USA 
Molecular Devices 
Molecular Devices 
1311 Orleans Drive 
Sunnyvale, CA 94089-1136 
USA 
Amersham 
Amersham Place 
Little Chalfont 
Buckinghamshire 
HP7 9NA 
United Kingdom 
NanoDrop Technologies 
NanoDrop Technologies 
3411 Silverside Rd 
Bancroft Building 
Wilmington, DE 19810 
USA 
Applied Biosystems 
Applied Biosystems 
850 Lincoln Centre Drive 
Foster City, CA 94404 
USA 
NeoLab 
neoLab Migge GmbH 
Rischerstr. 7-9 
69123 Heidelberg 
Germany 
B.Braun 
B. Braun Melsungen AG 
Carl-Braun-Straße 1 
34212 Melsungen 
Germany 
New England Biolabs 
New England Biolabs 
240 County Road 
Ipswich, MA 01938-2723 
USA 
Bio-Rad 
Bio-Rad Laboratories 
2000 Alfred Nobel Drive 
Hercules, CA 94547 
USA 
Operon 
Operon Biotechnologies, Inc. 
2211 Seminole Drive 
Huntsville, AL 35805 
USA 
Biospring 
BioSpring GmbH 
Alt Fechenheim 34 
60386 Frankfurt am Main 
Germany 
Promega 
Promega Corporation 
2800 Woods Hollow Road 
Madison, WI 53711 
USA 
Dako 
Dako Denmark A/S 
Produktionsvej 42 
DK-2600 Glostrup 
Denmark 
Qiagen 
QIAGEN GmbH 
QIAGEN Strasse 1 
40724 Hilden 
Germany 
Epicentre 
EPICENTRE Biotechnologies 
726 Post Road 
Madison, WI 53713 
USA 
Roche 
F. Hoffmann-La Roche Ltd 
Grenzacherstrasse 124 
4070 Basel 
Switzerland 
Eppendorf 
Eppendorf AG 
Barkhausenweg 1 
22339 Hamburg 
Germany 
Schott Nexterion 
SCHOTT Jenaer Glas GmbH 
Otto-Schott-Strasse 13 
07745 Jena 
Germany 
Fermentas 
Fermentas, Inc.   
798 Cromwell Park Drive   
Glen Burnie, MD 21061 
USA 
Sigma-Aldrich 
Sigma-Aldrich Co. 
3050 Spruce Street 
St. Louis, MO 63103 
USA 
Genomic Solutions 
Genomic Solutions Inc. 
4355 Varsity Drive 
Ann Arbor, MI 48108 
USA 
Stratagene 
11011 N. Torrey Pines Road 
La Jolla, CA 92037 
USA 
GibCo 
Invitrogen Corporation 
1600 Faraday Avenue 
Carlsbad, California 92008 
USA 
TeleChem 
TeleChem International, Inc. 
524 East Weddell Drive 
Sunnyvale, CA 94089 
USA 
Invitrogen 
Invitrogen Corporation 
1600 Faraday Avenue 
Carlsbad, California 92008 
USA 
Thermo Scientific 
Thermo Fisher Scientific, Inc. 
81 Wyman Street 
Waltham, MA 02454 
USA 
Kendro 
Thermo Fisher Scientific, Inc. 
81 Wyman Street 
Waltham, MA 02454 
USA 
Varian Inc. 
Varian, Inc. 
3120 Hansen Way 
Palo Alto, CA 94304-1030 
USA 
Marligen Bioscience 
Marligen Biosciences, Inc. 
2502 Urbana PikeIjamsville, MD 
21754USA 
Vector 
Vector Laboratories 
30 Ingold Road 
Burlingame, CA 94010USA 
  
Merck 
Merck KGaA 
Frankfurter Str. 250 
64293 Darmstadt 
Germany      
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C. Primers for Real-time Quantitative PCR 
 
Gene Primer  (Exon:Exon)§ Sequence, 5' -> 3' Tm [°C]
DCTN2 (2:3) upper CGCCATGGCGGACCCTAAAT 60.5DCTN2 
DCTN2 (2:3) lower TTGTCAGCTCCTCCGCATCGAA 61.5 
GALNAC4S-6ST (5:6,7) upper ATCCACGCCTTTCAGCCAAATG 59.8 
GALNAC4S-6ST 
GALNAC4S-6ST (5:6,7) lower AGCCCAACCTGGAGCCTCACA 60.4 
ERBB2 (16:17) upper CATCAACTGCACCCACTCCTGTGT 59.8 
HER2 
ERBB2 (16:17) lower CTCCACCAGCTCCGTTTCCTG 58.3 
ESR1 (6:7) upper CTCTTGGACAGGAACCAGGGAAAAT 59.6 
ESR1 
ESR1 (6:7) lower CAGGGTGCTGGACAGAAATGTGTAC 58.6 
BAMBI (1:2) upper CGTGCTGCTCACCAAAGGTGAAAT 61.1 
BAMBI 
BAMBI (1:2) lower CATGGGTGAGTGGGGAATTTGAG 59.1 
DAPK2 (7,8:9,10) upper GGCCAAGGACTTTATTCGGAAGC 59.1 
DAPK2 
DAPK2 (7,8:9,10) lower CACAGGGACACGATGCTGAAGGA 60.8 
LMO4 (4:5) upper GTCCCGGGAGATCGGTTTCACT 60.0 
LMO4 
LMO4 (4:5) lower ATGGGATCCACCTGTGATGAACAAA 60.2 
SMAD3 (3,4:5,6) upper GAGCCCCAGAGCAATATTCCAGA 58.3 
SMAD3 
SMAD3 (3,4:5,6) lower GGCCGGCTCGCAGTAGGTAACT 60.4 
SRC (3:4) upper CTGGCCGGTGGAGTGACCAC 59.8 
  
SRC 
SRC (3:4) lower CAAAATACCACTCCTCAGCCTGGAT 58.6 
 
§ primers spanning exon borders are denoted by kommata; PCR products spanning exon borders are denoted by colons 
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D. Genes Contained in the Predictive Gene Expression Signature 
Rank Symbol Description Mapping Ensembl ID Operon ID 
1 DAPK2 Death-associated protein kinase 2 (EC 2.7.1.37) (DAP kinase 2) (DAP- kinase related protein 1) (DRP- 15q22.31 ENSG00000035664 H200012808 
2 RASAL1 RasGAP-activating-like protein 1. 12q24.13 ENSG00000111344 H200014809 
3 THAP8 THAP domain protein 8. 19q13.12 ENSG00000161277 H200020498 
4         H200015020 
5 OAT Ornithine aminotransferase, mitochondrial precursor (EC 2.6.1.13) (Ornithineoxo-acid aminotransfer 10q26.13 ENSG00000065154 H200006115 
6 CPM Carboxypeptidase M precursor (EC 3.4.17.12). 12q15 ENSG00000135678 H200019714 
7 PITPNM2 phosphatidylinositol transfer protein, membrane-associated 2, PYK2 N-terminal domain-interacting rec 12q24.31 ENSG00000090975 H200016945 
8 SLC35B2 
solute carrier family 35, member B2, 3'-
phosphoadenosine 5'-phosphosulfate transporter 
[Homo sapiens 
6p21.1 ENSG00000157593 H200008629 
9 CRYBB2 Beta crystallin B2 (BP). 22q11.23 ENSG00000100058 H200007805 
10 TCF8 Transcription factor 8 (NIL-2-A zinc finger protein) (Negative regulator of IL2). 10p11.22 ENSG00000148516 H200015445 
11         H200001488 
12         H200019153 
13 TOR1B Torsin B precursor (Torsin family 1 member B) (FKSG18 protein). 9q34.11 ENSG00000136816 H200016328 
14 SMU1 
smu-1 suppressor of mec-8 and unc-52 homolog, 
ortholog of rat brain-enriched WD-repeat protein, 
homo 
9p21.1 ENSG00000122692 H200014545 
15 SMYD3 SET and MYND domain containing protein 3 (Zinc finger MYND domain containing protein 1). 1q44 ENSG00000185420 H200001594 
16 ARMC8 armadillo repeat containing 8, HSPC056 protein [Homo sapiens]. 3q22.3 ENSG00000114098 H200011194 
17 C18orf1   18p11.21 ENSG00000168675 H200013878 
18 PRDX1 Peroxiredoxin 1 (EC 1.11.1.-) (Thioredoxin peroxidase 2) (Thioredoxin- dependent peroxide reductase 1p34.1 ENSG00000117450 H200008482 
19 LMO4 LIM domain transcription factor LMO4 (LIM-only protein 4) (LMO-4) (Breast tumor autoantigen). 1p22.3 ENSG00000143013 H200000848 
20 CSNK2A2 Casein kinase II, alpha' chain (CK II) (EC 2.7.1.37). 16q21 ENSG00000070770 H200006904 
21 PTPN13 Protein tyrosine phosphatase, non-receptor type 13 (EC 3.1.3.48) (Protein-tyrosine phosphatase 1E) ( 4q21.3 ENSG00000163629 H200015130 
22         H200011178 
23 BAMBI 
BMP and activin membrane-bound inhibitor homolog 
precursor (Putative transmembrane protein NMA) 
(Non 
10p12.1 ENSG00000095739 H200006552 
24 EP300 E1A-associated protein p300 (EC 2.3.1.48). 22q13.2 ENSG00000100393 H200003499 
25   GT198, complete ORF, TBP-1 interacting protein [Homo sapiens]. 17q21.2 ENSG00000131470 H200017422 
26 SRF Serum response factor (SRF). 6p21.1 ENSG00000112658 H200014058 
27 STK32B serine/threonine kinase 32B, gene for serine/threonine protein kinase [Homo sapiens]. 4p16.2 ENSG00000152953 H200005311 
28 NICAL NEDD9 interacting protein with calponin homology and LIM domains (Molecule interacting with CasL pro 6q21 ENSG00000135596 H200010147 
29 TTC14 Tetratricopeptide repeat protein 14 (TPR repeat protein 14). 3q26.33 ENSG00000163728 H200004622 
30 ARAF1 A-Raf proto-oncogene serine/threonine-protein kinase (EC 2.7.1.37) (A- raf-1) (Proto-oncogene Pks). Xp11.3 ENSG00000078061 H200006361 
31 SLC6A8 Sodium- and chloride-dependent creatine transporter 1 (CT1). Xq28 ENSG00000130821 H200014389 
32 EVL Ena/vasodilator stimulated phosphoprotein-like protein (Ena/VASP-like protein). 14q32.2 ENSG00000196405 H200015749 
33 POLR1D DNA-directed RNA polymerase I 16 kDa polypeptide (EC 2.7.7.6) (RPA16). 13q12.2 ENSG00000186184 H200017450 
34     16p11.2 ENSG00000047578 H200004007 
35   ezrin-binding partner PACE-1 isoform 1 [Homo sapiens]. 1q24.2 ENSG00000000457 H200003382 
36 WDR5B WD repeat domain 5B [Homo sapiens]. 3q21.1 ENSG00000196981 H200013357 
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37 PAFAH1B3 
Platelet-activating factor acetylhydrolase IB gamma 
subunit (EC 3.1.1.47) (PAF acetylhydrolase 29 kD 19q13.2 ENSG00000079462 H200001306 
38     22q11.21 ENSG00000183597 H200020502 
39 WDR8 WD-repeat protein 8. 1p36.32 ENSG00000116213 H200004114 
40 PTPNS1 
Protein-tyrosine phosphatase non-receptor type 
substrate 1 precursor (SHP substrate-1) (SHPS-1) 
(Inh 
20p13 ENSG00000198053 H200014140 
41 AGTRAP 
angiotensin II receptor-associated protein, 
angiotensin II, type I receptor-associated protein 
[Homo 
1p36.22 ENSG00000177674 H200002197 
42 PIK3C2B Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide (EC 2.7.1.154) (Phos 1q32.1 ENSG00000133056 H200013011 
43     9q12, 9p11.2 
ENSG00000196635, 
ENSG00000197068, 
ENSG00000198119, 
ENSG00000196164, 
ENSG00000198052 
H200018900 
44 SULT1A3 Monoamine-sulfating phenol sulfotransferase (EC 2.8.2.1) (Sulfotransferase, monoamine-preferring), 16p11.2 
ENSG00000132207, 
ENSG00000181625 H200017186 
45 PAFAH2 
Platelet-activating factor acetylhydrolase 2, 
cytoplasmic (EC 3.1.1.47) (Serine dependent 
phospholip 
1p36.11 ENSG00000158006 H200015501 
46 C22orf8   22q13.31 ENSG00000100376 H200016550 
47 EPS8L2 epidermal growth factor receptor pathway substrate 8-like protein 2, EPS8-related protein 2, epiderm 11p15.5 ENSG00000177106 H200005141 
48 DAB2IP DAB2 interacting protein, nGAP-like protein, DOC-2/DAB2 interactive protein [Homo sapiens]. 9q33.2 ENSG00000136848 H200015622 
49 PCTP Phosphatidylcholine transfer protein (PC-TP) (StAR-related lipid transfer protein 2) (StARD2) (START 17q23.1 ENSG00000141179 H200008819 
50 TIMM17B Mitochondrial import inner membrane translocase subunit Tim17 B (JM3). Xp11.23 ENSG00000126768 H200002793 
51 C14orf122 UPF0172 protein C14orf122 (CGI-112). 14q11.2 ENSG00000100908 H200016750 
52 CKAP1 Tubulin-specific chaperone B (Tubulin folding cofactor B) (Cytoskeleton-associated protein CKAPI). 19q13.12 ENSG00000105254 H200004062 
53   Pygopus homolog 2. 1q22 ENSG00000163348 H200008025 
54 XRN2 5'-3' exoribonuclease 2 (EC 3.1.11.-). 20p11.22 ENSG00000088930 H200016651 
55   ubiquitin-conjugating enzyme HBUCE1 [Homo sapiens]. 7p13 ENSG00000078967 H200002803 
56 SEC14L2 SEC14-like protein 2 (Alpha-tocopherol associated protein) (TAP) (hTAP) (Supernatant protein factor) 22q12.2 ENSG00000100003 H200017232 
57     8q11.21 ENSG00000164808 H200017329 
58     22q13.31 ENSG00000075240 H200010685 
59         H200008383 
60         H200010303 
61     2q35 ENSG00000124006 H200013996 
62         H200011048 
63 GALK2 N-acetylgalactosamine kinase (EC 2.7.1.-) (GalNAc kinase) (Galactokinase 2). 15q21.1 ENSG00000156958 H200012811 
64 PKN3 protein kinase PKNbeta [Homo sapiens]. 9q34.11 ENSG00000160447 H200004669 
65 GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (BFA-resistant GEF 1). 10q24.32 ENSG00000107862 H200014080 
66     7p14.3 ENSG00000105778 H200013693 
67 EXT2 
Exostosin-2 (EC 2.4.1.224) (EC 2.4.1.225) 
(Glucuronosyl-N- acetylglucosaminyl-proteoglycan/N-
acetylg 
11p11.2 ENSG00000151348 H200006075 
68 MKRN2 Makorin 2 (HSPC070). 3p25.2 ENSG00000075975 H200017431 
69 ADCK1 aarF domain containing kinase 1 [Homo sapiens]. 14q24.3 ENSG00000063761 H200002462 
70         H200017729 
71 C9orf25   9p13.3 ENSG00000164970 H200001541 
72 C6orf199   6q21 ENSG00000155085 H200012502 
73 PEPD Xaa-Pro dipeptidase (EC 3.4.13.9) (X-Pro dipeptidase) (Proline dipeptidase) (Prolidase) (Imidodipept 19q13.11 ENSG00000124299 H200005894 
 xxix
74 BMS1L Ribosome biogenesis protein BMS1 homolog. 10q11.21 ENSG00000165733 H200001947 
75     2p23.3 ENSG00000163026 H200003419 
76 ZNF335 Zinc finger protein 335. 20q13.12 ENSG00000198026 H200007640 
77 AP1G2 
Adapter-related protein complex 1 gamma 2 subunit 
(Gamma2-adaptin) (Adaptor protein complex AP-1 
gam 
14q11.2 ENSG00000092051 H200019914 
78 HPS4 Hermansky-Pudlak syndrome 4 protein (Light-ear protein homolog). 22q12.1 ENSG00000100099 H200001277 
79         H200004418 
80 CACNG4 Voltage-dependent calcium channel gamma-4 subunit (Neuronal voltage- gated calcium channel gamma-4 s 17q24.2 ENSG00000075461 H200010418 
81         H200002313 
82 KDELR3 ER lumen protein retaining receptor 3 (KDEL receptor 3). 22q13.1 ENSG00000100196 H200016239 
83 MYST1 MYST histone acetyltransferase 1, histone acetyltransferase MYST1 [Homo sapiens]. 16p11.2 ENSG00000103510 H200004571 
84 OPTN optineurin, glaucoma 1, open angle, E (adult-onset), tumor necrosis factor alpha-inducible cellular 10p13 ENSG00000123240 H200017355 
85 PROCR Endothelial protein C receptor precursor (Endothelial cell protein C receptor) (Activated protein C 20q11.22 ENSG00000101000 H200006932 
86 ACTG1 Actin, cytoplasmic 1 (Beta-actin)., Actin, cytoplasmic 2 (Gamma-actin). 
7p22.1, 
17q25.3 
ENSG00000075624, 
ENSG00000184009 H200002375 
87 SLC1A3 
Excitatory amino acid transporter 1 (Sodium-
dependent glutamate/aspartate transporter 1) (Glial 
glut 
5p13.2 ENSG00000079215 H200006090 
88 BRAP BRCA1-associated protein (EC 6.3.2.-) (BRAP2) (Impedes mitogenic signal propagation) (IMP). 12q24.12 ENSG00000089234 H200012400 
89 INPP4B inositol polyphosphate-4-phosphatase, type II, 105kD, inositol polyphosphate 4-phosphatase II, 4-pho 4q31.21 ENSG00000109452 H200013899 
90         H200011830 
91         H200010509 
92         H200019925 
93 COL12A1 Collagen alpha 1(XII) chain precursor. 6q13 ENSG00000111799 H200011114 
94 HESX1 Homeobox expressed in ES cells 1 (Homeobox protein ANF) (hAnf). 3p14.3 ENSG00000163666 H200008014 
95 NMNAT1 Nicotinamide mononucleotide adenylyltransferase 1 (EC 2.7.7.1) (NMN adenylyltransferase 1). 1p36.22 ENSG00000173614 H200007228 
96 NPAS2 Neuronal PAS domain protein 2 (Neuronal PAS2) (Member of PAS protein 4) (MOP4). 2q11.2 ENSG00000170485 H200018956 
97 BMP4 Bone morphogenetic protein 4 precursor (BMP-4) (BMP-2B). 14q22.2 ENSG00000125378 H200005656 
98 CREB3 cAMP responsive element binding protein 3, cAMP responsive element binding protein 3 (luman), cyclic 9p13.3 ENSG00000107175 H200009202 
99   Regulatory associated protein of mTOR (Raptor) (P150 target of rapamycin (TOR)-scaffold protein). 17q25.3 ENSG00000141564 H200002921 
100 ATP6V1C2 
ATPase, H+ transporting, lysosomal 42kDa, V1 
subunit C isoform 2, V-ATPase C2 subunit, ATPase, 
H+ tr 
2p25.1 ENSG00000143882 H200008589 
101 C20orf14 U5 snRNP-associated 102 kDa protein (U5-102 kDa protein). 20q13.33 ENSG00000101161 H200004082 
102 AURKB Serine/threonine-protein kinase 12 (EC 2.7.1.37) (Aurora- and Ipl1- like midbody-associated protein 17p13.1 ENSG00000178999 H200008454 
103 FBXO18 F-box only protein 18 (EC 3.6.1.-) (F-box DNA helicase 1). 10p15.1 ENSG00000134452 H200001177 
104         H200009676 
105 RHOBTB1 Rho-related BTB domain-containing protein 1. 10q21.2 ENSG00000072422 H200002445 
106 PTP4A1 protein tyrosine phosphatase type IVA, member 1, Protein tyrosine phosphatase IVA1 [Homo sapiens]. 6q12 ENSG00000112245 H200015401 
107 SMURF2 Smad ubiquitination regulatory factor 2 (EC 6.3.2.-) (Ubiquitin protein ligase SMURF2) (Smad-speci 17q24.1 ENSG00000108854 H200014627 
108 UBTF Nucleolar transcription factor 1 (Upstream binding factor 1) (UBF-1) (Autoantigen NOR-90). 17q21.31 ENSG00000108312 H200010392 
109         H200002419 
110   Autoantigen NGP-1. 1p34.3 ENSG00000134697 H200006126 
 xxx 
111 SUPT4H1 Transcription initiation protein SPT4 homolog 1. 17q23.2 ENSG00000108372 H200006614 
112     17q21.2 ENSG00000141698 H200015595 
113     2p11.2 ENSG00000144115 H200001790 
114         H200008842 
115     12q13.2 ENSG00000135482 H200005456 
116         H200017299 
117 CCNL1 cyclin L1, cyclin L ania-6a [Homo sapiens]. 3q25.31 ENSG00000163660 H200000937 
118 RNU3IP2 U3 small nucleolar RNA interacting protein 2 (U3 small nucleolar ribonucleoproptein-associated 55-kD 3p21.2 ENSG00000114767 H200013906 
119 ASF1B ASF1 anti-silencing function 1 homolog B, anti-silencing function 1B, CCG1-interacting factor A-II [ 19p13.12 ENSG00000105011 H200003654 
120 C9orf100   9p13.3 ENSG00000137135 H200015825 
121 SUMO4 Ubiquitin-like protein SMT3B (Sentrin 2) (HSMT3). 17q25.1, Xq23 
ENSG00000180283, 
ENSG00000188612 H200008406 
122         H200007932 
123 WFDC2 WAP four-disulfide core domain protein 2 precursor (Major epididymis- specific protein E4) (Epididym 20q13.12 ENSG00000101443 H200000668 
124 PABPC4 Polyadenylate-binding protein 4 (Poly(A)-binding protein 4) (PABP 4) (Inducible poly(A)-binding prot 1p34.3 ENSG00000090621 H200007875 
125 C10orf7 D123 gene product [Homo sapiens]. 10p13 ENSG00000151465 H200006879 
126 GRM4 Metabotropic glutamate receptor 4 precursor (mGluR4). 6p21.31 ENSG00000124493 H200008305 
127 NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial precursor (EC 1.6.5.3) (EC 1.6.99.3) (C 2q33.3 ENSG00000023228 H200001624 
128   phosphatidylinositol-specific phospholipase C, X domain containing 1 [Homo sapiens]. Xp22.33 ENSG00000182378 H200003545 
129 TPCN1 two pore segment channel 1, two-pore channel 1, two-pore segment channel 1 [Homo sapiens]. 12q24.13 ENSG00000186815 H200003641 
130 TNFRSF7 Tumor necrosis factor receptor superfamily member 7 precursor (CD27L receptor) (T-cell activation an 12p13.31 ENSG00000139193 H200021166 
131 RKHD2 ring finger and KH domain containing 2 [Homo sapiens]. 18q21.1 ENSG00000176624 H200002191 
132 DTYMK 
Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase).,Thymidylate kinase (EC 2.7.4.9) (dTMP 
kinase). 
2q37.3 ENSG00000168393, ENSG00000188547 H200006601 
133 RAB32 Ras-related protein Rab-32. 6q24.3 ENSG00000118508 H200004149 
134 WBSCR18 Williams-Beuren syndrome chromosome region 18 protein. 7q11.23 ENSG00000176410 H200002733 
135 AKR1C1 Aldo-keto reductase family 1 member C1 (EC 1.1.1.-) (Trans-1,2- dihydrobenzene-1,2-diol dehydrogenas 10p15.1 ENSG00000187134 H200018207 
136 GLTSCR1 Glioma tumor suppressor candidate region gene 1 protein. 19q13.32 ENSG00000063169 H200010786 
137         H200016743 
138         H200000805 
139 SOX9 Transcription factor SOX-9. 17q24.3 ENSG00000125398 H200000590 
140 ST7 suppression of tumorigenicity 7 isoform a, family with sequence similarity 4, subfamily A, member 1, 7q31.2 ENSG00000004866 H200001109 
141 SLC39A14 solute carrier family 39 (zinc transporter), member 14, solute carrier family 39 (metal ion transpor 8p21.3 ENSG00000104635 H200010399 
142 RRAGC Ras-related GTP binding C, Rag C protein [Homo sapiens]. 1p34.3 ENSG00000116954 H200011726 
143         H200016422 
144 FAM20A Protein FAM20A precursor (UNQ9388/PRO34279). 17q24.2 ENSG00000108950 H200013465 
145         H200002577 
146 SALL2 Sal-like protein 2 (Zinc finger protein SALL2) (HSal2). 14q11.2 ENSG00000165821 H200006732 
147 SLC39A11 
solute carrier family 39 (metal ion transporter), 
member 11, chromosome 17 open reading frame 26 
[Ho 
17q24.3 ENSG00000133195 H200000782 
148 GFPT2 Glucosaminefructose-6-phosphate aminotransferase [isomerizing] 2 (EC 2.6.1.16) (Hexosephosphate am 5q35.3 ENSG00000131459 H200003997 
149 MRS2L MRS2-like, magnesium homeostasis factor, MRS2 (S. cerevisiae)-like, magnesium homeostasis factor [Ho 6p22.2 ENSG00000124532 H200003978 
150         H200009425 
 xxxi
151 GBA Glucosylceramidase precursor (EC 3.2.1.45) (Beta-glucocerebrosidase) (Acid beta-glucosidase) (D-gluc 1q22 ENSG00000177628 H200020059 
152 MYO9A myosin IXA [Homo sapiens]. 15q23 ENSG00000066933 H200003274 
153   HTPAP protein [Homo sapiens]. 8p12 ENSG00000147535 H200007814 
154 SETBP1 SET-binding protein (SEB). 18q12.3 ENSG00000152217 H200013788 
155 SRI Sorcin (22 kDa protein) (CP-22) (V19). 7q21.12 ENSG00000075142 H200009922 
156 ABCB8 
ATP-binding cassette, sub-family B, member 8, 
mitochondrial precursor (Mitochondrial ATP-binding 
cas 
7q36.1 ENSG00000197150 H200012134 
157     15q15.1 ENSG00000137824 H200001578 
158 HOXB6 Homeobox protein Hox-B6 (Hox-2B) (Hox-2.2) (HU-2). 17q21.32 ENSG00000108511 H200010880 
159 ATP11A Potential phospholipid-transporting ATPase IH (EC 3.6.3.1) (ATPase class I type 11A) (ATPase IS). 13q34 ENSG00000068650 H200003896 
160 TFCP2L2 leader-binding protein 32 isoform 1, LBP protein 32, leader-binding protein 32, mammalian grainyhead 2p25.1 ENSG00000134317 H200018964 
161 KIAA1117   6q14.1 ENSG00000083097 H200017268 
162 ABCD1 Adrenoleukodystrophy protein (ALDP). Xq28 ENSG00000101986 H200007466 
163 CCM2 cerebral cavernous malformation 2, chromosome 7 open reading frame 22 [Homo sapiens]. 7p13 ENSG00000136280 H200001861 
164   NY-REN-58 antigen [Homo sapiens]. 12q22 ENSG00000173588 H200005210 
165     17q21.2 ENSG00000131475 H200011600 
166   UPF0120 protein DKFZp564C186. 1p36.33 ENSG00000188976 H200013109 
167   CGI-29 protein, APAF1-interacting protein [Homo sapiens]. 11p13 ENSG00000149089 H200011285 
168 BAK1 Bcl-2 homologous antagonist/killer (Apoptosis regulator BAK) (BCL2- like 7 protein). 6p21.31 ENSG00000030110 H200010571 
169         H200003750 
170 CACNA1H Voltage-dependent T-type calcium channel alpha-1H subunit (Voltage- gated calcium channel alpha subu 16p13.3 ENSG00000196557 H200012371 
171 SRC Proto-oncogene tyrosine-protein kinase Src (EC 2.7.1.112) (p60-Src) (c-Src). 20q11.23 ENSG00000197122 H200014805 
172         H200013303 
173 CXorf37   Xp11.23 ENSG00000101997 H200003626 
174 GPNMB Putative transmembrane protein NMB precursor (Transmembrane glycoprotein HGFIN). 7p15.3 ENSG00000136235 H200006911 
175 RBM10 RNA-binding protein 10 (RNA binding motif protein 10) (DXS8237E). Xp11.3 ENSG00000182872 H200013980 
176     1p34.1 ENSG00000187147 H200010430 
177         H200012709 
178     12q24.13 ENSG00000139405 H200016259 
179 APG10L APG10 autophagy 10-like [Homo sapiens]. 5q14.1 ENSG00000152348 H200009074 
180 UBE2A Ubiquitin-conjugating enzyme E2 A (EC 6.3.2.19) (Ubiquitin-protein ligase A) (Ubiquitin carrier prot Xq24 ENSG00000077721 H200006776 
181 MRPS30 
Mitochondrial 28S ribosomal protein S30 (S30mt) 
(MRP-S30) (Programmed cell death protein 9) (BM-
047) 
5p12 ENSG00000112996 H200003850 
182         H200013007 
183 C10orf33   10q24.2 ENSG00000119943 H200010766 
184 TRIP10 Cdc42-interacting protein 4 (Thyroid receptor interacting protein 10) (TRIP-10). 19p13.3 ENSG00000125733 H200005905 
185         H200012966 
186     3p21.31 ENSG00000198530 H200020692 
187     1p34.3 ENSG00000163875 H200002622 
188   XTP3-transactivated protein A [Homo sapiens]. 16p11.2 ENSG00000179958 H200015610 
189 NFIB Nuclear factor 1 B-type (Nuclear factor 1/B) (NF1-B) (NFI-B) (NF-I/B) (CCAAT-box binding transcripti 9p22.3 ENSG00000147862 H200004230 
190 PRKCH Protein kinase C, eta type (EC 2.7.1.-) (nPKC-eta) (PKC-L). 14q23.1 ENSG00000027075 H200018874 
191         H200019805 
192   CGI-111 protein [Homo sapiens]. 5q23.3 ENSG00000066583 H200001967 
 xxxii 
193     12q21.31 ENSG00000111058 H200002237 
194 TRIM41 Tripartite motif protein 41. 5q35.3 ENSG00000146063 H200020110 
195 DHRS4 
Dehydrogenase/reductase SDR family member 4 (EC 
1.1.1.184) (NADPH- dependent carbonyl 
reductase/NADP 
14q11.2 ENSG00000157326 H200001202 
196 AMACR Alpha-methylacyl-CoA racemase (EC 5.1.99.4) (2-methylacyl-CoA racemase). 5p13.3 ENSG00000082196 H200012768 
197         H200020351 
198 MINA MYC induced nuclear antigen isoform 2, myc-induced nuclear antigen, 53 kDa, mineral dust induced gen 3q11.2 ENSG00000170854 H200003264 
199         H200010060 
200   Protein HSPC020. 11q13.4 ENSG00000110200 H200004421 
201 FGD1 Putative Rho/Rac guanine nucleotide exchange factor (Rho/Rac GEF) (Faciogenital dysplasia protein) ( Xp11.22 ENSG00000102302 H200000409 
202         H200010990 
203   Arylsulfatase G [Homo sapiens]. 17q24.2 ENSG00000141337 H200017561 
204 RKHD3 ring finger and KH domain containing 3 [Homo sapiens]. 15q25.2 ENSG00000183496 H200011330 
205   Guanine nucleotide exchange factor-related protein (Deafness locus associated putative guanine nucle 11p15.1 ENSG00000129158 H200004794 
206 PTPRU 
Receptor-type protein-tyrosine phosphatase U 
precursor (EC 3.1.3.48) (R-PTP-U) (Protein-tyrosine 
pho 
1p35.3 ENSG00000060656 H200002847 
207 B4GALT2 Beta-1,4-galactosyltransferase 2 (EC 2.4.1.-) (Beta-1,4-GalTase 2) (Beta4Gal-T2) (b4Gal-T2) (UDP-gal 1p34.1 ENSG00000117411 H200015011 
208 MRPL37 mitochondrial ribosomal protein L37, ribosomal protein, mitochondrial, L2 [Homo sapiens]. 1p32.3 ENSG00000116221 H200000887 
209 ASH2L ASH2-like protein. 8p12 ENSG00000129691 H200001319 
210 PIGS 
GPI transamidase component PIG-S 
(Phosphatidylinositol-glycan biosynthesis, class S 
protein). 
17q11.2 ENSG00000087111 H200020143 
211     5q32 ENSG00000145882 H200016427 
212     7p22.3 ENSG00000164818, ENSG00000188246 H200016943 
213 PEX6 Peroxisome assembly factor-2 (PAF-2) (Peroxisomal-type ATPase 1) (Peroxin-6) (Peroxisomal biogenesis 6p21.1 ENSG00000124587 H200010054 
214 ENTPD7 ectonucleoside triphosphate diphosphohydrolase 7, lysosomal apyrase-like protein 1 [Homo sapiens]. 10q24.2 ENSG00000198018 H200003172 
215         H200002658 
216 ARHGDIG Protein disulfide-isomerase A2 precursor (EC 5.3.4.1) (PDIp). 16p13.3 ENSG00000185615 H200010174 
217 ESPL1 Separin (EC 3.4.22.49) (Separase) (Caspase-like protein ESPL1) (Extra spindle poles-like 1 protein). 12q13.13 ENSG00000135476 H200013875 
218 PRKWNK2 Serine/threonine-protein kinase WNK2 (EC 2.7.1.37) (Protein kinase with no lysine 2) (Protein kinase 9q22.31 ENSG00000165238 H200013033 
219 BCKDHA 
2-oxoisovalerate dehydrogenase alpha subunit, 
mitochondrial precursor (EC 1.2.4.4) (Branched-chain 
a 
19q13.2 ENSG00000142046 H200006590 
220     11q23.1 ENSG00000137702 H200010909 
221 BIRC7 Baculoviral IAP repeat-containing protein 7 (Kidney inhibitor of apoptosis protein) (KIAP) (Melanoma 20q13.33 ENSG00000101197 H200016398 
222 TRIP6 Thyroid receptor interacting protein 6 (TRIP6) (OPA-interacting protein 1) (Zyxin related protein 1) 7q22.1 ENSG00000087077 H200012209 
223         H200018290 
224 NPY1R Neuropeptide Y receptor type 1 (NPY1-R). 4q32.2 ENSG00000164128 H200007802 
225   pyruvate dehydrogenase phosphatase regulatory subunit [Homo sapiens]. 16q22.1 ENSG00000090857 H200016507 
226 C20orf18 Ubiquitin conjugating enzyme 7 interacting protein 3 (Hepatitis B virus X-associated protein 4) (HBV 20p13 ENSG00000125826 H200015861 
227 RAB5A Ras-related protein Rab-5A. 3p24.3 ENSG00000144566 H200005896 
228         H200007233 
229 BRD8 bromodomain containing 8 isoform 1, skeletal muscle abundant protein, thyroid hormone receptor coact 5q31.2 ENSG00000112983 H200001063 
230     11p13 ENSG00000176148 H200003139 
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231 NIT1 nitrilase 1 [Homo sapiens]. 1q23.3 ENSG00000158793 H200013566 
232 DEPDC6 DEP domain containing 6 [Homo sapiens]. 8q24.12 ENSG00000155792 H200010250 
233 ZDHHC14 Zinc finger DHHC domain containing protein 14 (NEW1 domain containing protein) (NEW1CP). 6q25.3 ENSG00000175048 H200004435 
234 CPXM Potential carboxypeptidase X precursor (EC 3.4.17.-) (Metallocarboxypeptidase CPX-1). 20p13 ENSG00000088882 H200008267 
235 ARNTL Aryl hydrocarbon receptor nuclear translocator-like protein 1 (Brain and muscle ARNT-like 1) (Member 11p15.2 ENSG00000133794 H200005950 
236 PRPSAP2 Phosphoribosyl pyrophosphate synthetase-associated protein 2 (PRPP synthetase-associated protein 2) 17p11.2 ENSG00000141127 H200002257 
237   dudulin 2, tumor suppressor pHyde, six transmembrane prostate protein 3 [Homo sapiens]. 2q14.2 ENSG00000115107 H200005252 
238 ELOVL5 homolog of yeast long chain polyunsaturated fatty acid elongatio, homolog of yeast long chain polyun 6p12.1 ENSG00000012660 H200016204 
239         H200014395 
240 SOX13 SOX-13 protein (Type 1 diabetes autoantigen ICA12) (Islet cell antigen 12). 1q32.1 ENSG00000143842 H200014916 
241 CYR61 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) (Insulin-like growth factor-binding 1p22.3 ENSG00000142871 H200001697 
242         H200001611 
243         H200009962 
244 NT5M 5'(3')-deoxyribonucleotidase, cytosolic type (EC 3.1.3.-) (Cytosolic 5',3'-pyrimidine nucleotidase) 17q25.1 ENSG00000125458 H200005632 
245         H200001954 
246 LDLR Low-density lipoprotein receptor precursor (LDL receptor). 19p13.2 ENSG00000130164 H200015172 
247         H200003707 
248 C5orf19   5q31.2 ENSG00000132563 H200003814 
249 ADCY3 Adenylate cyclase type III (EC 4.6.1.1) (Adenylate cyclase, olfactive type) (ATP pyrophosphate-lyase 2p23.3 ENSG00000138031 H200001647 
250 C5orf3   5q33.2 ENSG00000055147 H200007691 
251 NF1 Neurofibromin (Neurofibromatosis-related protein NF-1) [Contains: Neurofibromin truncated]. 17q11.2 ENSG00000196712 H200010569 
252     5q31.1 ENSG00000145835 H200009573 
253         H200005644 
254 GNG11 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-11 subunit. 7q21.3 ENSG00000127920 H200007026 
255 ZNF259 Zinc-finger protein ZPR1 (Zinc finger protein 259). 11q23.3 ENSG00000109917 H200001377 
256 SUSD2 sushi domain containing 2, Sushi domain (SCR repeat) containing [Homo sapiens]. 22q11.23 ENSG00000099994 H200012965 
257 FGA Fibrinogen alpha/alpha-E chain precursor [Contains: Fibrinopeptide A]. 4q31.3 ENSG00000171560 H200021184 
258 FNTB Protein farnesyltransferase beta subunit (EC 2.5.1.58) (CAAX farnesyltransferase beta subunit) (RAS 14q23.3 ENSG00000125954 H200000075 
259 TIMM23 Mitochondrial import inner membrane translocase subunit Tim23. 10q11.23 ENSG00000138297 H200002039 
260         H200002087 
261         H200016707 
262         H200001644 
263 CLECSF12 C-type lectin, superfamily member 12 isoform b, beta-glucan receptor, lectin-like receptor 1, transm 12p13.2 ENSG00000172243 H200014156 
264         H200000829 
265         H200001681 
266 DGKG 
Diacylglycerol kinase, gamma (EC 2.7.1.107) 
(Diglyceride kinase) (DGK- gamma) (DAG kinase 
gamma). 
3q27.2 ENSG00000058866 H200010327 
267     19q13.2 ENSG00000090924 H200011738 
268 MICA MHC class I chain-related gene A protein [Homo sapiens]. 6p21.33 ENSG00000184444 H200010444 
269     11q23.2 ENSG00000180425 H200010517 
270 TMEM25 transmembrane protein 25, 0610039J01Rik [Homo sapiens]. 11q23.3 ENSG00000149582 H200021089 
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271         H200003472 
272         H200004592 
273 KEAP1 Kelch-like ECH-associated protein 1 (Cytosolic inhibitor of Nrf2). 19p13.2 ENSG00000079999 H200005267 
274 MRPL30 mitochondrial ribosomal protein L30 isoform a [Homo sapiens]. 2q11.2 ENSG00000185414 H200002065 
275 HELLS helicase, lymphoid-specific, SWI/SNF2-related, matrix-associated, actin-dependent regulator of chrom 10q23.33 ENSG00000119969 H200014971 
276 ENC1 Ectoderm-neural cortex-1 protein (ENC-1) (P53-induced protein 10) (Nuclear matrix protein NRP/B). 5q13.3 ENSG00000171617 H200011342 
277 PSME2 Proteasome activator complex subunit 2 (Proteasome activator 28-beta subunit) (PA28beta) (PA28b) (Ac 14q11.2 ENSG00000100911 H200008379 
278 CENPJ centromere protein J, centrosomal P4.1-associated protein, LYST-interacting protein LIP1, LAG-3-asso 13q12.12 ENSG00000151849 H200017688 
279 DSCR1 Calcipressin 1 (Down syndrome critical region protein 1) (Myocyte- enriched calcineurin interacting 21q22.12 ENSG00000159200 H200014262 
280 WNT5B Wnt-5b protein precursor. 12p13.33 ENSG00000111186 H200018203 
281   putative breast adenocarcinoma marker [Homo sapiens]. 19q13.43 ENSG00000130724 H200002069 
282     10q22.2 ENSG00000138286 H200004671 
283 SCAMP3 Secretory carrier-associated membrane protein 3 (Secretory carrier membrane protein 3). 1q22 ENSG00000116521 H200014894 
284         H200003033 
285 RAI3 Retinoic acid induced 3 protein (G protein-coupled receptor family C group 5 member A) (Retinoic aci 12p13.1 ENSG00000013588 H200014654 
286         H200004670 
287 NFX1 Transcriptional repressor NF-X1 (EC 6.3.2.-) (Nuclear transcription factor, X box-binding, 1). 9p13.3 ENSG00000086102 H200000753 
288 FOS Proto-oncogene protein c-fos (Cellular oncogene fos) (G0/G1 switch regulatory protein 7). 14q24.3 ENSG00000170345 H200003548 
289   Cappuccino protein homolog. 4p16.1 ENSG00000186222 H200001457 
290 CARM1 coactivator-associated arginine methyltransferase 1, coactivator-associated arginine methyltransfera 19p13.2 ENSG00000142453 H200013420 
291 FBXO17 F-box only protein 17 (F-box only protein 26). 19q13.2 ENSG00000161241 H200016187 
292 NANOG Nanog homeobox, homeobox transcription factor Nanog [Homo sapiens]. 
15q14, 
12p13.31 
ENSG00000179437, 
ENSG00000111704 H200019169 
293 PPIL1 Peptidyl-prolyl cis-trans isomerase like 1 (EC 5.2.1.8) (PPIase) (Rotamase) (CGI-124) (UNQ2425/PRO49 6p21.2 ENSG00000137168 H200003788 
294 MYO5A Myosin Va (Myosin 5A) (Dilute myosin heavy chain, non-muscle) (Myosin heavy chain 12) (Myoxin). 15q21.2 ENSG00000197535 H200007910 
295 C14orf138   14q21.3 ENSG00000100483 H200002224 
296 PRKR Interferon-induced, double-stranded RNA-activated protein kinase (EC 2.7.1.-) (Interferon-inducible 2p22.2 ENSG00000055332 H200017076 
297     2q37.1 ENSG00000185404 H200016714 
298 RASL11B RAS-like family 11 member B [Homo sapiens]. 4q12 ENSG00000128045 H200001570 
299 C16orf34 Crm, cramped-like, Crm (Cramped Drosophila)-like [Homo sapiens]. 16p13.3 ENSG00000007545 H200002479 
300 EDG4 Lysophosphatidic acid receptor Edg-4 (LPA receptor 2) (LPA-2). 19p13.11 ENSG00000064547 H200012385 
301 REN, KCTD11 
Renin precursor (EC 3.4.23.15) 
(Angiotensinogenase).,potassium channel 
tetramerisation domain containing 11, chromosome 
17 open reading frame 36, retinoi 
1q32.1,17
p13.1 
ENSG00000143839, 
ENSG00000184542 H200015103 
302 UST uronyl-2-sulfotransferase, uronyl 2-sulfotransferase, dermatan/chondroitin sulfate 2-sulfotransferas 6q25.1 ENSG00000111962 H200013102 
303 TCFL5 Transcription factor-like 5 protein (Cha transcription factor) (HPV-16 E2 binding protein 1) (E2BP-1 20q13.33 ENSG00000101190 H200004024 
304 HIVEP1 Zinc finger protein 40 (Human immunodeficiency virus type I enhancer- binding protein 1) (HIV-EP1) ( 6p24.1 ENSG00000095951 H200000081 
305 NUDT5 ADP-sugar pyrophosphatase (EC 3.6.1.13) (EC 3.6.1.-) (Nucleoside diphosphate-linked moiety X motif 5 10p14 ENSG00000165609 H200017987 
306 LAT Linker for activation of T cells (36 kDa phospho-tyrosine adaptor protein) (pp36) (p36-38). 16p11.2 ENSG00000169678 H200007039 
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307 RASA3 Ras GTPase-activating protein 3 (GAP1(IP4BP)) (Ins P4-binding protein). 13q34 ENSG00000185989 H200012198 
308         H200001307 
309         H200004113 
310 MTX2 Metaxin 2. 2q31.1 ENSG00000128654 H200004105 
311     7p22.3 ENSG00000146540 H200019508 
312 RHOBTB3 Rho-related BTB domain-containing protein 3. 5q15 ENSG00000164292 H200001910 
313 TAF1 Transcription initiation factor TFIID subunit 1 (EC 2.7.1.37) (Transcription initiation factor TFIID Xq13.1 ENSG00000147133 H200000303 
314         H200001320 
315 USP12 Ubiquitin carboxyl-terminal hydrolase 12 (EC 3.1.2.15) (Ubiquitin thiolesterase 12) (Ubiquitin-speci 13q12.13 ENSG00000152484 H200004574 
316 PHC1 
Polyhomeotic-like protein 1 (Early development 
regulator protein 1) (HPH1).,Polyhomeotic-like protein 
1 (Early development regulator protein 1) (HPH1). 
12q13.2, 
12p13.31 
ENSG00000179899, 
ENSG00000111752 H200018199 
317     15q15.3 ENSG00000137770 H200011302 
318 ATP5J2 ATP synthase f chain, mitochondrial (EC 3.6.3.14). 7q22.1 ENSG00000160916 H200014108 
319 PLXNA1 plexin A1, plexin 1 [Homo sapiens]. 3q21.2 ENSG00000114554 H200019013 
320 PLCB4 
1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase beta 4 (EC 3.1.4.11) 
(Phosphoinositide pho 
20p12.2 ENSG00000101333 H200017629 
321 C1orf6 Ataxin-1 ubiquitin-like interacting protein A1U. 1q22 ENSG00000160803 H200017798 
322 CCND3 G1/S-specific cyclin D3. 6p21.1 ENSG00000112576 H200007012 
323 C10orf81   10q25.3 ENSG00000148735 H200015418 
324 ZNF228 Zinc finger protein 228. 19q13.31 ENSG00000062370 H200004887 
325 TGIF2 Homeobox protein TGIF2 (TGFB-induced factor 2) (5'-TG-3' interacting factor 2) (TGF(beta)-induced tr 20q11.23 ENSG00000118707 H200010661 
326 RPP38 Ribonuclease P protein subunit p38 (EC 3.1.26.5) (RNaseP protein p38). 10p13 ENSG00000152464 H200010679 
327 PMS2L11 HPMSR6. 7q11.23 ENSG00000186704 H200018214 
328 IARS Isoleucyl-tRNA synthetase, cytoplasmic (EC 6.1.1.5) (IsoleucinetRNA ligase) (IleRS) (IRS). 9q22.31 ENSG00000196305 H200008082 
329 SUPT16H chromatin-specific transcription elongation factor large subunit [Homo sapiens]. 14q11.2 ENSG00000092201 H200002431 
330     1p34.1 ENSG00000159596 H200014285 
331 PSCD2L Cytohesin 2 (ARF nucleotide-binding site opener) (ARNO protein) (ARF exchange factor). 19q13.32 ENSG00000105443 H200018158 
332         H200020364 
333 CD1C T-cell surface glycoprotein CD1c precursor (CD1c antigen). 1q23.1 ENSG00000158481 H200000342 
334 POFUT2 GDP-fucose protein O-fucosyltransferase 2 precursor (EC 2.4.1.221) (Peptide O-fucosyltransferase) (O 21q22.3 ENSG00000186866 H200003223 
335 TBXA2R NY-REN-24 antigen (Fragment).Thromboxane A2 receptor (TXA2-R) (Prostanoid TP receptor). 19p13.3 
ENSG00000105298, 
ENSG00000179855, 
ENSG00000006638 
H200012751 
336         H200019921 
337 UBE1 Ubiquitin-activating enzyme E1 (A1S9 protein). Xp11.3 ENSG00000130985 H200000527 
338 CORO1C Coronin 1C (Coronin 3) (hCRNN4). 12q24.11 ENSG00000110880 H200002647 
339 ZNF41 Zinc finger protein 41. Xp11.3 ENSG00000147124 H200015400 
340         H200010439 
341 DPP3 Bardet-Biedl syndrome 1 protein (BBS2-like protein 2). 11q13.2 ENSG00000174483 H200003203 
342 PRAF2 JM4 protein [Homo sapiens]. Xp11.23 ENSG00000102050 H200003933 
343     1p36.12 ENSG00000090432 H200001884 
344     7q22.1 ENSG00000160993 H200016776 
345         H200015636 
346 TP53BP1 Tumor suppressor p53-binding protein 1 (p53-binding protein 1) (53BP1). 15q15.3 ENSG00000067369 H200007926 
347 WBP11 
WW domain binding protein 11, Npw38-binding 
protein NpwBP, SH3 domain-binding protein SNP70 
[Homo sa 
12p12.3 ENSG00000084463 H200019689 
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348         H200010493 
349 CDK2AP1 Cyclin-dependent kinase 2-associated protein 1 (CDK2-associated protein 1) (Putative oral cancer sup 12q24.31 ENSG00000111328 H200000786 
350   nucleostemin isoform 1, putative nucleotide binding protein, estradiol-induced [Homo sapiens]. 3p21.1 ENSG00000163938 H200017556 
351         H200008222 
352 VAV3 Vav-3 protein. 1p13.3 ENSG00000134215 H200016605 
353 PHKG2 
Phosphorylase B kinase gamma catalytic chain, 
testis/liver isoform (EC 2.7.1.38) (PHK-gamma-T) 
(Phos 
16p11.2 ENSG00000156873 H200014730 
354 ZNF346 zinc finger protein 346, double-stranded RNA-binding zinc finger protein JAZ [Homo sapiens]. 5q35.2 ENSG00000113761 H200008493 
355 CHEK2 Serine/threonine-protein kinase Chk2 (EC 2.7.1.37) (Cds1). 22q12.1 ENSG00000183765 H200013557 
356 NT5C2 Cytosolic purine 5'-nucleotidase (EC 3.1.3.5) (5'-nucleotidase cytosolic II). 10q24.33 ENSG00000076685 H200013286 
357 OSR1 oxidative-stress responsive 1 [Homo sapiens]. 3p22.2 ENSG00000172939 H200010689 
358 PRKAB1 5'-AMP-activated protein kinase, beta-1 subunit (AMPK beta-1 chain) (AMPKb). 12q24.23 ENSG00000111725 H200001142 
359 ATP6V1F Vacuolar ATP synthase subunit F (EC 3.6.3.14) (V-ATPase F subunit) (Vacuolar proton pump F subunit) 7q32.1 ENSG00000128524 H200006486 
360 FRAP1 FKBP-rapamycin associated protein (FRAP) (Rapamycin target protein). 1p36.22 ENSG00000198793 H200019855 
361 PHB Prohibitin. 17q21.32 ENSG00000167085 H200012361 
362 ZNF502 Zinc finger protein 502. 3p21.31 ENSG00000196653 H200015276 
363         H200002063 
364         H200010421 
365 OSBPL3 Oxysterol binding protein-related protein 3 (OSBP-related protein 3) (ORP-3). 7p15.3 ENSG00000070882 H200014777 
366 ACTG2 Actin, gamma-enteric smooth muscle (Alpha-actin 3). 2p13.1 ENSG00000163017 H200006478 
367         H200012250 
368 EXOC7 Exocyst complex component 7 (Exocyst complex component Exo70). 17q25.1 ENSG00000182473 H200016731 
369 STARD7 StAR-related lipid transfer protein 7 (StARD7) (START domain- containing protein 7) (GTT1 protein). 2q11.2 ENSG00000084090 H200017790 
370   CGI-62 protein [Homo sapiens]. 8q21.12 ENSG00000104427 H200012156 
371 ALG1 beta-1,4-mannosyltransferase, beta-1,4 mannosyltransferase [Homo sapiens]. 16p13.3 ENSG00000033011 H200004717 
372         H200004334 
373 DDX56 
Probable ATP-dependent 61 kDa nucleolar RNA 
helicase (EC 3.6.1.-) (DEAD-box protein 56) (DEAD-
box pr 
7p13 ENSG00000136271 H200001883 
374 TBC1D1 TBC1 domain family member 1. 4p14 ENSG00000065882 H200017315 
375 CYP27A1 Cytochrome P450 27, mitochondrial precursor (EC 1.14.-.-) (Cytochrome P-450C27/25) (Sterol 26-hydrox 2q35 ENSG00000135929 H200006956 
376 HEMK1 HemK protein homolog (EC 2.1.1.-) (M.HsaHemKP). 3p21.31 ENSG00000114735 H200004813 
377     17q25.3 ENSG00000178927 H200001827 
378         H200003632 
379     17q25.1 ENSG00000177728 H200009966 
380 LENG8 leukocyte receptor cluster (LRC) member 8 [Homo sapiens]. 19q13.42 ENSG00000167615 H200018209 
381         H200001270 
382 PSD4 pleckstrin and Sec7 domain containing 4, ADP-ribosylation factor guanine nucleotide-exchange factor 2q13 ENSG00000125637 H200011683 
383         H200014351 
384 APBB2 Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like protein) (Fragment). 4p14 ENSG00000163697 H200019090 
385 WISP2 WNT1 inducible signaling pathway protein 2 precursor (WISP-2) (Connective tissue growth factor-like 20q13.12 ENSG00000064205 H200014646 
386 TCF3 
Transcription factor E2-alpha (Immunoglobulin 
enhancer binding factor E12/E47) (Transcription 
factor 
19p13.3 ENSG00000071564 H200011103 
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387 SCRT2 UPF0238 protein c20orf139. 20p13 ENSG00000172070 H200013143 
388 TXNDC4 Thioredoxin domain containing protein 4 precursor (Endoplasmic reticulum protein ERp44). 9q31.1 ENSG00000023318 H200013926 
389         H200009570 
390 PLAGL2 Zinc finger protein PLAGL2 (Pleiomorphic adenoma-like protein 2). 20q11.21 ENSG00000126003 H200013939 
391         H200005593 
392         H200008282 
393 TUBGCP3 
Gamma-tubulin complex component 3 (GCP-3) 
(Spindle pole body protein Spc98 homolog) (hSpc98) 
(hGCP3) 
13q34 ENSG00000126216 H200001849 
394 C6orf79   6p23 ENSG00000050393 H200016505 
395         H200000866 
396 RASSF1 Ras association domain family 1 (Ras association, RalGDS/AF-6, domain family 1). 3p21.31 ENSG00000068028 H200003705 
397 PDE9A High-affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (EC 3.1.4.17). 21q22.3 ENSG00000160191 H200002780 
398 PECR peroxisomal trans-2-enoyl-CoA reductase, peroxisomal trans 2-enoyl CoA reductase, putative short cha 2q35 ENSG00000115425 H200017595 
399 UAP1 UDP-N-acetylhexosamine pyrophosphorylase (Antigen X) (AGX) (Sperm- associated antigen 2) [Includes: 1q23.3 ENSG00000117143 H200003000 
400 PBP Phosphatidylethanolamine-binding protein (PEBP) (Prostatic binding protein) (HCNPpp) (Neuropolypepti 12q24.23 ENSG00000089220 H200006761 
401 LRP5 Low-density lipoprotein receptor-related protein 5 precursor. 11q13.2 ENSG00000162337 H200001207 
402 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3, chondroitin 6-sulfotransferase [Homo sapiens]. 10q22.1 ENSG00000122863 H200007322 
403 LEPREL1 leprecan-like 1, myxoid liposarcoma associated protein 4, prolyl 3-hydroxylase 3 [Homo sapiens]. 3q28 ENSG00000090530 H200004600 
404 TNRC18 CAGL79 (Fragment). 7p22.1 ENSG00000182095 H200020510 
405 KBTBD2 Kelch repeat and BTB domain containing protein 2 (BTB and kelch domain containing protein 1). 7p14.3 ENSG00000170852 H200002891 
406 C20orf121   20q13.12 ENSG00000124120 H200008681 
407 PNKP Bifunctional polynucleotide phosphatase/kinase (Polynucleotide kinase- 3'-phosphatase) (DNA 5'-kinas 19q13.33 ENSG00000039650 H200006474 
408         H200004276 
409     10p11.23 ENSG00000165757 H200004811 
410 MYBBP1A MYB binding protein 1a, p53-activated protein-2 [Homo sapiens]. 17p13.2 ENSG00000132382 H200003194 
411 FOXC1 Forkhead box protein C1 (Forkhead-related protein FKHL7) (Forkhead- related transcription factor 3) 6p25.3 ENSG00000054598 H200020379 
412 RHEB GTP-binding protein Rheb (Ras homolog enriched in brain). 7q36.1 ENSG00000106615 H200017539 
413 GPRC5C G protein-coupled receptor family C group 5 member C precursor (Retinoic acid induced gene 3 protein 17q25.1 ENSG00000170412 H200005296 
414   Tetraspan NET-7. 10q22.1 ENSG00000099282 H200010703 
415 ETV5 Ets-related protein ERM (ETS translocation variant 5). 3q27.2 ENSG00000171656 H200004645 
416 PGD 6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44). 1p36.22 ENSG00000142657 H200006228 
417 RGS2 Regulator of G-protein signaling 2 (RGS2) (G0/G1 switch regulatory protein 8). 1q31.2 ENSG00000116741 H200006587 
418 BCL6 B-cell lymphoma 6 protein (BCL-6) (Zinc finger protein 51) (LAZ-3 protein) (BCL-5) (Zinc finger and 3q27.3 ENSG00000113916 H200014019 
419 UBAP2 ubiquitin associated protein 2 isoform 1, AD-012 protein [Homo sapiens]. 9p13.3 ENSG00000137073 H200002430 
420 COPB Coatomer beta subunit (Beta-coat protein) (Beta-COP). 11p15.2 ENSG00000129083 H200000730 
421 GNB4 Guanine nucleotide-binding protein beta subunit 4 (Transducin beta chain 4). 3q26.32 ENSG00000114450 H200008063 
422 MPHOSPH6 M-phase phosphoprotein 6. 16q23.3 ENSG00000135698 H200013829 
423     12p13.33 ENSG00000171792 H200007245 
424         H200016752 
 xxxviii
425 C13orf12   13q12.3 ENSG00000132963 H200017498 
426 CYP1B1 Cytochrome P450 1B1 (EC 1.14.14.1) (CYPIB1). 2p22.2 ENSG00000138061 H200013981 
427 GSDML gasdermin-like [Homo sapiens]. 17q21.1 ENSG00000073605 H200002789 
428         H200018267 
429   CDA02 protein [Homo sapiens]. 3q25.1 ENSG00000144895 H200019327 
430     2q21.1 ENSG00000169606 H200018879 
431 ZNF160 Zinc finger protein Kr18 (HKr18). 19q13.41 ENSG00000170949 H200015014 
432 IQCB1 IQ calmodulin-binding motif containing protein 1. 3q13.33 ENSG00000173226 H200007819 
433 IPO4 Importin 4 (Importin 4b) (Imp4b) (Ran-binding protein 4) (RanBP4). 14q11.2 ENSG00000196497 H200005457 
434 ZA20D2 Zinc finger A20 domain containing protein 2 (Zinc finger protein 216). 9q21.13 ENSG00000107372 H200000830 
435         H200018807 
436     20p11.21 ENSG00000101004 H200015397 
437 MTMR2 Myotubularin-related protein 2 (EC 3.1.3.-). 11q21 ENSG00000087053 H200008529 
438 PRPF18 Pre-mRNA splicing factor 18 (PRP18 homolog) (hPRP18). 10p13 ENSG00000165630 H200014051 
439 CDC42EP1 CDC42 effector protein 1 (Serum protein MSE55). 22q13.1 ENSG00000128283 H200013626 
440 FAM8A1 Autosomal Highly Conserved Protein [Homo sapiens]. 6p22.3 ENSG00000137414 H200010692 
441 NRD1 Nardilysin precursor (EC 3.4.24.61) (N-arginine dibasic convertase) (NRD convertase) (NRD-C). 1p32.3 ENSG00000078618 H200000873 
442 LASS2 LAG1 longevity assurance homolog 2 (Tumor metastasis-suppressor gene 1 protein) (SP260). 1q21.2 ENSG00000143418 H200008861 
443 C19orf33 Immortalization-up-regulated protein (Hepatocyte growth factor activator inhibitor type 2-related sm 19q13.2 ENSG00000167644 H200020296 
444 ASPSCR1 alveolar soft part sarcoma chromosome region, candidate 1, ASPL protein, renal cell carcinoma gene o 17q25.3 ENSG00000169696 H200009864 
445 ALG2 
Alpha-1,3-mannosyltransferase ALG2 (EC 2.4.1.-) 
(GDP- Man:Man(1)GlcNAc(2)-PP-dolichol 
mannosyltransf 
9q22.33 ENSG00000119523 H200004499 
446 TP53RK TP53 regulating kinase (EC 2.7.1.37) (p53-related protein kinase) (Nori-2). 20q13.12 ENSG00000172315 H200017627 
447 SSR1 
Translocon-associated protein, alpha subunit 
precursor (TRAP-alpha) (Signal sequence receptor 
alpha 
6p24.3 ENSG00000124783 H200016256 
448 CYLN2 cytoplasmic linker 2 isoform 1, Williams-Beuren syndrome chromosome region 4 [Homo sapiens]. 7q11.23 ENSG00000106665 H200011328 
449 VIP, CPAMD8 
Vasoactive intestinal peptide precursor (VIP).,C3 and 
PZP-like, alpha-2-macroglobulin domain containing 8, 
alpha-2 macroglobulin family protein VIP 
6q25.2, 
19p13.11 
ENSG00000146469, 
ENSG00000160111 H200012267 
450     7q34 ENSG00000006530 H200016499 
451   HBxAg transactivated protein 2 [Homo sapiens]. 1q24.3 ENSG00000117523 H200005686 
452 MRPL2 mitochondrial ribosomal protein L2 [Homo sapiens]. 6p21.1 ENSG00000112651 H200005144 
453     22q11.21 ENSG00000099972 H200017971 
454 PACSIN2 Protein kinase C and casein kinase substrate in neurons protein 2. 22q13.2 ENSG00000100266 H200002767 
455 ZNF553 zinc finger protein 553 [Homo sapiens]. 16p11.2 ENSG00000180035 H200002116 
456         H200020420 
457         H200009382 
458 C4orf14   4q12 ENSG00000084092 H200001673 
459 ICAM3 Intercellular adhesion molecule-3 precursor (ICAM-3) (ICAM-R) (CDw50) (CD50 antigen). 19p13.2 ENSG00000076662 H200011041 
460 SF3A2 Splicing factor 3A subunit 2 (Spliceosome associated protein 62) (SAP 62) (SF3a66). 19p13.3 ENSG00000104897 H200011943 
461 EPHB3 Ephrin type-B receptor 3 precursor (EC 2.7.1.112) (Tyrosine-protein kinase receptor HEK-2). 3q27.1 ENSG00000182580 H200000705 
462     1p36.13 ENSG00000169991 H200002318 
463         H200013074 
464   Protein AF1q. 1q21.2 ENSG00000143443 H200006209 
465 RWDD1 RWD domain containing protein 1 (CGI-24) (PTD013). 6q22.1 ENSG00000111832 H200003183 
 xxxix
466 NDST2 Heparin sulfate N-deacetylase/N-sulfotransferase (EC 2.8.2.-) (N-HSST) (N-heparin sulfate sulfotrans 10q22.2 ENSG00000166507 H200006518 
467 PRKCZ Protein kinase C, zeta type (EC 2.7.1.37) (nPKC-zeta). 1p36.33 ENSG00000067606 H200006556 
468 PAPD1 PAP associated domain containing 1 [Homo sapiens]. 10p11.23 ENSG00000107951 H200008184 
469 MTRF1 Peptide chain release factor 1, mitochondrial precursor (MRF-1). 13q14.11 ENSG00000120662 H200006786 
470     19q13.31 ENSG00000105771 H200001886 
471 KCND1 Potassium voltage-gated channel subfamily D member 1 (Voltage-gated potassium channel subunit Kv4.1) Xp11.23 ENSG00000102057 H200005164 
472 UPF2 UPF2 regulator of nonsense transcripts homolog, regulator of nonsense transcripts 2, yeast Upf2p hom 10p14 ENSG00000151461 H200000853 
473     7q34 ENSG00000006459 H200015246 
474   down-regulated in metastasis [Homo sapiens]. 12q23.2 ENSG00000120800 H200008329 
475 C20orf23 Kinesin-like motor protein C20orf23 (Sorting nexin 23). 20p12.1 ENSG00000089177 H200011141 
476         H200011386 
477 SGSH N-sulphoglucosamine sulphohydrolase precursor (EC 3.10.1.1) (Sulfoglucosamine sulfamidase) (Sulphami 17q25.3 ENSG00000181523 H200004063 
478 MPP1 55 kDa erythrocyte membrane protein (p55) (Membrane protein, palmitoylated 1). Xq28 ENSG00000130830 H200000477 
479 THUMPD2 THUMP domain containing protein 2. 2p22.1 ENSG00000138050 H200004437 
480 DGCR8 DGCR8 protein (DiGeorge syndrome critical region 8). 22q11.21 ENSG00000128191 H200017967 
481         H200012395 
482         H200008747 
483 B4GALT1 Beta-1,4-galactosyltransferase 1 (EC 2.4.1.-) (Beta-1,4-GalTase 1) (Beta4Gal-T1) (b4Gal-T1) (UDP-gal 9p21.1 ENSG00000086062 H200014787 
484 RSU1 Ras suppressor protein 1 (Rsu-1) (RSP-1). 10p13 ENSG00000148484 H200006130 
485     7q11.21 ENSG00000198874 H200002559 
486         H200009822 
487 RAD51C DNA repair protein RAD51 homolog 3. 17q23.2 ENSG00000108384 H200001999 
488 TBC1D16 TBC1 domain family, member 16 [Homo sapiens]. 17q25.3 ENSG00000167291 H200010522 
489         H200012718 
490 DRG1 Developmentally regulated GTP-binding protein 1 (DRG 1). 22q12.2 ENSG00000185721 H200011945 
491 ARID1A SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1 (SWI 1p36.11 ENSG00000117713 H200012438 
492 TNFSF5IP1 
tumor necrosis factor superfamily, member 5-induced 
protein 1, hepatocellular carcinoma susceptibili 18p11.21 ENSG00000128789 H200000820 
493 MRPS22 Mitochondrial 28S ribosomal protein S22 (S22mt) (MRP-S22) (GK002). 3q23 ENSG00000175110 H200011494 
494 ZDHHC6 Zinc finger DHHC domain containing protein 6 (Zinc finger protein 376) (Transmembrane protein H4). 10q25.2 ENSG00000023041 H200003136 
495         H200009543 
496 CHD8 Chromodomain-helicase-DNA-binding protein 8 (CHD-8) (Helicase with SNF2 domain 1) (Fragment). 14q11.2 ENSG00000100888 H200008140 
497 KIAA1618   17q25.3 ENSG00000180843 H200018846 
498 BHLHB2 Class B basic helix-loop-helix protein 2 (bHLHB2) (Differentially expressed in chondrocytes protein 3p26.1 ENSG00000134107 H200007994 
499 USP5 Ubiquitin carboxyl-terminal hydrolase 5 (EC 3.1.2.15) (Ubiquitin thiolesterase 5) (Ubiquitin-specifi 12p13.31 ENSG00000111667 H200000826 
500 ESRRAP 28S ribosomal protein S31, mitochondrial precursor (S31mt) (MRP-S31) (Imogen 38). 13q14.11 ENSG00000102738 H200013982 
501 FNTA Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit (EC 2.5.1.58) (EC 2.5.1.5 8p11.21 ENSG00000168522 H200020470 
502     2q31.1 ENSG00000138382 H200016971 
503 ADCK4 aarF domain containing kinase 4 [Homo sapiens]. 19q13.2 ENSG00000123815 H200012914 
504 BCCIP 
BRCA2 and CDKN1A-interacting protein isoform 
BCCIPalpha, BRCA2 and CDKN1A-interacting protein, 
cdk i 
10q26.2 ENSG00000107949 H200017518 
505 METAP1 Methionine aminopeptidase 1 (EC 3.4.11.18) (MetAP 1) (MAP 1) (Peptidase M 1). 4q23 ENSG00000164024 H200006871 
506 C10orf97   10p13 ENSG00000148481 H200008813 
 xl 
507     1p13.2 ENSG00000143079 H200003341 
508 CSPG6 Structural maintenance of chromosome 3 (Chondroitin sulfate proteoglycan 6) (Chromosome-associated p 10q25.2 ENSG00000108055 H200003409 
509 ORC5L Origin recognition complex subunit 5. 7q22.1 ENSG00000164815 H200013856 
510 AKAP1 A kinase anchor protein 1, mitochondrial precursor (Protein kinase A anchoring protein 1) (PRKA1) (A 17q23.2 ENSG00000121057 H200006583 
511     19q13.43 ENSG00000105136 H200018815 
512 CDC16 
Cell division cycle protein 16 homolog (CDC16Hs) 
(Anaphase promoting complex subunit 6) (APC6) 
(Cycl 
13q34 ENSG00000130177 H200000418 
      
for Operon IDs http://omad.operon.com/human2/index.php    
for ensembl IDs http://www.ensembl.org/Homo_sapiens/textview    
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